US Patent Applications in Excipients, Delivery and Release of
Pharmaceutical Compositions and Actives Published in 2010

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENT APPLICATIONS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATION PUBLISHED IN 2011



Application No.: US20110002968A1  Published: 06/Jan/2011

Title: COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING AN ORCHID EXTRACT, AND COSMETIC CARE METHOD USING SAID COMPOSITION

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/745654   Filing Date: 28/Nov/2008

Abstract:

Cosmetic or dermatological compositions contain an orchid extract obtained from at least a part of the species Vanda teres. These compositions and extracts are used as a cosmetic or dermatological agent for maintaining the structure of the skin, in particular by limiting the degradation of the extracellular matrix of the upper layers of the dermis and of the epidermis, and/or for reducing or delaying the effects of skin ageing, in particular the formation of wrinkles, and/or for obtaining a protective, corrective or restructuring effect on the skin, and/or as an anti-inflammatory agent. A method of cosmetic care for the skin is particularly intended for obtaining an effect of prevention or slowing down of the appearance of skin ageing signs.

Priority: FR20070059482 Applic. Date: 2007-11-30; WO2008FR52154 Applic. Date: 2008-11-28

Inventor: LEPLANQUAIS VIRGINIE [FR]; SAUVAN NANCY [FR]; PECHER VIRGINIE [FR]; GERARD FRANCOIS [FR]


Application No.: US20110002973A1  Published: 06/Jan/2011

Title: MATERIALS AND METHODS FOR MINIMALLY-INVASIVE ADMINISTRATION OF A CELL-CONTAINING FLOWABLE COMPOSITION

Applicant/Assignee: PERVASIS THERAPEUTICS, INC

Application No.: 12/880931   Filing Date: 13/Sep/2010

Abstract:

The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery that a heretofore undescribed implantable flowable composition is capable of sustaining a confluent population of sufficiently viable cells which can be effectively administered via a minimally-invasive surgical procedure without diminishing the clinical effectiveness or the viability of the cells. The disclosed invention can be used to treat vasculature as well as non-vascular tubular structures such as a fallopian tube.

Priority: US2007-792284 Applic. Date: 2007-06-05; WO2005US43844 Applic. Date: 2005-12-06; US20040634155P Applic. Date: 2004-12-08; US20050663859P Applic. Date: 2005-03-21; US20050682054P Applic. Date: 2005-05-18

Inventor: NUGENT HELEN MARIE [US]; EDELMAN ELAZER [US]; BOLLINGER STEVE [US]


Application No.: US20110002986A1  Published: 06/Jan/2011

Title: Stable Shellac Enteric Coating Formulation for Nutraceutical and Pharmaceutical Dosage Forms

Applicant/Assignee: HERCULES INCORPORATED

Application No.: 12/828556   Filing Date: 01/Jul/2010

Abstract:

The present invention relates to formulations for use as enteric coatings. More particularly, the present invention relates to a formulation comprising a blend of food grade ingredients that can be readily dispersed in water. This dispersion exhibits low viscosity and can easily be coated onto solid dosage forms through spraying and the like to provide an enteric coating on the solid dosage form.

Priority: US20090222514P Applic. Date: 2009-07-02

Inventor: DURIG THOMAS [US]; ZONG YUDA [US]


Application No.: US20110002994A1  Published: 06/Jan/2011

Title: METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT

Applicant/Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Application No.: 12/681294   Filing Date: 02/Oct/2008

Abstract:

It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to modulate the biological activity of Th17 cells, and its associated metabolic pathway, for a preventative or a therapeutic purpose of a variety of health applications in the field of immunity or obesity related diseases.

Priority: US20070976983P Applic. Date: 2007-10-02; WO2008CA01755 Applic. Date: 2008-10-02

Inventor: BEAULIEU JOSEE [CA]; LAPOINTE JEAN-FRANCOIS [CA]; DUPONT CLAUDE [CA]; LEMIEUX PIERRE [CA]; SIMARD ERIC [CA]; TROTTIER ERIC [CA]


Application No.: US20110002995A1  Published: 06/Jan/2011

Title: PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE

Applicant/Assignee: MAZENCE INC, KT & G CORPORATION

Application No.: 12/747874   Filing Date: 18/Dec/2008

Abstract:

Provided is a pharmaceutical composition for the treatment and prevention of cardiac diseases, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.

Priority: KR20070141303 Applic. Date: 2007-12-31; WO2008KR07506 Applic. Date: 2008-12-18

Inventor: KWAK TAEHWAN [KR]; PARK MYUNG-GYU [KR]


Application No.: US20110002996A1  Published: 06/Jan/2011

Title: ACELLULAR TISSUE MATRICES MADE FROM ALPHA-1,3-GALACTOSE-DEFICIENT TISSUE

Applicant/Assignee: LIFECELL CORPORATION

Application No.: 12/883515   Filing Date: 16/Sep/2010

Abstract:

The invention provides acellular tissue matrices made from collagen-containing tissues of animals genetically modified so as to be deficient in the galactose 1,3-galactose epitope and methods of making and using such acellular tissue matrices.

Priority: US2004-896594 Applic. Date: 2004-07-21; US20030489245P Applic. Date: 2003-07-21

Inventor: MCQUILLAN DAVID J [US]; GRIFFEY EDWARD S [US]; BENIKER HERBERT DANIEL [US]; XU HUI [US]


Application No.: US20110003898A1  Published: 06/Jan/2011

Title: MEDICAL GLUES FOR SURGERY COMPRISING BIOACTIVE COMPOUNDS

Applicant/Assignee: BAYER MATERIALSCIENCE AG

Application No.: 12/920680   Filing Date: 21/Feb/2009

Abstract:

The present invention relates to novel, rapidly curing adhesives based on hydrophilic polyisocyanate prepolymers for use in surgery, which contain pharmacologically active ingredients. The adhesive system contains A) isocyanate group-containing prepolymers obtainable from A1) aliphatic isocyanates and A2) polyols with number-averaged molecular weights of >=400 g/mol and average OH group contents of from 2 to 6 B) a curing component comprising B1) amino group-containing aspartate esters of the general formula (I) wherein X is an n-valent organic radical, which is obtained by removal of the primary amino groups of an n-functional amine, R1 and R2 are the same or different organic radicals, which contain no Zerevitinov active hydrogen and n is a whole number of at least 2 and B2) organic fillers which have a viscosity at 23 DEG C. measured to DIN 53019 in the range from 10 to 6000 mPas and C) optionally reaction products of isocyanate group-containing prepolymers according to the definition of component A) with aspartate esters according to component B1) and/or organic fillers according to component B2) and D) at least one pharmacologically active compound.

Priority: EP20080004134 Applic. Date: 2008-03-06; WO2009EP01262 Applic. Date: 2009-02-21

Inventor: HECKROTH HEIKE [DE]; KOEHLER BURKHARD [DE]; DOERR SEBASTIAN [DE]


Application No.: US20110004150A1  Published: 06/Jan/2011

Title: Transdermal Delivery Using Encapsulated Agent Activated by Ultrasound and or Heat

Applicant/Assignee: ULTRA-SONIC TECHNOLOGIES, L.L.C

Application No.: 12/883153   Filing Date: 15/Sep/2010

Abstract:

A method for delivery of substance through at least one dermal layer, by providing a substance in microcapsules at a predetermined size, within a medium (150) for holding the microcapsules

placing the medium for holding the microcapsules on a surface of a patch (100) adjacent the skin (320) of a human or animal

and applying energy (200) to the patch, the energy having a characteristic of disturbing the integrity of the microcapsules, thereby resulting in release of the substance from the microcapsules. The energy may be selectively applied to release the substance at desired times. The substance may be a drug or other active agent.

Priority: US2005-541001 Applic. Date: 2005-06-28; WO2003US41850 Applic. Date: 2003-12-31; US20020437541P Applic. Date: 2002-12-31

Inventor: WEIMANN LUDWIG J [US]


Application No.: US20110004304A1  Published: 06/Jan/2011

Title: CULTURING RETINAL CELLS AND TISSUES

Applicant/Assignee:

Application No.: 12/727881   Filing Date: 19/Mar/2010

Abstract:

Disclosed are various methods and bioreactor devices for culturing retinal cells and/or tissues. The bioreactor devices may, in certain embodiments, include a microchannel network, a scaffold for culturing neuroretinal cells, and a porous membrane separating the microchannel network from the scaffold.

Priority: US20090162106P Applic. Date: 2009-03-20; US20090216947P Applic. Date: 2009-05-21

Inventor: TAO SARAH L [US]; REDENTI STEPHEN [US]; SODHA SONAL [US]; BORENSTEIN JEFFREY T [US]; YOUNG MICHAEL [US]


Application No.: US20110008260A1  Published: 13/Jan/2011

Title: Use of Nanocrystals for Drug Delivery from a Balloon

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 12/815158   Filing Date: 14/Jun/2010

Abstract:

A drug delivery balloon (10) has a drug thereon in the form of crystalline particles (12), the drug having a predetermined size distribution. Optionally marker particles (14, 16) are also provided. A texturized coating (18), a cap layer (20) and/or other methods may be used to increase particle loading capacity of the balloon.

Priority: US20090224723P Applic. Date: 2009-07-10

Inventor: FLANAGAN AIDEN [IE]; WEBER JAN [NL]; CLARKE JOHN [IE]


Application No.: US20110008266A1  Published: 13/Jan/2011

Title: POLOXAMER FOAMABLE PHARMACEUTICAL COMPOSITIONS WITH ACTIVE AGENTS AND/OR THERAPEUTIC CELLS AND USES

Applicant/Assignee: FOAMIX LTD

Application No.: 12/836444   Filing Date: 14/Jul/2010

Abstract:

Pharmaceutical or cosmetic compositions and methods for their use are provided comprising water and a surfactant polymer system comprising a Poloxamer at a concentration of about 0.1% to about 15% by weight

wherein when the Poloxamer is between about 0.1% to about 5% Poloxamer. The composition can further comprise a supporting agent comprising a non-ionic surface active agent or a supporting agent comprising a non surfactant polymer or polysaccharide and an active agent, where the Poloxamer is capable of fixing the composition on delivery to a body surface. There are further provided therapeutic cell compositions and their uses.

Priority: WO2009IB05012 Applic. Date: 2009-01-14; US20080020950P Applic. Date: 2008-01-14; US20080077779P Applic. Date: 2008-07-02

Inventor: TAMARKIN DOV [IL]; BESONOV ALEX [IL]; BERMAN TAL [IL]; SCHUZ DAVID [IL]; GAZAL ELANA [IL]


Application No.: US20110008304A1  Published: 13/Jan/2011

Title: USE OF CELLS TO FACILITATE TARGETED DELIVERY OF NANOPARTICLE THERAPIES

Applicant/Assignee: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION

Application No.: 12/668281   Filing Date: 09/Jul/2008

Abstract:

The present invention is related to the use of cells, such as stem cells or immune system cells, to deliver nanogels comprising an active agent to a desired site in the body. The present invention utilizes cells as a delivery system for active agents that are difficult to deliver, such as active agents with poor solubility, that degrade easily, or that are toxic to the body. The nanogels are preferably non-toxic and can optionally include a lytic agent to program apoptosis of the cell to deliver the nanogel and active agent to a desired sire within the body.

Priority: US20070958753P Applic. Date: 2007-07-09; WO2008US69525 Applic. Date: 2008-07-09

Inventor: TROYER DERYL [US]; HUA DUY H [US]


Application No.: US20110008428A1  Published: 13/Jan/2011

Title: SOLID PHARMACEUTICAL COMPOSITION COMPRISING A NON-PEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC

Applicant/Assignee: RATIOPHARM GMBH

Application No.: 12/922893   Filing Date: 17/Mar/2009

Abstract:

The present invention relates to a solid pharmaceutical composition comprising at least two layers, wherein the first layer contains a non-peptide angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof in a dissolving matrix and the second layer contains a diuretic or a pharmaceutically acceptable salt thereof. The invention also provides methods for the production of said pharmaceutical compositions.

Priority: IN2008DE00700 Applic. Date: 2008-03-19; WO2009EP01966 Applic. Date: 2009-03-17

Inventor: MHASE SUNIL R [IN]; GAT GANESH V [IN]; HUSSAIN JAWED [IN]


Application No.: US20110008435A1  Published: 13/Jan/2011

Title: Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds

Applicant/Assignee: ELAN CORPORATION PLC

Application No.: 11/672263   Filing Date: 07/Feb/2007

Abstract:

The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.

Priority: US2006-455600 Applic. Date: 2006-06-19; US2006-372857 Applic. Date: 2006-03-10; US2004-827689 Applic. Date: 2004-04-19; US2003-354483 Applic. Date: 2003-01-30; US2002-331754 Applic. Date: 2002-12-30; US2001-850425 Applic. Date: 2001-05-07; US2000-566636 Applic. Date: 2000-05-08; WO1999US25632 Applic. Date: 1999-11-01; US19980106726P Applic. Date: 1998-11-02; US20050692096P Applic. Date: 2005-06-20

Inventor: DEVANE JOHN G [IE]; STARK PAUL [IE]; FANNING NIALL M M [IE]; REKHI GURVINDER SINGH [US]; JENKINS SCOTT A [US]; LIVERSIDGE GARY [US]


Application No.: US20110008436A1  Published: 13/Jan/2011

Title: Silk Fibroin Hydrogels and Uses Thereof

Applicant/Assignee:

Application No.: 12/764038   Filing Date: 20/Apr/2010

Abstract:

The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.

Priority: US20090170895P Applic. Date: 2009-04-20

Inventor: ALTMAN GREGORY H [US]; HORAN REBECCA L [US]; COLLETTE ADAM L [US]; CHEN JINGSONG [US]


Application No.: US20110008437A1  Published: 13/Jan/2011

Title: Silk Fibroin Hydrogels and Uses Thereof

Applicant/Assignee:

Application No.: 12/764039   Filing Date: 20/Apr/2010

Abstract:

The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.

Priority: US20090170895P Applic. Date: 2009-04-20

Inventor: ALTMAN GREGORY H [US]; HORAN REBECCA L [US]; COLLETTE ADAM L [US]; CHEN JINGSONG [US]


Application No.: US20110008438A1  Published: 13/Jan/2011

Title: Bone Repair Composition and a Method of Making the Same

Applicant/Assignee:

Application No.: 12/812100   Filing Date: 09/Jan/2009

Abstract:

Bone repair composition and method of making the same, the bone repair composition being formed by firstly mixing a first aqueous calcium phosphate suspension with bone graft granules to form an intermediate mixture. The intermediate mixture is then mixed with a second aqueous calcium phosphate suspension, wherein the first aqueous calcium phosphate suspension contains a lower weight concentration of calcium phosphate than the second aqueous calcium phosphate suspension.

Priority: GB20080000370 Applic. Date: 2008-01-09; GB20080000371 Applic. Date: 2008-01-09; WO2009GB50017 Applic. Date: 2009-01-09

Inventor: MYINT PETER [GB]; KUIPER JAN HERMAN [GB]


Application No.: US20110008439A1  Published: 13/Jan/2011

Title: DULOXETIN COMPOSITION

Applicant/Assignee: LEK PHARMACEUTICALS D.D

Application No.: 12/521410   Filing Date: 21/Dec/2007

Abstract:

The present invention relates to a stable pharmaceutical pellet composition comprising duloxetine or a pharmaceutically acceptable salt thereof and a method for making such composition. In particular, the composition comprises duloxetine hydrochloride and a separating layer comprising a water soluble inorganic salt.

Priority: EP20060127212 Applic. Date: 2006-12-27; EP20070112543 Applic. Date: 2007-07-16; WO2007EP64448 Applic. Date: 2007-12-21

Inventor: JAKLIC MIHA TOMAZ [SI]; JURECIC ROK [SI]


Application No.: US20110008443A1  Published: 13/Jan/2011

Title: PHOTOCROSSLINKED BIODEGRADABLE HYDROGEL

Applicant/Assignee:

Application No.: 12/649700   Filing Date: 30/Dec/2009

Abstract:

A photocrosslinked biodegradable hydrogel includes a plurality of natural polymer macromers cross-linked with a plurality of hydrolyzable acrylate cross-links. The hydrogel is cytocompatible and produces substantially non-toxic products upon degradation.

Priority: US20080141266P Applic. Date: 2008-12-30

Inventor: ALSBERG EBEN [US]; JEON OJU [US]


Application No.: US20110014143A1  Published: 20/Jan/2011

Title: KETONES AS PERFUMING INGREDIENTS

Applicant/Assignee: FIRMENICH SA

Application No.: 12/920703   Filing Date: 14/Apr/2009

Abstract:

The present invention relates to the field of perfumery and concerns the use as perfuming ingredient of ketones of formula wherein n represents 0, 1 or 2, m represents 0, 1 or 2, the dotted lines represent only single bonds or one double bond and two single bonds, R1 represents a hydrogen atom or a methyl or ethyl group, said R1 group being located at any of the position of the cyclic moiety, R2 represents a C1-C3 O-alkyl or O-alkenyl group or a substituted or unsubstituted ethylene or cyclopropyl group. Said compounds are useful to impart a clean and natural fruity, pineapple odor type. The present invention concerns also the compositions or articles containing said compounds (I) as well as some of said compounds (I).

Priority: EP20080007519 Applic. Date: 2008-04-17; WO2009IB51550 Applic. Date: 2009-04-14

Inventor: CHAPUIS CHRISTIAN [CH]; BIRKBECK ANTHONY [CH]; MARTY MAURUS [CH]


Application No.: US20110014248A1  Published: 20/Jan/2011

Title: Cosmetic use of microorganism(s) for the treatment of scalp disorders

Applicant/Assignee: L'OREAL, NESTEC SA

Application No.: 12/659597   Filing Date: 15/Mar/2010

Abstract:

The present invention relates to a use of an effective amount of at least one probiotic microorganism and/or a fraction thereof and/or a metabolite thereof for preventing and/or treating dandruff disorders of the scalp, as well as a cosmetic process for preventing and/or treating a dandruff condition including the administration a first cosmetic active agent and of at least a second cosmetic active agent, topically, the said first and second cosmetic active agents being formulated in separate compositions, the first cosmetic active agent being chosen from probiotic microorganisms, and mixtures thereof, and the second cosmetic active agent being chosen from antidandruff active agents.

Priority: FR20080057865 Applic. Date: 2008-11-19; FR20090053611 Applic. Date: 2009-06-02; US2009-509756 Applic. Date: 2009-07-27; US20080084582P Applic. Date: 2008-07-29; US20090213517P Applic. Date: 2009-06-16

Inventor: CASTIEL ISABELLE [FR]; GUENICHE AUDREY [FR]


Application No.: US20110014287A1  Published: 20/Jan/2011

Title: Silk Fibroin Hydrogels and Uses Thereof

Applicant/Assignee:

Application No.: 12/764052   Filing Date: 20/Apr/2010

Abstract:

The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.

Priority: US20090170895P Applic. Date: 2009-04-20

Inventor: ALTMAN GREGORY H [US]; HORAN REBECCA L [US]; COLLETTE ADAM L [US]; CHEN JINGSONG [US]


Application No.: US20110014288A1  Published: 20/Jan/2011

Title: MICROCAPSULES COMPRISING A FAT-SOLUBLE ACTIVE SUBSTANCE

Applicant/Assignee:

Application No.: 12/809664   Filing Date: 18/Dec/2008

Abstract:

The invention relates to microcapsule comprising at least one fat-soluble active substance selected from provitamins, vitamins and esters thereof, monounsaturated fatty acids, polyunsaturated fatty acids (PUFA's), carotenoids and benzoquinones embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, wherein the content of active substance(s) is from 30 to 60% of total weight of the microcapsule, and wherein the ratio between said fat-soluble active substance(s) and said hydrocolloid is at least 4:1, as well as a process for preparing such microcapsules. The microcapsules of the invention may be used for the preparation of tablets, food products and other products including an active substance.

Priority: EP20070123992 Applic. Date: 2007-12-21; WO2008EP67887 Applic. Date: 2008-12-18

Inventor: HANSEN MOHR MORTEN [DK]; MUSAEUS NINA [DK]; HANSEN CARSTEN LYNGGAARD [DK]


Application No.: US20110014290A1  Published: 20/Jan/2011

Title: SYSTEM AND METHOD FOR FACILITATING HEMOSTASIS WITH AN ABSORBABLE SPONGE

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 12/887945   Filing Date: 22/Sep/2010

Abstract:

The present invention provides for a method and apparatus to provide hemostasis at a blood vessel puncture site, having a hemostasis material and a clot formation accelerator, wherein said clot formation accelerator is substantially dispersed throughout said hemostasis material.

Priority: WO2004US18707 Applic. Date: 2004-06-14; US2006-557333 Applic. Date: 2006-11-20; US2006-537024 Applic. Date: 2006-09-29; US2009-578088 Applic. Date: 2009-10-13; US2002-107539 Applic. Date: 2002-03-25; US1999-365674 Applic. Date: 1999-08-02; US1997-888851 Applic. Date: 1997-07-07; US1995-528892 Applic. Date: 1995-09-15; US2004-978321 Applic. Date: 2004-10-29; US2001-966611 Applic. Date: 2001-09-27; US2000-630814 Applic. Date: 2000-08-02; US1999-335452 Applic. Date: 1999-06-17; US1998-071670 Applic. Date: 1998-05-01; US1998-071284 Applic. Date: 1998-05-01; US20030478307P Applic. Date: 2003-06-12

Inventor: SING EDUARDO CHI [US]; ASHBY MARK [US]; TRAN TIN [US]; GREFF RICHARD [US]


Application No.: US20110015075A1  Published: 20/Jan/2011

Title: HYDROLYSIS RESISTANT ORGANOMODIFIED DISILOXANE IONIC SURFACTANTS

Applicant/Assignee: MOMENTIVE PERFORMANCE MATERIALS INC

Application No.: 12/834548   Filing Date: 12/Jul/2010

Abstract:

An asymmetric organomodified disiloxane surfactant having the formula: MM' wherein M comprises branched hydrocarbon substituents and M' comprises a cationic, anionic or zwitterionic substituent and a polyether substituent that may be combined as one moiety, wherein the disiloxane surfactant has an enhanced resistance to hydrolysis between a pH of about 3 to about 12.

Priority: US2007-964231 Applic. Date: 2007-12-26

Inventor: LEATHERMAN MARK D [US]; POLICELLO GEORGE A [US]; PENG WENQING [CN]; ZHENG LIPING [CN]; WAGNER ROLAND [DE]; RAJARAMAN SURESH K [US]; XIA ZIJUN [CN]


Application No.: US20110020226A1  Published: 27/Jan/2011

Title: PARTICLE STRUCTURES COMPRISING STEROLS AND SAPONINS

Applicant/Assignee: NORDIC VACCINE TECHNOLOGY A/S

Application No.: 12/724253   Filing Date: 15/Mar/2010

Abstract:

The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. The present invention also pertains to pharmaceutical compositions and methods of treatment of an individual by therapy and/or surgery, methods of cosmetic treatment, and diagnostic methods practised on the human or animal body.

Priority: DK20010000560 Applic. Date: 2001-04-04; US2002-114957 Applic. Date: 2002-04-04; US20010308609P Applic. Date: 2001-07-31

Inventor: DALSGAARD KRISTIAN [DK]; KIRKBY NIKOLAI SOEREN [DK]


Application No.: US20110020444A1  Published: 27/Jan/2011

Title: ABUSE-RESISTANT OPIOID DOSAGE FORM

Applicant/Assignee: ENDO PHARMACEUTICALS, INC

Application No.: 12/894614   Filing Date: 30/Sep/2010

Abstract:

We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.

Priority: US2002-143140 Applic. Date: 2002-05-10; US20010290438P Applic. Date: 2001-05-11

Inventor: KAO HUAI-HUNG [US]; ZENG YADI [US]; HOWARD-SPARKS MICHELLE [US]; JIM FAI [US]


Application No.: US20110020448A1  Published: 27/Jan/2011

Title: PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF GLAUCOMA

Applicant/Assignee: MAZENCE, INC, KT & G CORPORATION

Application No.: 12/747867   Filing Date: 18/Dec/2008

Abstract:

Provided is a pharmaceutical composition for the treatment and prevention of glaucoma, containing (a) a therapeutically effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.

Priority: WO2008KR07507 Applic. Date: 2008-12-18; KR20070136105 Applic. Date: 2007-12-24

Inventor: PARK MYUNG-GYU [KR]; KWAK TAEHWAN [KR]


Application No.: US20110020449A1  Published: 27/Jan/2011

Title: METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (TB4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES

Applicant/Assignee: REGENERX BIOPHARMACEUTICALS, INC

Application No.: 12/775959   Filing Date: 07/May/2010

Abstract:

Pain or irritation of the eyes, caused by injury due to dry eye syndrome, chemical burns or the like can be accompanied by corneal stromal edema. It has been discovered that administration of thymosin [beta]4 and/or oxidized thymosin [beta]4 to cornea in need of treatment of corneal stromal edema is a useful treatment for decreasing such corneal stromal edema.

Priority: US2007-841575 Applic. Date: 2007-08-20; US2004-471621 Applic. Date: 2004-02-26; WO2002US07730 Applic. Date: 2002-03-14; US2001-772445 Applic. Date: 2001-01-29; WO1999US17282 Applic. Date: 1999-07-29; US20010275645P Applic. Date: 2001-03-15; US19980094690P Applic. Date: 1998-07-30

Inventor: GOLDSTEIN ALLAN L [US]; SOSNE GABRIEL [US]


Application No.: US20110020450A1  Published: 27/Jan/2011

Title: TITRATABLE DOSAGE TRANSDERMAL DELIVERY SYSTEM

Applicant/Assignee: EURO-CELTIQUE

Application No.: 12/894512   Filing Date: 30/Sep/2010

Abstract:

The present invention relates to a titratable dosage transdermal delivery system for systemic delivery of a therapeutic agent or drug. The system comprises a plurality of patch units that are connected along one or more borders. The plurality of patch units are divisible into units along the one or more borders having one or more lines of separation. Each patch unit is surrounded by a border. The therapeutic patch has at least a backing layer and a therapeutic agent comprising layer. The dosage of therapeutic agent delivered to a patient is proportional to the number of patch unit applied per treatment. The system enables systemic administration of a titratable dosage of therapeutic agent, adjustable by the patient under the direction of a physician, through the skin or mucosa. Moreover, the invention relates to a method of making the titratable dosage transdermal delivery system. Furthermore, the invention relates to a method of providing a titratable amount of therapeutic agent to a patient using the transdermal delivery system of the invention.

Priority: US2003-690384 Applic. Date: 2003-10-20; US2000-714604 Applic. Date: 2000-11-16

Inventor: WRIGHT IV CURTIS [US]


Application No.: US20110020452A1  Published: 27/Jan/2011

Title: PROGENITOR CELL REPLICATION AND DIFFERENTIATION IN 3D

Applicant/Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Application No.: 12/438543   Filing Date: 22/Aug/2007

Abstract:

The present invention is directed to a new approach towards in situ differentiation of tissue progenitor cells, without the coventional requirements of weeks of cellular manipulation and treatment. Such approach circumvents the need for 2D culturing and differentiation of tissue progenitor cells before implanting in a 3D biocompatible matrix, thus providing convenience, cost savings, and time savings. One aspect of the invention provides an engineered tissue composition comprising substantially undifferentiated tissue progenitor cells in a biphasic matrix material, along with growth factors or encapsulated growth factors. Another aspect of the invention includes methods for making the compositions described herein. Another aspect of the invention includes methods of therapeutic treatment using the compositions described herein.

Priority: US20060823249P Applic. Date: 2006-08-22; WO2007US18586 Applic. Date: 2007-08-22

Inventor: MAO JEREMY J [US]


Application No.: US20110021899A1  Published: 27/Jan/2011

Title: CONDUCTIVE POLYMER COATINGS

Applicant/Assignee: SURMODICS, INC

Application No.: 12/831539   Filing Date: 07/Jul/2010

Abstract:

An electrically conductive coating composition that includes a polymeric mixture, an electrically conductive material dispersed within the polymeric mixture and, optionally, one or more bioactive agents is described.

Priority: US20090227843P Applic. Date: 2009-07-23

Inventor: ARPS JAMES H [US]; BARNETT PETER J [US]; MISSLING JEFFREY J [US]


Application No.: US20110027172A1  Published: 03/Feb/2011

Title: DRUG DELIVERY SYSTEM FOR PHARMACEUTICALS AND RADIATION

Applicant/Assignee:

Application No.: 12/747040   Filing Date: 10/Dec/2008

Abstract:

The present invention provides a drug delivery system for delivery of an agent and a radiopharmaceutical agent. The drug delivery system may specifically target an organ, tissue, cells, extracellular matrix, or intracellular compartment. Typically, the drug delivery system is a particle. Pharmaceutical compositions comprising the inventive particles are also provided. The present invention provides methods of preparing and using the inventive particles and pharmaceutical compositions. The inventive particles are useful in treating and diagnosing a variety of diseases including cancer. The inventive particles are also useful in tracking particles in vivo.

Priority: US20070012617P Applic. Date: 2007-12-10; WO2008US86255 Applic. Date: 2008-12-10

Inventor: WANG ZHUANG [US]; FAROKHZAD OMID C [US]; ZHANG LIANGFANG [US]; RADOVIC-MORENO ALEKSANDAR FILIP [US]; GU FRANK X [CA]; LANGER ROBERT S [US]


Application No.: US20110027346A1  Published: 03/Feb/2011

Title: Lyase Enzymes, Nucleic Acids Encoding Them and Methods for Making and Using Them

Applicant/Assignee: VERENIUM CORPORATION

Application No.: 12/303088   Filing Date: 29/May/2007

Abstract:

This invention provides polypeptides having lyase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having ammonia lyase activity, e.g., phenylalanine ammonia lyase, tyrosine ammonia lyase and/or histidine ammonia lyase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.

Priority: US20060810528P Applic. Date: 2006-06-02; WO2007US69877 Applic. Date: 2007-05-29

Inventor: WEINER DAVID [US]; VARVAK ALEXANDER [US]; RICHARDSON TOBY [US]; PODAR MIRCEA [US]; BURKE ELLEN [US]; HEALEY SHAUN [US]


Application No.: US20110027356A1  Published: 03/Feb/2011

Title: Combination of Oral Medicaments Bonded by a Wrapping

Applicant/Assignee: DUO-GE

Application No.: 12/864397   Filing Date: 26/Jan/2009

Abstract:

Oral pharmaceutical dosage form containing at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another, at least one of the medicaments being selected from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, clopidogrel.

Priority: FR20080050460 Applic. Date: 2008-01-25; FR20080050461 Applic. Date: 2008-01-25; US20080006652P Applic. Date: 2008-01-25; US20080006651P Applic. Date: 2008-01-25; WO2009EP50858 Applic. Date: 2009-01-26

Inventor: LUGRIN ANNE-EMMANUELLE [FR]; GRISCELLI CLAUDE [FR]; EL GLAOUI MEHDI [CH]; EL GLAOUI GUILLAUME [FR]; HOFFELT JEAN [FR]


Application No.: US20110027360A1  Published: 03/Feb/2011

Title: PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS

Applicant/Assignee: METHYLATION SCIENCES INTERNATIONAL SRL

Application No.: 12/845600   Filing Date: 28/Jul/2010

Abstract:

Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast

that is prior to food intake in the morning.

Priority: US20090229186P Applic. Date: 2009-07-28

Inventor: HARRISON NANCY [CA]; MACDONALD I DAVID [CA]; TAKACS-COX ANIKO [CA]; MILLER ROBERT [CA]


Application No.: US20110027361A1  Published: 03/Feb/2011

Title: EXTENDED RELEASE DOSAGE FORM OF PALIPERIDONE

Applicant/Assignee: TORRENT PHARMACEUTICALS LTD

Application No.: 12/865801   Filing Date: 03/Feb/2009

Abstract:

The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same.

Priority: IN2008MU00232 Applic. Date: 2008-02-04; WO2009IN00072 Applic. Date: 2009-02-03

Inventor: MURUGESAN GANESAN [IN]; ABRAHAM JAYA [IN]; GUPTA VINODKUMAR [IN]; SHAH BHAVESH [IN]


Application No.: US20110027363A1  Published: 03/Feb/2011

Title: Nouvelle forme d'administration de proteines osteogeniques

Applicant/Assignee: ADOCIA

Application No.: 12/591447   Filing Date: 19/Nov/2009

Abstract:

Osteogenic compositions are formed from a coprecipitate that contains at least one insoluble calcium salt and at least one osteogenic protein, the coprecipitate being in divided form. A process for preparing the coprecipitate in divided form contains at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide. The invention also relates to the formulations, pharmaceutical products, kits and medical devices comprising the coprecipitate.

Priority: FR20090003802 Applic. Date: 2009-07-31; US20090213938P Applic. Date: 2009-07-31

Inventor: SOULA REMI [FR]; SOULA OLIVIER [FR]; SOULA GERARD [FR]


Application No.: US20110027364A1  Published: 03/Feb/2011

Title: BIOACTIVE AND RESORBABLE SOYBEAN-BASED BIOMATERIALS

Applicant/Assignee: UNIVERSITY OF BRIGHTON

Application No.: 12/744848   Filing Date: 26/Nov/2008

Abstract:

A method of producing a soybean-based biomaterial which is suitable for use in a biomedical product, the method comprising: defatting soy flour

either prior to or at the same time as, performing a solvent extraction

to produce a biomaterial comprising variable levels of soy proteins, carbohydrates and isoflavones. The resulting biomaterials have a range of biomedical uses and are particularly desirable because of their isoflavone content. Examples of biomedical products containing the biomaterials include wound dressings

scaffolds for tissue engineering

fillers or implants for use in surgery

temporary barriers for use in dental or surgical procedures or to prevent post-surgical tissue adherence

carriers for the delivery of drugs, bioactive peptides or plasmids

anti-inflammatory agents

coatings for wound dressings or for dental, medical, surgical or veterinary devices or implants

and compositions for soothing skin or gum irritation.

Priority: GB20070023102 Applic. Date: 2007-11-26; WO2008GB51117 Applic. Date: 2008-11-26

Inventor: AMBROSIO LUIGI [IT]; NICOLAIS LUIGI [IT]; SALVAGE JONATHAN PETER [GB]; SANTIN MATTEO [GB]; STANDEN GUY [GB]


Application No.: US20110027365A1  Published: 03/Feb/2011

Title: Patch Formulation For External Use

Applicant/Assignee: HISAMITSU PHARMACEUTICAL CO., INC

Application No.: 12/831190   Filing Date: 06/Jul/2010

Abstract:

A patch formulation for external use where a basic drug, an organic acid and an organic acid salt are combined as essential components is disclosed. The basic drug is preferably in the form of its acid addition salt. The organic acid is preferably a carboxylic acid having carbon atoms of 2 to 7, and more preferably at least one acid selected from the group consisting of acetic, lactic, tartaric, citric, malic, benzoic and salicylic acids. The organic acid salt is preferably a metal salt of a carboxylic acid, and more preferably sodium acetate.

Priority: JP19990212921 Applic. Date: 1999-07-27; US2004-754592 Applic. Date: 2004-01-12; US2002-031747 Applic. Date: 2002-01-24; WO2000JP04945 Applic. Date: 2000-07-25

Inventor: CHONO HIDEHARU [JP]; YAMAGUCHI TOSHIRO [JP]; KURITA HISAKAZU [JP]; TATEISHI TETSURO [JP]; HIGO NARUHITO [JP]


Application No.: US20110027366A1  Published: 03/Feb/2011

Title: SKIN EQUIVALENT CULTURE

Applicant/Assignee: DFB TECHNOLOGY HOLDINGS, LLC

Application No.: 12/902710   Filing Date: 12/Oct/2010

Abstract:

Disclosed is a method of preparing a collagenous construct comprising casting a support matrix comprising fibrin and viable collagen-producing cells onto a support material, wherein said cells include human dermal fibroblasts, incubating in situ said support matrix in a collagen-inducing medium thereby, inducing or enhancing collagen production by said cells to form a collagenous construct, and degrading said fibrin, and rendering said collagenous construct free of said viable collagen-producing cells.

Priority: GB20050005202 Applic. Date: 2005-03-14; US2008-886113 Applic. Date: 2008-06-24; WO2006GB00890 Applic. Date: 2006-03-14

Inventor: KEMP PAUL [GB]; SHERING DAVID [GB]; SHERING ANDREW [GB]; JOHNSON PENNY [GB]; MARSHALL DAMIAN [GB]


Application No.: US20110027367A1  Published: 03/Feb/2011

Title: ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, S.N.C

Application No.: 12/902931   Filing Date: 12/Oct/2010

Abstract:

Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.

Priority: FR20020003070 Applic. Date: 2002-03-12; US2008-103182 Applic. Date: 2008-04-15; US2004-937612 Applic. Date: 2004-09-10; WO2003EP03246 Applic. Date: 2003-03-12; US20020370223P Applic. Date: 2002-04-08

Inventor: GRAEBER MICHAEL [US]; CZERNIELEWSKI JANUSZ [FR]


Application No.: US20110027369A1  Published: 03/Feb/2011

Title: PHARMACEUTICAL COMPOSITION IN THE FORM OF A HYDROGEL FOR TRANSDERMAL ADMINISTRATION OF ACTIVE INGREDIENTS

Applicant/Assignee:

Application No.: 12/858883   Filing Date: 18/Aug/2010

Abstract:

The invention relates to a pharmaceutical composition in the form of a hydrogel that comprises a carboxylic acid diester, a C2-C4 alkyl alcohol, an active ingredient and a polymer matrix. The invention also relates to the use of a carboxylic acid diester as a transdermal permeation enhancer for an active ingredient in a pharmaceutical composition in the form of a hydrogel, whereby the composition comprises a polymer matrix and a C2-C4 alkyl alcohol. The invention also relates to a sweat-resistant composition in the form of a hydrogel, which comprises an acrylic polymer in combination with a cellulose derivative.

Priority: EP20030008856 Applic. Date: 2003-04-28; US2004-833273 Applic. Date: 2004-04-28; US20030465808P Applic. Date: 2003-04-28

Inventor: FRANKE PATRICK [DE]


Application No.: US20110028569A1  Published: 03/Feb/2011

Title: MIXTURES OF HYDROLYSIS RESISTANT ORGANOMODIFIED TRISILOXANE IONIC SURFACTANTS

Applicant/Assignee:

Application No.: 12/810663   Filing Date: 26/Dec/2008

Abstract:

The present invention provides for a mixture comprising a siloxane having the formula: M1 D M2 wherein M1=(R1)(R2)(R3)SiO1/2

M2=(R4)(R5)(R6) SiO1/2 and D=(R7)(Z) SiO2/2 where R1, R2, R3, R4, R5, W and R7 are each independently selected from the group consisting of 1 to 4 carbon monovalent hydrocarbon radicals, aryl, and a hydrocarbon group of 4 to 9 carbons containing an aryl group

Z is a pendant hydrophilic ionic group selected from the group consisting of R8-RA, R9Rc, and R10-Rz

RA being an anionic substituent, Rc a cationic substituent or Rz a zwitterionic substituent on the D group and an additional component selected from the group consisting of agricultural components, coating components, personal care components, home care components, oil or gas treating components, water processing components, and pulp or paper treating components, wherein said mixture has an enhanced resistance to hydrolysis.

Priority: US2007-964167 Applic. Date: 2007-12-26; WO2008US14065 Applic. Date: 2008-12-26

Inventor: LEATHERMAN MARK D [US]; POLICELLO GEORGE A [US]; PENG WENGING N [CN]; ZHENG LIPING [CN]; WAGNER ROLAND [DE]; RAJARAMAN SURESH K [US]; ZIJUN XIA [CN]


Application No.: US20110033402A1  Published: 10/Feb/2011

Title: Solubilized benzoyl small molecule

Applicant/Assignee:

Application No.: 12/803544   Filing Date: 29/Jun/2010

Abstract:

The invention relates to a novel solubilized small molecule topical formulation for the transdermal delivery of small molecule agents comprising: a small molecule agent, one or more micelle forming compounds, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the small molecule agent is solubilized in the solvent. The invention further relates to the use of the topical formulation as well as the process for making the topical formulation.

Priority: US2005-057481 Applic. Date: 2005-02-14

Inventor: MODI PANKAJ [CA]


Application No.: US20110033413A1  Published: 10/Feb/2011

Title: METHOD FOR PRODUCING OIL-IN-WATER EMULSIONS FROM SELF-EMULSIFYING GEL CONCENTRATES

Applicant/Assignee:

Application No.: 12/810042   Filing Date: 19/Dec/2008

Abstract:

The object of the present invention is a method for producing oil-in-water (O/W) emulsions from self-emulsifying gel concentrates without agitation, such as stirring, or in a laminar flow field.

Priority: DE200710063134 Applic. Date: 2007-12-24; WO2008DE02115 Applic. Date: 2008-12-19

Inventor: KWETKAT KLAUS [DE]; JAKOBS BRITTA [DE]; DAHMS GERD M [DE]


Application No.: US20110033512A1  Published: 10/Feb/2011

Title: PERSONAL CARE COMPOSITION WITH IMPROVED SPREADABILITY

Applicant/Assignee:

Application No.: 12/851921   Filing Date: 06/Aug/2010

Abstract:

A stable personal care composition in the form of a substantially anhydrous oil matrix having improved spreadability that may comprise a hydrocarbon wax, a polar oil, and a non-emulsifying silicone elastomer. The weight ratio of the hydrocarbon wax to the polar oil is from about 0.01 to about 0.5. The personal care composition may exhibit a spreadability of 1.0 kg to about 5.0 kg and a hardness of about 3 g to about 120 g

Priority: US20090232614P Applic. Date: 2009-08-10

Inventor: BREYFOGLE LAURIE ELLEN [US]


Application No.: US20110033516A1  Published: 10/Feb/2011

Title: METHODS AND COMPOSITIONS FOR BONE HEALING BY PERIOSTIN

Applicant/Assignee: MEDICAL UNIVERSITY OF SOUTH CAROLINA

Application No.: 12/851100   Filing Date: 05/Aug/2010

Abstract:

The present invention provides methods and compositions for increasing bone production and/or decreasing bone fracture healing time in a subject, by administering an effective amount of periostin and/or active peptides and/or fragments thereof.

Priority: US20090231742P Applic. Date: 2009-08-06

Inventor: MARKWALD ROGER R [US]; KERN MICHAEL J [US]; NORRIS RUSSELL A [US]; KOKKO KYLE P [US]


Application No.: US20110033540A1  Published: 10/Feb/2011

Title: POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS

Applicant/Assignee:

Application No.: 12/526027   Filing Date: 05/Feb/2008

Abstract:

Disclosed in the present application are compositions comprising a bioresorbable polymer matrix and a bio active agent, wherein the bioactive agent is dispersed within polymer matrix as a solid. Also provided herein are methods for preparing a bioactive agent formulation, wherein the agent is present in a solid form and, wherein the agent is occluded into a polymeric matrix by polymerization of polymer matrix precursors or by self assembly of the polymer.

Priority: US20070888251P Applic. Date: 2007-02-05; WO2008US53108 Applic. Date: 2008-02-05

Inventor: DANILOFF GEORGE [US]; GRAVETT DAVID [US]; SPIRO ROBERT C [US]


Application No.: US20110033541A1  Published: 10/Feb/2011

Title: SUBLINGUAL AND BUCCAL FILM COMPOSITIONS

Applicant/Assignee: MONOSOL RX, LLC

Application No.: 12/537571   Filing Date: 07/Aug/2009

Abstract:

The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

Priority:

Inventor: MYERS GARRY L [US]; HILBERT SAMUEL D [US]; BOONE BILL J [US]; BOGUE B ARLIE [US]; SANGHVI PRADEEP [US]; HARIHARAN MADHUSUDAN [US]


Application No.: US20110033542A1  Published: 10/Feb/2011

Title: SUBLINGUAL AND BUCCAL FILM COMPOSITIONS

Applicant/Assignee: MONOSOL RX, LLC

Application No.: 12/537580   Filing Date: 07/Aug/2009

Abstract:

The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

Priority:

Inventor: MYERS GARRY L [US]; HILBERT SAMUEL D [US]; BOONE BILL J [US]; BOGUE B ARLIE [US]; SANGHVI PRADEEP [US]; HARIHARAN MADHUSUDAN [US]


Application No.: US20110033543A1  Published: 10/Feb/2011

Title: HYDROGELS WITH COVALENT AND NONCOVALENT CROSSLINKS

Applicant/Assignee:

Application No.: 12/814826   Filing Date: 14/Jun/2010

Abstract:

A method for targeted delivery of therapeutic compounds from hydrogels is presented. The method involves administering to a cell a hydrogel in which a therapeutic compound is noncovalently bound to heparin. The hydrogel may contain covalent and non-covalent crosslinks.

Priority: US2006-395902 Applic. Date: 2006-03-31; US20050666787P Applic. Date: 2005-03-31

Inventor: KIICK KRISTI L [US]; YAMAGUCHI NORI [US]


Application No.: US20110034414A1  Published: 10/Feb/2011

Title: FLUOROALKYLOXY ALKANES, PROCESS FOR PRODUCTION AND USES THEREOF

Applicant/Assignee: AL.CHI.MI.A. S.R.L

Application No.: 12/937915   Filing Date: 28/Apr/2008

Abstract:

The present invention relates to fluoroalkyloxy alkanes having formula (I): RF-R1-O-R2 wherein: RF is a linear or branched perfluoroalkyl group, having from 1 to 12, preferably from 2 to 8, carbon atoms

R1 is a linear or branched, non-fluorinated alkylene group, having from 1 to 6, preferably from 2 to 4, carbon atoms, -R2 is a linear or branched, non-fluorinated alkyl group, having from 1 to 12, preferably from 2 to 8, carbon atoms, possibly containing at least one ether bond -O- along the chain. The present invention further relates to a process for preparation and use thereof, possibly in mixture with at least one silicone oil, as medicaments in ophthalmology, in particular as tamponade liquids in an operation for the treatment of retinal detachment.

Priority: WO2008IT00293 Applic. Date: 2008-04-28

Inventor: CONTE LINO [IT]; BECCARO MAURO [IT]; BETTINI ENRICO [IT]; SIGNORI PAOLO [IT]; ZAGGIA ALESSANDRO [IT]


Application No.: US20110034568A1  Published: 10/Feb/2011

Title: Compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity

Applicant/Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Application No.: 12/883873   Filing Date: 16/Sep/2010

Abstract:

A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration.

Priority: US2003-433454 Applic. Date: 2003-11-06; WO2001US51605 Applic. Date: 2001-12-19; US20000256711P Applic. Date: 2000-12-19

Inventor: LICHTENBERGER LENARD M [US]


Application No.: US20110038927A1  Published: 17/Feb/2011

Title: CONTROLLED RELEASE HYDROCODONE FORMULATIONS

Applicant/Assignee: PURDUE PHARMA LP

Application No.: 12/914054   Filing Date: 28/Oct/2010

Abstract:

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.

Priority: US2009-378586 Applic. Date: 2009-02-17; US2003-660349 Applic. Date: 2003-09-11; US2001-016651 Applic. Date: 2001-10-30; US20000244424P Applic. Date: 2000-10-30

Inventor: OSHLACK BENJAMIN [US]; HUANG HUA-PIN [US]; MASSELINK JOHN K [US]; TONELLI ALFRED P [US]


Application No.: US20110038935A1  Published: 17/Feb/2011

Title: ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE THEREOF

Applicant/Assignee:

Application No.: 12/746622   Filing Date: 08/Dec/2008

Abstract:

The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.

Priority: US20070005725P Applic. Date: 2007-12-06; US20080091599P Applic. Date: 2008-08-25; WO2008US85876 Applic. Date: 2008-12-08

Inventor: MARASCO WAYNE A [US]; SUI JIANHUA [US]; LIDDINGTON ROBERT C [US]


Application No.: US20110038936A1  Published: 17/Feb/2011

Title: SYSTEM AND METHOD FOR ELECTROSPUN DRUG LOADED BIODEGRADABLE CHEMOTHERAPY APPLICATIONS

Applicant/Assignee:

Application No.: 12/858435   Filing Date: 17/Aug/2010

Abstract:

Biodegradable resorbable drug delivery systems characterized by an electrospun biodegradable resorbable polymeric fiber matrix with at least one therapeutic agent incorporated into the fibers of the matrix, wherein the fiber matrix has an interfibrillar space of at least 65% by volume. Therapeutic methods for delivering a chemotherapeutic agent to body cavities from which a tumor has been excised and for strengthening weakened blood vessel walls are also disclosed.

Priority: US20090234546P Applic. Date: 2009-08-17

Inventor: GRISWOLD KIMBERLY ANN [US]; PRESTIGIACOMO CHARLES J [US]


Application No.: US20110038938A1  Published: 17/Feb/2011

Title: Compositions for tissue augmentation

Applicant/Assignee:

Application No.: 12/859004   Filing Date: 18/Aug/2010

Abstract:

The embodiments set forth herein provide biocompatible self-setting compositions suitable for use in tissue augmentation applications. The biocompatible self-setting compositions described herein exhibit advantageous theological properties and may be applied to a site in the body of a patient by injecting the composition through a 20-30 gauge needle. Once applied to a site in the body, the composition sets to a slow resorbing or substantially non-resorbing matrix. Advantageously, exposure of the composition material to body heat at its site of use enhances setting of the composition. Composition materials prepared in accordance with the present disclosure may find use in applications involving, for example, soft tissue augmentation such as for dermal fold augmentation, prevention of adhesions, soft tissue void filling, soft tissue bleb creation, urethral sphincter augmentation for treatment of urinary incontinence, treatment of unilateral vocal fold paralysis, and lower esophageal sphincter augmentation for treatment of gastroesophageal reflux disease. In some embodiments, the presently described biocompatible compositions may serve as bone void fillers.

Priority: WO2009US34640 Applic. Date: 2009-02-20; US20080030812P Applic. Date: 2008-02-22

Inventor: ISON IRA C [US]; CAMPBELL BROOKE [US]


Application No.: US20110039800A1  Published: 17/Feb/2011

Title: PROLONGED RELEASE BIOADHESIVE THERAPEUTIC SYSTEMS

Applicant/Assignee:

Application No.: 12/830090   Filing Date: 02/Jul/2010

Abstract:

The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.

Priority: FR20010009811 Applic. Date: 2001-07-23; US2007-715967 Applic. Date: 2007-03-09; US2005-113072 Applic. Date: 2005-04-25; US2002-307938 Applic. Date: 2002-12-03; WO2002FR02635 Applic. Date: 2002-07-23

Inventor: AIACHE JEAN-MARC [FR]; COSTANTINI DOMINIQUE [FR]; CHAUMONT CHRISTINE [FR]


Application No.: US20110039947A1  Published: 17/Feb/2011

Title: SURFACE-MODIFIED NANOPARTICLES

Applicant/Assignee: 3M INNOVATIVE PROPERTIES COMPANY

Application No.: 12/989432   Filing Date: 06/May/2009

Abstract:

A composition comprises surface-modified nanoparticles of at least one metal phosphate. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising at least one organosilane surface modifier comprising at least one organic moiety comprising at least about six carbon atoms.

Priority: US20080051468P Applic. Date: 2008-05-08; US20080051477P Applic. Date: 2008-05-08; WO2009US43003 Applic. Date: 2009-05-06

Inventor: SHARMA NEERAJ [US]; VU CHOUA C [US]


Application No.: US20110045041A1  Published: 24/Feb/2011

Title: COMPOSITIONS AND METHODS FOR THE DELIVERY OF AGENTS

Applicant/Assignee:

Application No.: 12/933337   Filing Date: 26/Mar/2009

Abstract:

The present invention relates to methods and compositions for the delivery of cosmetics and medicants. In some embodiments, the invention relates to compositions comprising both hydrophobic and hydrophilic polymers. In preferred embodiments, the invention relates to the delivery of peptides, small molecules and other bioactive compounds using the compositions and methods disclosed herein.

Priority: US20080040016P Applic. Date: 2008-03-27; WO2009US01910 Applic. Date: 2009-03-26

Inventor: GOLUBOVIC-LIAKOPOULOS NEVENKA [US]; SHAH BHAVDEEP [US]; ANDERSEN ERIK [DK]


Application No.: US20110045070A1  Published: 24/Feb/2011

Title: COMBINATION THERAPY

Applicant/Assignee:

Application No.: 12/920345   Filing Date: 27/Feb/2009

Abstract:

The present invention provides a composition comprising zinc and trimethoprim, particularly in a weight ration of about 1:3 to about 1:7, as well as a sustained- or prolonged-release preparation which comprises trimethoprim and zinc and a biodegradable polymer providing a clinically useful composition which has prolonged release over a long period of time.

Priority: GB20080003948 Applic. Date: 2008-03-03; WO2009EP52394 Applic. Date: 2009-02-27

Inventor: EL-HABBAL MAGDI [GB]


Application No.: US20110045071A1  Published: 24/Feb/2011

Title: GENERATION OF A NOVEL TYPE OF ANTI-INFLAMMATORY MACROPHAGES FOR CLINICAL USE

Applicant/Assignee:

Application No.: 12/862506   Filing Date: 24/Aug/2010

Abstract:

The invention relates to a purified, novel anti-inflammatory population of macrophage and methods of making and using such macrophage.

Priority: US20090236427P Applic. Date: 2009-08-24

Inventor: HEMATTI PEIMAN [US]; KIM JAEHYUP [US]


Application No.: US20110045072A1  Published: 24/Feb/2011

Title: PHARMACEUTICAL COMPOSITION, DRESSING AND METHOD FOR TREATING SKIN LESION, INTERMEDIATE COMPOSITION AND PROCESS FOR PREPARING SAID DRESSING, AND USE OF CERIUM SALT ASSOCIATED WITH A COLLAGEN MATRIX

Applicant/Assignee:

Application No.: 12/866726   Filing Date: 09/Feb/2009

Abstract:

The present invention refers to a pharmaceutical composition for treating skin lesion, comprising a cerium salt on a collagen matrix and a dermatologically acceptable carrier. In addition, the present invention also provides an intermediate composition for preparing a dressing for treating skin lesion and a process for preparing such dressing by lyophilizing said intermediate composition. The present invention also refers to a dressing for treating skin lesion, comprising a cerium salt on a collagen matrix, as well as to the use of a cerium salt associated with collagen in the preparation of the pharmaceutical composition or dressing according to the present invention. Another embodiment of the present invention is a method for treating skin lesion by applying such pharmaceutical composition or dressing on said skin lesion. The composition or dressing of the present invention can be used in topical applications in a variety of lesion types, such as skin lesions involving the release of toxins related to microbial proteins on human or animal organisms, or those so-called HSPs (heat shock proteins)

burns which involve burned skin toxin formation or LPC (lipoprotein complex)

chronically ulcerate skin lesions in which there is an overproduction of proteinase

skin lesions of difficult resolution, in which control of exudate overproduction is required

and critically infected or colonized skin lesions.

Priority: BR2008PI00085 Applic. Date: 2008-02-08; US2008-202599 Applic. Date: 2008-09-02; WO2009BR00031 Applic. Date: 2009-02-09

Inventor: DA CRUZ LUIZ EDUARDO [BR]


Application No.: US20110045073A1  Published: 24/Feb/2011

Title: METHODS AND COMPOSITIONS OF SPHINGOLIPID FOR PREVENTING AND TREATING MICROBIAL INFECTIONS

Applicant/Assignee: INNOPACT B.V

Application No.: 12/867481   Filing Date: 19/Feb/2009

Abstract:

The present invention relates to controlled release composition for preventing and/or treating microbial infections in the oral cavity of a subject, said composition comprising a controlled delivery matrix which matrix has releasably associated therewith an amount of between 0.000009 and 5 wt % of a sphingolipid, wherein the composition provides a sphingolipid-release-profile in the oral cavity of a subject, wherein said release-profile is maintained for between 15 seconds and 24 hours and wherein said release-profile provides for a concentration of said sphingolipid in the saliva of said subject of between 20 [mu]mole/L and 250 [mu]mole/L.

Priority: EP20080151619 Applic. Date: 2008-02-19; WO2009NL50075 Applic. Date: 2009-02-19

Inventor: EKHART PETER FRANK [NL]


Application No.: US20110045074A1  Published: 24/Feb/2011

Title: MATRIX TYPE SUSTAINED-RELEASE PREPARATION CONTAINING BASIC DRUG OR SALT THEREOF AND, METHOD FOR MANUFACTURING THE SAME

Applicant/Assignee: EISAI R&D MANAGEMENT CO., LTD

Application No.: 12/910313   Filing Date: 22/Oct/2010

Abstract:

A matrix type sustained-release preparation and a manufacturing method therefor are provided wherein dissolution with low pH dependence of a basic drug or a salt thereof at the early stage of dissolution can be ensured in a dissolution test, and wherein as the dissolution test proceeds, a ratio of a dissolution rate of the basic drug or the salt thereof in an acidic test solution to a dissolution rate of the basic drug or the salt thereof in a neutral test solution (dissolution rate in the acidic test solution/dissolution rate in the neutral test solution) decreases with dissolution time at the late stage of dissolution, as compared to the early stage of dissolution. According to the present invention, the matrix type sustained-release preparation contains a basic drug or a salt thereof and at least one enteric polymer, in which solubility of the basic drug or the salt thereof in a 0.1 N hydrochloric acid solution and a neutral aqueous solution, pH 6.0 is higher than in a basic aqueous solution, pH 8.0.

Priority: JP20040376770 Applic. Date: 2004-12-27; JP20050110404 Applic. Date: 2005-04-06; JP20050132338 Applic. Date: 2005-04-28; US2008-794212 Applic. Date: 2008-04-01; WO2005JP23853 Applic. Date: 2005-12-27; US20050675482P Applic. Date: 2005-04-28

Inventor: UEKI YOSUKE [JP]; FUJIOKA SATOSHI [JP]


Application No.: US20110045075A1  Published: 24/Feb/2011

Title: TISSUE COATING FOR PREVENTING UNDESIRED TISSUE-TO-TISSUE ADHESIONS

Applicant/Assignee: E. I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/989843   Filing Date: 01/Jun/2009

Abstract:

Disclosed herein are a kit and a method for forming a tissue coating that prevents undesired tissue-to-tissue adhesions resulting from trauma, surgery, infection, or other stimulus. The tissue coating is a hydrogel formed by reacting an aminocarboxymethyldextran containing primary amine groups with an oxidized carboxymethylcellulose containing aldehyde groups.

Priority: US20080058232P Applic. Date: 2008-06-03; US20080058239P Applic. Date: 2008-06-03; WO2009US45777 Applic. Date: 2009-06-01

Inventor: SHUEY STEVEN W [US]


Application No.: US20110045077A1  Published: 24/Feb/2011

Title: ENCAPSULATED PANCREATIC ISLET CELL PRODUCTS AND METHODS OF USE THEREOF

Applicant/Assignee:

Application No.: 12/514753   Filing Date: 13/Nov/2007

Abstract:

This invention is directed, inter alia, to encapsulated cell products, compositions comprising the same and uses thereof to treat diabetes, and related complications, increase islet cell masses, improve a metabolic profile in a subject, and other related conditions. Processes to produce the encapsulated islet cell product are described.

Priority: US20060858352P Applic. Date: 2006-11-13; WO2007US23760 Applic. Date: 2007-11-13

Inventor: WEIR GORDON [US]; COLTON CLARK K [US]; O'SULLIVAN ESTHER [IE]; LEWIS AMY [US]


Application No.: US20110046606A1  Published: 24/Feb/2011

Title: Catheter injectable depot compositions and uses thereof

Applicant/Assignee: DURECT CORPORATION

Application No.: 12/925408   Filing Date: 18/Oct/2010

Abstract:

Catheter injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having miscibility in water of less than or equal to 7 wt. % at 25 DEG C., in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent. The solvent comprises an aromatic alcohol, an ester of an aromatic acid, an aromatic ketone, or mixtures thereof. The compositions are have substantially improved the shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.

Priority: US2002-295603 Applic. Date: 2002-11-14; US20010336307P Applic. Date: 2001-11-14; US20020399882P Applic. Date: 2002-07-31

Inventor: CHEN GUOHUA [US]; HOUSTON PAUL R [US]; KLEINER LOTHAR [US]; SPALTRO JOHN J [US]


Application No.: US20110052682A1  Published: 03/Mar/2011

Title: METHODS FOR ENHANCING THE RELEASE AND ABSORPTION OF WATER INSOLUBLE ACTIVE AGENTS

Applicant/Assignee:

Application No.: 12/638212   Filing Date: 15/Dec/2009

Abstract:

Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.

Priority: US20080122497P Applic. Date: 2008-12-15

Inventor: FATMI AQEEL [US]; KIM TAE KYOUNG [US]; MADRIGAL KARLA E [US]


Application No.: US20110052684A1  Published: 03/Mar/2011

Title: PHARMACEUTICAL COMPOSITION

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 12/864453   Filing Date: 28/Jan/2009

Abstract:

The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.

Priority: US20080023951P Applic. Date: 2008-01-28; WO2009EP50924 Applic. Date: 2009-01-28

Inventor: WALSH EDWIN [IE]; JACKSON GRAHAM [BB]; OBEREGGER WERNER [CA]; JIN XIAOPIN [CA]


Application No.: US20110052685A1  Published: 03/Mar/2011

Title: GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHEN

Applicant/Assignee: DEPOMED, INC

Application No.: 12/872723   Filing Date: 31/Aug/2010

Abstract:

Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

Priority: US20090238374P Applic. Date: 2009-08-31

Inventor: HOU SUI YUEN EDDIE [US]; VARGAS THADD [US]


Application No.: US20110052691A1  Published: 03/Mar/2011

Title: Sustained Release Systems and Preparation Method Thereof

Applicant/Assignee: KAOHSIUNG MEDICAL UNIVERSITY

Application No.: 12/832248   Filing Date: 08/Jul/2010

Abstract:

The present invention relates to a hydrophilic drug and [beta]-tricalcium phosphate ([beta]-TCP) coating on a surface area of biopolymer matrix to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising providing a surface are of biopolymer matrix coated with a hydrophilic drug and [beta]-TCP.

Priority: US20090237696P Applic. Date: 2009-08-28

Inventor: FU YIN-CHIN [TW]; WANG CHIH-KUANG [TW]; WANG GWO-JAW [TW]; HO MEI-LING [TW]; CHANG JE-KEN [TW]; TZENG CHERNG-CHYI [TW]


Application No.: US20110052692A1  Published: 03/Mar/2011

Title: NOVEL HYDROGELS AND USES THEREOF

Applicant/Assignee: UNIVERSITY OF DELAWARE

Application No.: 12/847476   Filing Date: 30/Jul/2010

Abstract:

The present invention provides novel hydrogels and methods of making and using such hydrogels. The present invention provides hydrogels that may be formed by the self-assembly of peptides in solution. Such self-assembly may be brought about by a change in one or more characteristics of the solution. Characteristics of the solution that may be changed include pH, ionic strength, temperature, and concentration of one or more specific ions. In addition, hydrogels of the invention may be disassembled by changing one or more characteristic of the hydrogel such as pH, ionic strength, temperature, and concentration of one or more specific ions.

Priority: US2006-598763 Applic. Date: 2006-11-14; US20050735846P Applic. Date: 2005-11-14; US20060827156P Applic. Date: 2006-09-27

Inventor: OZBAS BULENT [US]; KRETSINGER JULIANA [US]; BUTTERICK LISA A [US]; RAJAGOPAL KARTHIKAN [US]; POCHAN DARRIN J [US]; SCHNEIDER JOEL P [US]


Application No.: US20110052693A1  Published: 03/Mar/2011

Title: METHOD FOR PRODUCING ARTIFICIAL SKIN

Applicant/Assignee:

Application No.: 12/867357   Filing Date: 19/Sep/2008

Abstract:

An object of the invention is to provide artificial skin that does not contain any animal-derived material or pathogen and has excellent biocompatibility. The invention provides, as a solution means, a method for producing artificial skin comprising the steps of: (A) forming a dermal layer by solidifying a mixture of dermal fibroblasts and a peptide hydrogel having a fibrous structure

and (B) forming an epidermal layer by seeding skin keratinocytes onto the dermal layer obtained in Step (A), and culturing the epidermal keratinocytes.

Priority: JP20080049337 Applic. Date: 2008-02-29; WO2008JP67024 Applic. Date: 2008-09-19

Inventor: KAO BUNSHO [JP]; HOSAKA YOSHIAKI [JP]; IIJIMA AYUMI [JP]


Application No.: US20110052694A1  Published: 03/Mar/2011

Title: USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES

Applicant/Assignee: ALLTRANZ INC

Application No.: 12/873248   Filing Date: 31/Aug/2010

Abstract:

Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.

Priority: US20090238524P Applic. Date: 2009-08-31

Inventor: STINCHCOMB AUDRA LYNN [US]; BANKS STAN LEE [US]; GOLINSKI MIROSLAW JERZY [US]; HOWARD JEFFERY LYNN [US]; HAMMELL DANA CARMEL [US]


Application No.: US20110052695A1  Published: 03/Mar/2011

Title: DRUG DELIVERY PLATFORMS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF

Applicant/Assignee: ALLERGAN, INC

Application No.: 12/873563   Filing Date: 01/Sep/2010

Abstract:

The present specification provides drug delivery platforms useful for the controlled release of a compound over time in an individual.

Priority: US2010-764039 Applic. Date: 2010-04-20; US20090170895P Applic. Date: 2009-04-20

Inventor: JIANG GUANG-LIANG [US]; COLLETTE ADAM L [US]; HORAN REBECCA L [US]; CHEN JING SONG [US]; ALTMAN GREGORY H [US]; IM WHA BIN [US]


Application No.: US20110052696A1  Published: 03/Mar/2011

Title: DENDRIMERS WITH INTERIOR AND EXTERIOR FUNCTIONALITIES COMPRISING OF AZIDE OR ALKYNE GROUPS FOR POST-FUNCTIONALIZATION BY THE HUISGEN CLICK CYCLOADDITION

Applicant/Assignee: POLYMER FACTORY SWEDEN AB

Application No.: 12/990676   Filing Date: 06/May/2009

Abstract:

A dendritic structure includes a core and repeating units, wherein the repeating units comprise units of the type ABxCy, wherein x is 2, 3, or 4, wherein y is 1, 2, or 3, wherein C is selected from the group consisting of azides and alkynes, and wherein every repeating unit is bound to at least one other unit with at least one bond selected from the group consisting of the group consisting of an ester, an amide, a thioether, an ether, a urethane, an amine, and an imine. Advantages include that a "one-pot" growth of the dendritic structure is possible. It is possible to have more functional groups in a dendritic structure. It is possible to add different functional groups simultaneously both to an inner layer and to an outer layer in a dendritic structure.

Priority: SE20080001015 Applic. Date: 2008-05-07; US20080051212P Applic. Date: 2008-05-07; WO2009SE50488 Applic. Date: 2009-05-06

Inventor: HULT ANDERS [SE]; MALKOCH MICHAEL [SE]; ANTONI PER [SE]


Application No.: US20110054041A1  Published: 03/Mar/2011

Title: Oil-In-Water Type Cosmetic Emulsion

Applicant/Assignee:

Application No.: 12/920576   Filing Date: 11/Mar/2009

Abstract:

The invention provides an oil-in-water type cosmetic emulsion which can be applied to the skin without stickiness, and impart resilient and supple feel to the skin, while having good stability without causing viscosity decrease or separation even during a long-term storage. The oil-in-water type cosmetic emulsion comprises (a) a higher alcohol having 14 to 22 carbon atoms, (b) a hydrophilic polyoxyethylene alkyl ether, and (c) a glycerin monoalkyl ether, wherein alkyl moieties in (b) and (c) are linear saturated alkyl chains, and molar concentrations of (a) to (c) satisfy a relation [(b)+(c)]/(a)=0.1 to 1.0, and preferably satisfy a relation [(a)+(c)]/(b)=3 to 20.

Priority: JP20080060824 Applic. Date: 2008-03-11; WO2009JP01085 Applic. Date: 2009-03-11

Inventor: ASAI AYUMI [JP]


Application No.: US20110059169A1  Published: 10/Mar/2011

Title: Method and Composition for Administering an NMDA Receptor Antagonist to a Subject

Applicant/Assignee: ADAMAS PHARMACEUTICALS, INC

Application No.: 12/840132   Filing Date: 20/Jul/2010

Abstract:

The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.

Priority: US2009-512701 Applic. Date: 2009-07-30; US2005-285905 Applic. Date: 2005-11-22; US20040630885P Applic. Date: 2004-11-23; US20050701857P Applic. Date: 2005-07-22; US20040635365P Applic. Date: 2004-12-10

Inventor: WENT GREGORY T [US]; FUITZ TIMOTHY J [US]; PORTER SETH [US]; MEYERSON LAURENCE R [US]; BURKOTH TIMOTHY S [US]


Application No.: US20110059172A1  Published: 10/Mar/2011

Title: THERAPEUTIC COMPOSITIONS

Applicant/Assignee:

Application No.: 12/865094   Filing Date: 28/Jan/2009

Abstract:

Therapeutic compositions containing therapeutic agents and poly(beta-amino esters) or polymers thereof are described. These tertiary amine-containing polymers are preferably biodegradable and biocompatible. Nanoparticles and microparticles containing polymer/therapeutic agent complexes are also described.

Priority: US20080024451P Applic. Date: 2008-01-29; WO2009US32263 Applic. Date: 2009-01-28

Inventor: TZIANABOS ARTHUR [US]; HEARTLEIN MICHAEL W [US]


Application No.: US20110059173A1  Published: 10/Mar/2011

Title: COMPOSITIONS AND METHODS FOR PROMOTING WOUND HEALING AND TISSUE REGENERATION

Applicant/Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Application No.: 12/871461   Filing Date: 30/Aug/2010

Abstract:

Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.

Priority: US2007-721529 Applic. Date: 2007-06-12; WO2005US46442 Applic. Date: 2005-12-20; US20040638366P Applic. Date: 2004-12-21; US20050671796P Applic. Date: 2005-04-15

Inventor: GOURDIE ROBERT [US]; GHATNEKAR GAUTAM [US]; JOURDAN JANE [US]


Application No.: US20110059174A1  Published: 10/Mar/2011

Title: PKCdelta REGULATES NEUROINFLAMMATORY EVENTS

Applicant/Assignee: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC

Application No.: 12/876666   Filing Date: 07/Sep/2010

Abstract:

This invention relates to methods and pharmaceutical compositions for regulating the levels of proinflammatory substances released from activated microglia using a protein kinase C delta (PKCd) inhibitor. In particular, it relates to decreasing the levels of proinflammatory substances produced within the microglial cells or released from activated microglical cells or both. Accordingly, the invention provides for the treatment of diseases, disorders, and conditions where neuroinflammation is implicated. The invention also relates to methods of using PKCd inhibitors and pharmaceutical compositions to treat diseases, disorders, and conditions associated with activated microglia.

Priority: US20090240906P Applic. Date: 2009-09-09

Inventor: KANTHASAMY ANUMANTHA GOUNDER [US]; KANTHASAMY ARTHI [US]


Application No.: US20110059985A1  Published: 10/Mar/2011

Title: NOVEL FORMULATION

Applicant/Assignee:

Application No.: 12/739518   Filing Date: 22/Oct/2008

Abstract:

The present invention relates to a pharmaceutical formulation comprising a pharmaceutically activeagent

water

a polyethylene glycol or a poloxamer

and a polyethylene glycol mono- or di-ether. Preferably the pharmaceutically active agent is an anti-fungal or anti-mycotic agent. Preferably the pharmaceutically active agent is lipophilic and/or keratinophilic. The present invention also relates to the use of the formulation in treating diseases, disorders or pathological conditions of the nail or skin, such as onychomycosis, dermatomycosis and other mycoses. The present invention also relates to a method of administering a pharmaceutically active agent to a subject by applying the formulation comprising the pharmaceutically active agent to a nail or skin of the subject. The present invention further relates to a method of preparing the formulation.

Priority: GB20070020716 Applic. Date: 2007-10-23; WO2008GB50978 Applic. Date: 2008-10-22

Inventor: SCHMIDTS THOMAS M [DE]; RUNKEL FRANK [DE]


Application No.: US20110064800A1  Published: 17/Mar/2011

Title: NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CYCLOSPORINE

Applicant/Assignee:

Application No.: 12/888530   Filing Date: 23/Sep/2010

Abstract:

The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.

Priority: US2007-568692 Applic. Date: 2007-08-22; WO2006US13631 Applic. Date: 2006-04-12; US20050670836P Applic. Date: 2005-04-12

Inventor: JENKINS SCOTT A [US]; LIVERSIDGE GARY [US]


Application No.: US20110064809A1  Published: 17/Mar/2011

Title: SCAFFOLDS

Applicant/Assignee:

Application No.: 12/673600   Filing Date: 14/Aug/2008

Abstract:

The invention relates to methods of preparing tissue implants for use in the augmentation, repair and regeneration of tissues.

Priority: GB20070015806 Applic. Date: 2007-08-14; GB20070021840 Applic. Date: 2007-11-07; GB20080008645 Applic. Date: 2008-05-13; WO2008GB02743 Applic. Date: 2008-08-14

Inventor: LANGFORD KELLY [GB]; BURDON DREW [GB]; WHYTE MUNA [GB]


Application No.: US20110064810A1  Published: 17/Mar/2011

Title: TISSUE ENGINEERING METHOD FOR ORGAN RECONSTRUCTION USING INJECTABLE MATRIX

Applicant/Assignee:

Application No.: 12/948918   Filing Date: 18/Nov/2010

Abstract:

The various embodiments herein relate to an injectable matrix used for regeneration, reconstruction, repair or replacement of organ or tissue. The injectable matrix consists of a synthetic and natural polymer, a stem cell niche and nanoparticles in the form of cups filled with growth factor and physiologic agent. The embodiments herein also provide a method for regeneration, reconstruction, repair or replacement of organ or tissue. In the method, an injectable matrix is injected to create three dimensional matrix system or network in an area of the desired tissue or organ, migration of blood circulatory stem cells or tissue-specific progenitor cells occur to the injected area of the tissue or organ. The growth factors and physiological agent present in the nanocups are released. The stem cells proliferate and differentiate to form the desired organ or tissue.

Priority:

Inventor: GHANAVI JALALEDIN [IR]


Application No.: US20110070173A1  Published: 24/Mar/2011

Title: Oil-in-Water Type Emulsion Cosmetic Composition

Applicant/Assignee: SHISEIDO CO., LTD

Application No.: 10/540041   Filing Date: 26/Dec/2003

Abstract:

This object of the invention is to provide an oil-in water emulsion cosmetic composition having fine sense of use and excellent dispersion stability, and does not occur twisting upon drying. In advance, a hydrophobicized powder is dispersed in an oil phase and processed with wet type disperser such as beads mill, dispersing solution is obtained. And then said dispersing solution and a water phase are processed with homomixer, an oil-in water emulsion composition having excellent sense of use and dispersibility of powder after applying to skin can be obtained. The dispersing stability of powder is extremely good by using a particular dispersant and a particular oil component. The dispersion stability of powder is further improved, and the precipitation and creaming of the emulsion particle can be solved by blending thickener having salt tolerance. Sticky feeling is solved by using succinoglycan as a thickener, and twisting is solved by plasticizing said succinoglycan.

Priority: JP20020376841 Applic. Date: 2002-12-26; JP20020381342 Applic. Date: 2002-12-27; WO2003JP16953 Applic. Date: 2003-12-26

Inventor: YOSHIDA SUSUMU [JP]; NAKAMURA TADASHI [JP]; NAKAMURA-SOLE HEIR KEIKO [JP]; ISHIKUBO AKIRA [JP]; NASU AKIO [JP]


Application No.: US20110070276A1  Published: 24/Mar/2011

Title: BIOACTIVE KERATIN PEPTIDES

Applicant/Assignee: KERAPLAST TECHNOLOGIES, LTD

Application No.: 12/393694   Filing Date: 26/Feb/2009

Abstract:

Compositions containing biologically active peptides are disclosed. Active peptides are isolated fragments derived from human hair or sheep wool keratin proteins. Compositions may be prepared for pharmaceutical or topical administration or for use in cosmetic preparations.

Priority: US2003-352786 Applic. Date: 2003-01-28; US20020352396P Applic. Date: 2002-01-28

Inventor: COWSAR DONALD R [US]


Application No.: US20110070284A1  Published: 24/Mar/2011

Title: BIOLOGIC MATRICES COMPRISING ANTI-INFECTIVE METHODS AND COMPOSITIONS RELATED THERETO

Applicant/Assignee: MUSCULOSKELETAL TRANSPLANT FOUNDATION

Application No.: 12/918991   Filing Date: 23/Feb/2009

Abstract:

Described herein are methods and compositions related to biologic matrices comprising at least one anti-infective. In certain embodiments, the invention relates to a biologic matrix comprising a slowed release anti-infective agent. In a particular embodiment, the invention relates to an acellular dermal matrix comprising a slowed release antiinfective agent, wherein the anti-infective agent is triclosan. In further embodiments, the the biologic matrix is suitable for use in surgical procedures, such as, for example, for the replacement of damaged or inadequate integumental tissue or for the repair, reinforcement or supplemental support of soft tissue defects.

Priority: US20080030930P Applic. Date: 2008-02-22; WO2009US34891 Applic. Date: 2009-02-23

Inventor: DEPAULA CARL ALEXANDER [US]; GERTZMAN ARTHUR A [US]; SUNWOO MOONHAE [US]


Application No.: US20110070306A1  Published: 24/Mar/2011

Title: Antimicrobial nanoemulsion compositions and methods

Applicant/Assignee:

Application No.: 11/506442   Filing Date: 18/Aug/2006

Abstract:

The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs.

Priority: US2002-179547 Applic. Date: 2002-06-25; US2001-965447 Applic. Date: 2001-09-27; US2001-891086 Applic. Date: 2001-06-25; US2000-751059 Applic. Date: 2000-12-29; US2000-561111 Applic. Date: 2000-04-28; US1999-474866 Applic. Date: 1999-12-30; US19990131638P Applic. Date: 1999-04-28

Inventor: BAKER JR JAMES R [US]; HAMOUDA TAREK [US]; SHIH AMY [US]; MYC ANDRZEJ [US]


Application No.: US20110070307A1  Published: 24/Mar/2011

Title: TISSUE REGENERATION

Applicant/Assignee:

Application No.: 12/955101   Filing Date: 29/Nov/2010

Abstract:

A method including positioning a delivery device at a location in a vessel within a mammalian body, introducing a first treatment agent including a cellular component through the delivery device, and introducing a different second treatment agent disposed in a carrier through the delivery device. A method including identifying an infarct region within myocardial tissue and a border region of perfused tissue adjacent the infarct region, introducing a treatment agent including a cellular component to the border region, and introducing a plurality of microparticles to the infarct region. A kit including a treatment agent including a cellular component in a form suitable for percutaneous delivery, and a separate amount of a plurality of microparticles in a form suitable for percutaneous delivery.

Priority: US2004-016017 Applic. Date: 2004-12-17

Inventor: MANDRUSOV EVGENIA [US]; CLAUDE CHARLES [US]; MICHAL EUGENE T [US]


Application No.: US20110070309A1  Published: 24/Mar/2011

Title: PHARMACEUTICAL FORMULATION COMPRISING A WATER-INSOLUBLE ACTIVE AGENT

Applicant/Assignee: NOVARTIS PHARMA AG

Application No.: 12/953259   Filing Date: 23/Nov/2010

Abstract:

A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second solvents are removed from the solution to produce particles comprising the active agent and the excipient. In one version, the excipient comprises an amino acid and/or a phospholipid. A pharmaceutical formulation made by a version of the invention comprises particles comprising an active agent and an excipient which at least partially encapsulates the active agent, wherein the excipient is more soluble in water than the active agent.

Priority: US2004-855798 Applic. Date: 2004-05-27; US20030474087P Applic. Date: 2003-05-28

Inventor: VEHRING REINHARD [US]; MILLER DANFORTH P [US]; LECHUGA-BALLESTEROS DAVID [US]


Application No.: US20110071228A1  Published: 24/Mar/2011

Title: INSECTICIDAL FORMULATIONS WITH IMPROVED LONG-TERM EFFECT ON SURFACES

Applicant/Assignee: BAYER CROPSCIENCE AG

Application No.: 12/993154   Filing Date: 19/May/2009

Abstract:

The present invention relates to compositions for the control of pests, in particular insecticidal suspension concentrates and spray solutions made from them, to processes for their preparation, and to the use of such formulations for the sustained control of animal pests (arthropods) on a variety of surfaces. The present invention furthermore relates to the use of certain polymer dispersions in pesticides, in particular to their use for extending the long-term activity of these compositions when they are applied to surfaces. The present invention furthermore relates to the use of the compositions according to the invention for controlling parasites, in particular ectoparasites, in animals.

Priority: EP20080156623 Applic. Date: 2008-05-21; EP20080158297 Applic. Date: 2008-06-16; US20090172265P Applic. Date: 2009-04-24; WO2009EP03546 Applic. Date: 2009-05-19

Inventor: KIJLSTRA JOHAN [DE]; ROSENFELDT FRANK [DE]; NENTWIG GUENTHER [DE]; GUTSMANN VOLKER [DE]; SONNECK RAINER [DE]; ROSS DOUGLAS [US]


Application No.: US20110076239A1  Published: 31/Mar/2011

Title: REDUCED-SWEETENER PRODUCTS, FLAVORING MIXTURES FOR SAID REDUCED-SWEETENER PRODUCTS AND PROCESS FOR THE PRODUCTION OF PRODUCTS OF THIS TYPE

Applicant/Assignee: SYMRISE AG

Application No.: 12/871303   Filing Date: 30/Aug/2010

Abstract:

A flavoring mixture, comprising (i) one or more sweet-tasting substances, selected from the group of naturally occurring sweet-tasting substances and the physiologically compatible salts thereof without phyllodulcin and the physiologically compatible salts thereof, and (ii) phyllodulcin and/or one or more of the physiologically compatible salts thereof, wherein the ratio of the sucrose equivalence of the concentration of the substance or substances of group (i) to the sucrose equivalence of the concentration of the substance or substances of group (i) is >=2.

Priority: US20090237866P Applic. Date: 2009-08-28

Inventor: REICHELT KATHARINA [DE]; LEY JAKOB PETER [DE]; HOFFMANN-LUECKE PETRA [DE]; BLINGS MARIA [DE]; PAETZ SUSANNE [DE]; RIESS THOMAS [DE]


Application No.: US20110076311A1  Published: 31/Mar/2011

Title: CERAMIDE DISPERSION

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: 12/994769   Filing Date: 29/May/2009

Abstract:

A ceramide dispersion, which includes at least: natural-ceramide-containing particles that are dispersed in an aqueous phase as an oil-phase component

and at least one surfactant, wherein the natural-ceramide-containing particles contain one or more natural ceramides in an amount of 50% by mass or higher with respect to the total mass of the oil components contained in an oil phase, and have a volume average particle diameter of from 0.5 nm to 100 nm

and the ceramide dispersion contains, in the at least one surfactant, at least one polyglycerin fatty acid ester having an HLB of from 10 to 16.

Priority: JP20080141181 Applic. Date: 2008-05-29; WO2009JP59865 Applic. Date: 2009-05-29

Inventor: SERIZAWA SHINICHIRO [JP]; MORI HISAHIRO [JP]; ARAKAWA JUN [JP]; TASHIRO TOMOKO [JP]; KUBO TOSHIAKI [JP]; NAKAMURA YOSHISADA [JP]; UEYAMA TOMOHIDE [JP]


Application No.: US20110076321A1  Published: 31/Mar/2011

Title: SELF-ADHESIVE POLYMER MATRIX CONTAINING SEA ALGAE EXTRACT

Applicant/Assignee: BEIERSDORF AG

Application No.: 12/887578   Filing Date: 22/Sep/2010

Abstract:

A self-adhesive polymer matrix which comprises a polymer that forms a gel in water, water, a sea algae extract, and a monohydric or polyhydric alcohol.

Priority: DE20021060872 Applic. Date: 2002-12-23; DE20021060873 Applic. Date: 2002-12-23; US2005-157959 Applic. Date: 2005-06-22; WO2003EP14793 Applic. Date: 2003-12-23; US2005-157946 Applic. Date: 2005-06-22; WO2003EP14792 Applic. Date: 2003-12-23

Inventor: WOELLER KARL-HEINZ [DE]; BERG THORSTEN [DE]; KRUSE INGE [DE]; WOLBER RAINER [DE]


Application No.: US20110076322A1  Published: 31/Mar/2011

Title: Amphoteric liposomes

Applicant/Assignee:

Application No.: 12/807707   Filing Date: 09/Sep/2010

Abstract:

A serum-stable mixture of lipids capable of encapsulating an active agent to form a liposome, said mixture comprising phosphatidylcholine and phosphatidylethanolamine in a ratio in the range of about 0.5 to about 8. The mixture may also include pH sensitive anionic and cationic amphiphiles, such that the mixture is amphoteric, being negatively charged or neutral at pH 7.4 and positively charged at pH 4. Amphoteric liposomes comprising such a mixture may be used for encapsulating nucleic acid therapeutics, such as oligonucleotides and DNA plasmids. The drug/lipid ratio may be adjusted to target the liposomes to particular organs or other sites in the body.

Priority: EP20050020216 Applic. Date: 2005-09-15; EP20050020217 Applic. Date: 2005-09-15; EP20050020218 Applic. Date: 2005-09-15; WO2005EP11905 Applic. Date: 2005-11-04; WO2005EP11908 Applic. Date: 2005-11-04; EP20050090322 Applic. Date: 2005-11-21; EP20060113784 Applic. Date: 2006-05-10; US2006-521857 Applic. Date: 2006-09-15; US20050717199P Applic. Date: 2005-09-15; US20050717291P Applic. Date: 2005-09-15; US20050717293P Applic. Date: 2005-09-15

Inventor: PANZNER STEFFEN [DE]; KERWITZ YVONNE [DE]; RAUCHHAUS UNA [DE]; LUTZ SILKE [DE]; ENDERT GEROLD [DE]


Application No.: US20110076326A1  Published: 31/Mar/2011

Title: MODIFIED PROTEIN EXCIPIENT FOR DELAYED-RELEASE TABLET

Applicant/Assignee:

Application No.: 12/995891   Filing Date: 11/Jun/2009

Abstract:

The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as succmylation, deammation, glytarylation or phosphorylation which decrease the isoelectric point of the protein compared to the protein's native isoelectric point and enhance protem-protem interactions, thereby reducing solubility and swelling, and delaying release of the active ingredient when the formulation is ingested orally. Particularly, the invention relates to tablets that comprise an excipient of chemically-modified food proteins such as soy proteins or -lactoglobulm useful for delaying release of an active ingredient such as a pharmaceutical drug or a probiotic.

Priority: US20080060849P Applic. Date: 2008-06-12; WO2009CA00819 Applic. Date: 2009-06-11

Inventor: CAILLARD ROMAIN [CA]; LECLERC PIERRE-LOUIS [CA]; SUBIRADE MURIEL [CA]


Application No.: US20110076329A1  Published: 31/Mar/2011

Title: GRAFT PROSTHESIS, MATERIAL AND METHODS

Applicant/Assignee:

Application No.: 12/693908   Filing Date: 26/Jan/2010

Abstract:

A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby making the purified structure biocompatible and suitable for grafting on and/or in a patient.

Priority: US2004-811343 Applic. Date: 2004-03-26; US2001-798441 Applic. Date: 2001-03-02; US1997-916490 Applic. Date: 1997-08-22; US19960024542P Applic. Date: 1996-08-23; US19960024693P Applic. Date: 1996-09-06

Inventor: COOK WILLIAM A [US]; HILES MICHAEL C [US]; KOZMA THOMAS G [US]; PATEL UMESH H [US]


Application No.: US20110076330A1  Published: 31/Mar/2011

Title: USE OF ADIPOSE TISSUE-DERIVED STROMAL CELLS IN SPINAL FUSION

Applicant/Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

Application No.: 12/791537   Filing Date: 01/Jun/2010

Abstract:

The present invention encompasses methods and compositions for treating a bone condition. The isolated adipose tissue-derived stromal cell of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications such as in spinal fusion procedures.

Priority: US2005-194270 Applic. Date: 2005-08-01

Inventor: GIMBLE JEFFREY M [US]; LOPEZ MANDI [US]


Application No.: US20110076331A1  Published: 31/Mar/2011

Title: Use of Deuterium Oxide as an Elastase Inhibitor

Applicant/Assignee:

Application No.: 12/988694   Filing Date: 16/Apr/2009

Abstract:

The invention relates to the use of deuterium oxide (D2O) as an elastase inhibitor and especially as an inhibitor of the human neutrophil elastase (HNE). The invention also relates to the use of deuterium oxide for the prophylaxis and/or treatment of HNE-related diseases.

Priority: EP20080007676 Applic. Date: 2008-04-20; WO2009IB05999 Applic. Date: 2009-04-16

Inventor: BAYERL THOMAS [GB]


Application No.: US20110077309A1  Published: 31/Mar/2011

Title: HUMECTANT COMPOSITION

Applicant/Assignee: TAKASAGO INTERNATIONAL CORPORATION

Application No.: 12/959670   Filing Date: 03/Dec/2010

Abstract:

The present invention relates to a humectant composition containing, as component (A), at least one member selected from a menthol derivative represented by the following formula (1) and p-menthane-3,8-diol: in which R is an alkylene group having 2 to 5 carbon atoms which may be substituted with at least one member selected from the group consisting of a methyl group and a hydroxyl group, and n is an integer of 1 to 3. The humectant composition of the present invention provides an excellent moisture-retention effect.

Priority: JP20070008321 Applic. Date: 2007-01-17; US2008-014925 Applic. Date: 2008-01-16

Inventor: YAMAMOTO TETSUYA [JP]; ISHIDA KENYA [JP]


Application No.: US20110081398A1  Published: 07/Apr/2011

Title: MULTI-MECHANISM SURGICAL COMPOSITIONS

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 12/888453   Filing Date: 23/Sep/2010

Abstract:

The present disclosure provides hydrogel compositions having multiple gelation mechanisms. The composition includes at least one component which forms a hydrogel, in combination with a second component which includes a self-assembling peptide capable of forming a self-assembled macromer.

Priority: US20090247707P Applic. Date: 2009-10-01

Inventor: SARGEANT TIMOTHY [US]; STOPEK JOSHUA [US]


Application No.: US20110081411A1  Published: 07/Apr/2011

Title: Orally Administered Corticosteroid Compositions

Applicant/Assignee:

Application No.: 12/896005   Filing Date: 01/Oct/2010

Abstract:

The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

Priority: US20090247642P Applic. Date: 2009-10-01

Inventor: PERRETT STEPHEN [US]; COHEN FREDRIC JAY [US]; VENKATESH GOPI [US]


Application No.: US20110081416A1  Published: 07/Apr/2011

Title: ORDERED MESOPOROUS SILICA MATERIAL

Applicant/Assignee: FORMAC PHARMACEUTICALS N.V

Application No.: 12/905759   Filing Date: 15/Oct/2010

Abstract:

A process for preparing a 2D-hexagonal ordered mesoporous silica material with a substantially uniform pore size in the range of 4 to 30 nm comprising the steps of: preparing an aqueous solution comprising an alkali silicate solution

preparing an aqueous solution comprising a poly(alkylene oxide) triblock copolymer and a buffer with a pH greater than 2 and less than 8, adding said aqueous alkali silicate solution to said aqueous solution giving a pH greater than 2 and less than 8 and allowing a reaction between the components to take place at a temperature in the range of 10 to 100 DEG C., and filtering off, drying and calcinating the reaction product to produce said 2D-hexagonal ordered mesoporous silica material with a substantially uniform pore size. In an alternative procedure both aqueous solutions are fed as liquid streams into an elongated mixing receptacle having a first and a second opening such that the liquid streams of the solutions are each discharged independently into said first opening of said elongated mixing receptacle such that they directly impinge thereby giving a pH in the resulting mixture of greater than 2 and less than 8 and producing a reaction product at a temperature in the range of 10 to 100 DEG C. in said elongated mixing receptacle, which upon emergence from said second opening of said elongated mixing receptacle is filtered off, dried and the surfactant removed.

Priority: GB20080007696 Applic. Date: 2008-04-28; GB20090003395 Applic. Date: 2009-02-27; WO2009EP55122 Applic. Date: 2009-04-28; US20080201532P Applic. Date: 2008-12-11; US20080137673P Applic. Date: 2008-08-01; US20080125795P Applic. Date: 2008-04-28; US20100324070P Applic. Date: 2010-04-14

Inventor: JAMMAER JASPER [BE]; AERTS ALEXANDER [BE]; VAN DEN MOOTER GUY [BE]; MARTENS JOHAN [BE]


Application No.: US20110082214A1  Published: 07/Apr/2011

Title: PROCESS FOR THE PREPARATION OF A SOLID DOSAGE FORM, IN PARTICULAR A TABLET, FOR PHARMACEUTICAL USE AND PROCESS FOR THE PREPARATION OF A PRECURSOR FOR A SOLID DOSAGE FORM, IN PARTICULAR A TABLET

Applicant/Assignee: GRUENTHAL GMBH

Application No.: 12/916988   Filing Date: 01/Nov/2010

Abstract:

Process for preparing a powder comprising the steps of providing at least one first component in liquid form at ambient temperature, providing at least one second component having a melting point or melting range in the range from above ambient temperature to below the degradation temperature of said first component, forming a homogenous liquid mixture comprising the at least one first component and the at least one second component by stirring and heating the mixture to or keeping the mixture at a temperature in the range from above the melting point or melting range of the second component and below the degradation temperature of the first component, transferring the liquid mixture to at least one spray congealing unit, spray congealing the mixture, and isolating the powder obtained upon spray congealing.

Priority: EP20080008749 Applic. Date: 2008-05-09; WO2009EP03290 Applic. Date: 2009-05-08

Inventor: FAURE ANNE [BE]; VOORSPOELS JODY FIRIM MARCELINE [BE]; MERTENS ROEL JOS M [BE]; KIEKENS FILIP RENE IRENA [BE]


Application No.: US20110082482A1  Published: 07/Apr/2011

Title: Materials and Methods for Nerve Repair

Applicant/Assignee:

Application No.: 12/966540   Filing Date: 13/Dec/2010

Abstract:

The subject invention pertains to compositions and methods for promoting repair of damaged nerve tissue. The compositions and methods of the subject invention can be employed to restore the continuity of nerve interrupted by disease, traumatic events or surgical procedures. Compositions of the subject invention comprise one or more chondroitin sulfate proteoglycan (CSPG)-degrading enzymes that promote axonal penetration into damaged nerve tissue. The invention also concerns methods for promoting repair of damaged nerve tissue using the present compositions and nerve tissue treated according to such methods. The invention also pertains to kits for nerve repair.

Priority: US2002-218316 Applic. Date: 2002-08-13; US20010311870P Applic. Date: 2001-08-13

Inventor: MUIR DAVID F [US]


Application No.: US20110086085A1  Published: 14/Apr/2011

Title: Carbohydrate Entrapped Active Agent Delivery Composition and Articles Using the Same

Applicant/Assignee:

Application No.: 12/578348   Filing Date: 13/Oct/2009

Abstract:

Delivery compositions and substrates for imparting a volatile active agent to a surface are disclosed herein. To achieve the delivery of the volatile component, a delivery composition of a carbohydrate matrix and a volatile component is incorporated into the carbohydrate matrix to stabilize the volatile for extended periods of time. The delivery composition further comprises a self-generating expelling agent to expel the volatile component onto the contaminated surface or skin upon addition of a triggering agent.

Priority:

Inventor: WENZEL SCOTT W [US]; KOENIG DAVID WILLIAM [US]; SEIDLING JEFFERY RICHARD [US]; CHEN MICHAEL MEIHAN [US]


Application No.: US20110086099A1  Published: 14/Jan/2010

Title: CRYSTALLINE MESOPOROUS OXIDE BASED MATERIALS USEFUL FOR THE FIXATION AND CONTROLLED RELEASE OF DRUGS

Applicant/Assignee: K.U. LEUVEN RESEARCH & DEVELOPMENT

Application No.: 12/498015   Filing Date: 06/Jul/2009

Abstract:

The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.

Priority: GB20030015012 Applic. Date: 2003-06-27; US2005-562307 Applic. Date: 2005-12-23; WO2004BE00094 Applic. Date: 2004-06-28

Inventor: MARTENS JOHAN ADRIAAN [BE]; ANTONIA KIRSCHHOCK CHRISTINE EVA [DE]; BRIGITTE KREMER SEBASTIEN PHILIPPE [BE]; EUGEEN AERTS ALEXANDER JAN MARIA [BE]; MOOTER GUY VAN DEN [BE]; HUMBEECK JAN VAN [BE]


Application No.: US20110086100A1  Published: 14/Apr/2011

Title: Polyethylene Glycol Aerogels for Targeted Delivery of Pharmaceutical Drubs

Applicant/Assignee:

Application No.: 12/902184   Filing Date: 12/Oct/2010

Abstract:

A polyethylene glycol (PEG) aerogel particles having an average particle diameter not substantially above about 2[mu], a volumetric porosity of greater than about 50%, and pore sizes capable of retaining drug molecules. A method for preparing such polyethylene glycol (PEG) aerogel particles includes initiating a catalyzed reaction using a catalyst of PEG forming ingredients to form PEG particles

partially drying the formed PEG particles under conditions to control pore size

and subjecting the partially dried formed PEG particles to CO2 supercritical extraction for form the PEG aerogel particles. Drug molecules include chemotherapeutic agents. The surface of the PEG aerogel particles are reactable with a variety of agents, for example, to selectively target tumors, protects irreversible damage to labile proteins, and protects degradation of sensitive drugs with subsequent loss of biological efficacy.

Priority: US20090250928P Applic. Date: 2009-10-13

Inventor: ATTIA YOSRY A [US]


Application No.: US20110086101A1  Published: 14/Apr/2011

Title: Dispersinb, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K-Based Antibiofilm Compositions and Uses Thereof

Applicant/Assignee:

Application No.: 12/935982   Filing Date: 03/Apr/2009

Abstract:

The present invention provides antibiofilm composition comprising two or more agents selected from the group consisting of DispersinB(TM), 5-Fluorouracil, Deoxyribonuclease I and Proteinase K for preventing growth and proliferation of biofilm-embedded microorganisms in wound care, oral care, and disease-related infections and methods of treatment in mammals. The invention further provides methods for preparing medical devices, and wound care devices using an antibiofilm composition comprising two or more antimicrobial agents selected from the group consisting of DispersinB(TM), 5-Fluorouracil, Deoxyribonuclease I and Proteinase K.

Priority: US20080041941P Applic. Date: 2008-04-03; WO2009CA00430 Applic. Date: 2009-04-03

Inventor: MADHYASTHA SRINIVASA [CA]; GAWANDE PURUSBOTTAM [CA]; LOVETRI KAREN [CA]; YAKANDAWALA NANDADEVA [CA]; KAPLAN JEFFREY [US]


Application No.: US20110086102A1  Published: 14/Apr/2011

Title: DELAYED RELEASE COMPOSITIONS

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 12/578434   Filing Date: 13/Oct/2009

Abstract:

The present invention provides delayed release pharmaceutical compositions comprising an active pharmaceutical ingredient, e.g. mycophenolate sodium, and an enteric polymer, and methods for preparing the same. Preferably, the pharmaceutical compositions do not contain a coating.

Priority:

Inventor: SILVER DAVID ISAAC [IL]; HRAKOVSKY JULIA [IL]; SOLOMONOVICH ROEY [IL]; ARIELI DAFNA [IL]


Application No.: US20110086924A1  Published: 14/Apr/2011

Title: Method of manufacturing an eutectic crystalline sugar alcohol

Applicant/Assignee: B FOOD SCIENCE CO., LTD

Application No.: 12/925426   Filing Date: 21/Oct/2010

Abstract:

A method of manufacturing an eutectic crystalline sorbitol/maltitol that represents a single melting peak obtained by differential scanning calorimetry. The method includes combining a liquid composition containing two or more kinds of the sugar alcohol at a predetermined ratio with a powder containing crystals of the same two or more kinds of the sugar alcohol at substantially the same usage ratio as that of the sugar alcohol to obtain a mixture, and kneading and aging the mixture.

Priority: JP20050014975 Applic. Date: 2005-01-24; JP20050125948 Applic. Date: 2005-04-25; US2007-793262 Applic. Date: 2007-06-15; WO2006JP300687 Applic. Date: 2006-01-19

Inventor: OKAZAKI SATOSHI [JP]; TODA YOSHINORI [JP]; NAKAMURA YOSHINOBU [JP]; SHINJI KAZUNORI [JP]; URAJI TATSUYA [JP]


Application No.: US20110087153A1  Published: 14/Apr/2011

Title: Transdermal Methods And Systems For The Delivery Of Rizatriptan

Applicant/Assignee:

Application No.: 12/902837   Filing Date: 12/Oct/2010

Abstract:

Iontophoretic patches for the delivery of rizatriptan and methods of using the patches are described.

Priority: US20090250933P Applic. Date: 2009-10-13

Inventor: ANGELOV ANGEL S [US]; LEBO DAVID B [US]


Application No.: US20110091531A1  Published: 21/Apr/2011

Title: Cooling Composition

Applicant/Assignee: GIV AUDAN SA

Application No.: 12/992375   Filing Date: 19/May/2009

Abstract:

A liquid cooling composition, which is a mixture of at least one primary cooling compound, at least one different secondary cooling compound and at least one ingestible non-polar solvent for the primary cooling compound, the weight ratios of primary cooling compound:secondary cooling compound:solvent being 1:1.5-2.25:2-4.4.

Priority: US20080055363P Applic. Date: 2008-05-22; WO2009CH00161 Applic. Date: 2009-05-19

Inventor: FURRER STEFAN MICHAEL [US]; BELL KAREN ANN [US]; CAMPANILE FABIO [CH]; DOORN ALOYSIUS LAMBERTUS [NL]; HAGEN JOSHUA ANDREW [US]


Application No.: US20110091549A1  Published: 21/Apr/2011

Title: Modulating Drug Release Rate By Controlling The Kinetics Of The pH Transition In Hydrogels

Applicant/Assignee: CONFLUENT SURGICAL, INC

Application No.: 12/724458   Filing Date: 16/Mar/2010

Abstract:

Methods and compositions relate to modulating the release profile of drug molecules from a hydrogel by controlling the kinetics of the pH transition of the hydrogel. The hydrogel is formed by in situ polymerization and includes a drug molecule having a pKa between the pH of the formed hydrogel and the physiologic environment in which the hydrogel is placed.

Priority: US20090252268P Applic. Date: 2009-10-16

Inventor: BLASKOVICH PHILLIP [US]; OHRI RACHIT [US]; COSTA DANIEL S [US]


Application No.: US20110091550A1  Published: 21/Apr/2011

Title: Methods for Promoting the Revascularization and Reenervation of CNS Lesions

Applicant/Assignee: CLEMSON UNIVERSITY RESEARCH FOUNDATION

Application No.: 12/794556   Filing Date: 04/Jun/2010

Abstract:

The present invention provides methods of promoting the revascularization and/or reenervation of central nervous system lesions using an in-situ crosslinkable hydrogel.

Priority: US20090184163P Applic. Date: 2009-06-04

Inventor: ZHANG NING [US]; WEN XUEJUN [US]


Application No.: US20110091551A1  Published: 21/Apr/2011

Title: WOUND COVERING COMPRISING OCTENIDINE DIHYDROCHLORIDE FOR USE IN THE ANTISEPSIS OF CATHETER INSERTION POINTS

Applicant/Assignee: LAIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE CLAUDE

Application No.: 12/903486   Filing Date: 13/Oct/2010

Abstract:

A wound covering includes a) a transparent film and b) applied to the film, a transparent hydrogel which includes octenidine dihydrochloride. The wound covering is suitable in particular for use in the antisepsis of catheter insertion points. The active ingredient octenidine dihydrochloride is released from the hydrogel quickly, but in a long-lasting manner. A wound covering set and a hydrogel including octenidine dihydrochloride for use for the antisepsis of catheter insertion points are also described.

Priority: DE200910049506 Applic. Date: 2009-10-15

Inventor: BAUR BORIS [DE]; DETTMANN ANDREAS [DE]; BEHRENDS SABINE [DE]


Application No.: US20110091552A1  Published: 21/Apr/2011

Title: Use of Bcl Inhibitors for the Treatment of Scarring Caused By Cutaneous Wounds, Burns and Abrasions

Applicant/Assignee:

Application No.: 12/978776   Filing Date: 27/Dec/2010

Abstract:

The present invention relates to use of Bcl inhibitors for the prevention of fibroproliferation resulting in the growth of visible or disfiguring scar tissue on human skin, including without limitation keloids and hypertrophic scars. In particular, the present invention relates to the new use of small molecule inhibitors of the Bcl-2/Bcl-XL family of anti-apoptotic proteins for the treatment of cutaneous wounds, burns and abrasions during the healing phase.

Priority: US2007-848459 Applic. Date: 2007-08-31

Inventor: MCCAFFREY TIM [US]; GAGARIN DMITRY [US]; YANG ZHAOQING [US]


Application No.: US20110091553A1  Published: 21/Apr/2011

Title: METHOD FOR PRODUCING MICROCAPSULES USING SOLID FAT

Applicant/Assignee: KANEKA CORPORATION

Application No.: 12/995819   Filing Date: 02/Jun/2009

Abstract:

An object of the present invention is to provide a method for production of fine microcapsules which encapsulate a hydrophilic bioactive substance at a high content and can be used in wide range of applications such as foods and medical drugs, which method enabling efficient industrial production. The present invention is directed to a method for production of S/O type microcapsules in which a hydrophilic bioactive substance is polydispersed in a solid fat matrix, including steps of: dispersing a complex of the hydrophilic bioactive substance with a surfactant (A) in a solid fat at a temperature not lower than the melting point of the solid fat to obtain an S/O suspension, followed by permitting liquid droplet dispersion of the S/O suspension, and hardening the solid fat by cooling the S/O suspension liquid droplets to lower than the melting point of the solid fat to obtain solid particles

and an S/O type microcapsule wherein a milk protein-derived ingredient such as lactoferrin is polydispersed in a solid fat matrix.

Priority: JP20080144608 Applic. Date: 2008-06-02; JP20090116540 Applic. Date: 2009-05-13; WO2009JP60085 Applic. Date: 2009-06-02

Inventor: KANAYA KENTO [JP]; SATO MASAO [JP]


Application No.: US20110092604A1  Published: 21/Apr/2011

Title: FRAGRANCE SUBSTANCE MIXTURES COMPRISING ISOLONGIFOLANOL AND MUSK

Applicant/Assignee: SYMRISE AG

Application No.: 12/907725   Filing Date: 19/Oct/2010

Abstract:

The present invention relates to fragrance substance mixtures, in particular perfume oils, comprising (a) compound (A) and (b) at least one musk fragrance substance wherein the mass ratio of the total quantity of the musk fragrance substance or substances of component (b) to compound (A) is greater than or equal to 1:1. The present invention also relates to perfumed products comprising fragrance substance mixtures of this type according to the invention, in particular perfume oils, and to a process for the production of the fragrance substance mixtures and perfume oils according to the invention.

Priority: EP20090173455 Applic. Date: 2009-10-19

Inventor: WOEHRLE INGO [DE]; EH MARCUS [DE]; VAN DIJK MARINUS CORNELIUS [DE]


Application No.: US20110092605A1  Published: 21/Apr/2011

Title: Encapsulation

Applicant/Assignee: APPLETON PAPERS INC

Application No.: 12/904755   Filing Date: 14/Oct/2010

Abstract:

Disclosed are encapsulating methods and encapsulated products. A payload material may be encapsulated within a wall material. The carrier material and payload material form a combination that is at least substantially solid at room temperature but that is sufficiently fluid at milling temperature to permit milling and subsequent encapsulation. The payload material may be, for instance, a bitter tasting material. In some embodiments, the microcapsules will serve a taste masking function. In other embodiments, the microcapsules may be used where a slow release of the payload material is desired.

Priority: US20090251822P Applic. Date: 2009-10-15

Inventor: YAN NIANXI [US]


Application No.: US20110092953A1  Published: 21/Apr/2011

Title: Flowable Carrier Matrix

Applicant/Assignee: WARSAW ORTHOPEDIC, INC, WARSAW OTHOPEDIC, INC

Application No.: 12/977310   Filing Date: 23/Dec/2010

Abstract:

A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2009-634323 Applic. Date: 2009-12-09; US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Application No.: US20110094972A1  Published: 28/Apr/2011

Title: Water treatment

Applicant/Assignee:

Application No.: 12/925661   Filing Date: 26/Oct/2010

Abstract:

A sanitizing agent for maintaining a biocidal effective bacteria count in a body of water comprising a metal ion donor for donating a metal ion and a compound containing a hydantoin ring with the combination of the compound containing the hydantoin ring with the metal ion donor enhancing the effectiveness of the sanitizing agent to enable the sanitizing agent to maintain a biocidal effective bacteria count in the body of water.

Priority: US20090279859P Applic. Date: 2009-10-27

Inventor: KING JOSEPH A [US]; HILL JOHN [US]


Application No.: US20110097296A1  Published: 28/Apr/2011

Title: Novel Pyran Derivatives, Their Preparation and Use Thereof in Perfumery

Applicant/Assignee:

Application No.: 12/988704   Filing Date: 21/Apr/2009

Abstract:

A process of preparing a compound of formula (I) wherein R represents a linear or branched C5 alkyl group, as well as the use of such compounds in a fragrant and/or flavouring composition.

Priority: EP20080305118 Applic. Date: 2008-04-22; WO2009EP54691 Applic. Date: 2009-04-21

Inventor: MANE JEAN [FR]; PLESSIS CAROLINE [FR]; CHANOT JEAN-JACQUES [FR]


Application No.: US20110097377A1  Published: 28/Apr/2011

Title: Methods and Devices for Correcting Spinal Deformity With Pharmaceutical-Eluting Pedicle Screws

Applicant/Assignee:

Application No.: 12/730469   Filing Date: 24/Mar/2010

Abstract:

A method of correcting spinal deformity, which includes locating pharmaceutical-loaded implants adjacent to targeted spinal growth plates, and then eluting the pharmaceutical onto the growth plates. Preferably, the method involves correcting spinal deformity by simply inserting a pharmaceutical-eluting pedicle screw onto the concave side of a scoliotic curve. In some embodiments, the screw has a cannulated internal reservoir that contains a growth-inhibiting pharmaceutical (such as a tetracycline) and at least one fenestration that allows the pharmaceutical to elute onto the vertebral body growth plate.

Priority: US2009-605122 Applic. Date: 2009-10-23

Inventor: SERHAN HASSAN [US]; O'NEIL MICHAEL J [US]; LILIENFELD SEAN [US]; DIMAURO THOMAS M [US]


Application No.: US20110097402A1  Published: 28/Apr/2011

Title: NON-ADHESIVE ELASTIC GELATIN MATRICES

Applicant/Assignee: COVALON TECHNOLOGIES INC

Application No.: 11/664184   Filing Date: 15/Jun/2005

Abstract:

The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making the non-adhesive elastic gelatin matrix.

Priority: US20040614414P Applic. Date: 2004-09-30; WO2005CA00925 Applic. Date: 2005-06-15

Inventor: DITIZIO VALERIO [CA]; DICOSMO FRANK [CA]; XIAO YUEHUA [CA]


Application No.: US20110097403A1  Published: 28/Apr/2011

Title: EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER

Applicant/Assignee: HISTOGEN, INC

Application No.: 12/822126   Filing Date: 23/Jun/2010

Abstract:

The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.

Priority: US2009-363479 Applic. Date: 2009-01-30; US20080114966P Applic. Date: 2008-11-14

Inventor: NAUGHTON GAIL K [US]; PINNEY EMMETT [US]


Application No.: US20110097404A1  Published: 28/Apr/2011

Title: TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS

Applicant/Assignee: PURDUE PHARMA L.P

Application No.: 12/909614   Filing Date: 21/Oct/2010

Abstract:

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.

Priority: US2003-689866 Applic. Date: 2003-10-21; US2001-781081 Applic. Date: 2001-02-08; US20000181369P Applic. Date: 2000-02-08

Inventor: OSHLACK BENJAMIN [US]; WRIGHT CURTIS [US]; HADDOX J DAVID [US]


Application No.: US20110097405A1  Published: 28/Apr/2011

Title: ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM

Applicant/Assignee: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Application No.: 12/867409   Filing Date: 05/Feb/2009

Abstract:

The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen.

Priority: EP20080002633 Applic. Date: 2008-02-13; US20080028302P Applic. Date: 2008-02-13; WO2009EP51303 Applic. Date: 2009-02-05

Inventor: FUNKE ADRIAN [DE]; GENERAL SASCHA [DE]; TEREBESI ILDIKO [DE]; ZURTH CHRISTIAN [DE]; ALINCIC-KUNZ SOFIA [DE]; SCHAEFER MATTHIAS [DE]; HOLLER THOMAS [DE]; DIEFENBACH KONSTANZE [DE]


Application No.: US20110097406A1  Published: 28/Apr/2011

Title: METHODS AND COMPOSITIONS FOR RETAINING ECM MATERIALS IN HYDROGELS

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODYCORPORATE

Application No.: 12/911515   Filing Date: 25/Oct/2010

Abstract:

The present invention provides cell-laden and/or extracellular matrix material laden hydrogels for use in tissue engineering and methods for producing such hydrogels. In some particular embodiments, hydrogels comprise chondrocytes, which are typically encapsulated within the hydrogels. In many instances, such hydrogels are subjected to dynamic loading prior to being administered to a subject to treat a clinical condition that is helped by tissue engineering, including, but not limited to, cosmetic surgery such as craniofacial reconstruction surgery, and cartilage regeneration.

Priority: US20090254738P Applic. Date: 2009-10-25

Inventor: BRYANT STEPHANIE J [US]; NICODEMUS GARRET D [US]


Application No.: US20110098363A1  Published: 28/Apr/2011

Title: AMPHIPHILIC MOLECULES WITH A TRIAZINE CORE

Applicant/Assignee: BASF SE

Application No.: 12/993049   Filing Date: 28/May/2009

Abstract:

The present invention is directed to chemical compounds of formula (I) wherein A1 is selected from the group consisting of alkyl, aryl, alkylaryl and (formula A), A2, A3, A4, A5 and in case A1 is (formula A) also A6 and A7 comprise a polymer selected from the group consisting of [EO]k[XO]m, [PO]p[EO]q, [EO]k[XO]m[EO]n and [PO]p[EO]q[XO]m with [XO] being [PO] or [BuO] and with EO having the meaning of ethylene oxide, PO having the meaning of propylene oxide and BuO having the meaning of butylene oxide.

Priority: EP20080157285 Applic. Date: 2008-05-30; EP20080157287 Applic. Date: 2008-05-30; WO2009EP56537 Applic. Date: 2009-05-28

Inventor: GARNIER SEBASTIEN [DE]; REINOSO GARCIA MARTA [DE]; OETTER GUENTER [DE]


Application No.: US20110104052A1  Published: 05/May/2011

Title: METHODS OF SYNTHESIS AND USE OF CHEMOSPHERES

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: 12/746030   Filing Date: 03/Dec/2008

Abstract:

The present invention provides, in general, compositions comprising a hydrogel and an agent, for example a therapeutic agent or an imaging agent, for locoregional delivery. In certain preferred embodiments of the invention, the hydrogel compositions are detectable by Magnetic Responance and CT Scan and are used for locoregional delivery of therapeutic agents, for example chemotherapeutic agents. The invention also features polymer matrix compositions comprising nanoparticles that can be loaded after polymerization with bioactive agents, for example a diagnostic agent or therapeutic agent.

Priority: US20070005228P Applic. Date: 2007-12-03; US20080093619P Applic. Date: 2008-09-02; WO2008US13336 Applic. Date: 2008-12-03

Inventor: BARNETT BRADLEY POWERS [US]; GESCHWIND JEFFREY [US]


Application No.: US20110104062A1  Published: 05/May/2011

Title: Biomarkers for Head-And-Neck Cancers and Precancers

Applicant/Assignee:

Application No.: 12/866567   Filing Date: 06/Feb/2009

Abstract:

The invention provides markers and methods for detecting head-and-neck precancers, (including OPLs), cancers and related disease conditions in a subject. The invention also provides localization and imaging methods for head-and-neck precancers (including OPLs) and cancers, along with kits for carrying out methods of the invention. The invention further provides therapeutic applications for head-and-neck precancers (including OPLs) and cancers which employ head-and-neck precancer and cancer markers, polynucleotides encoding the markers, and binding agents for the markers.

Priority: CA20082618163 Applic. Date: 2008-02-07; CA20082643611 Applic. Date: 2008-11-10; WO2009CA00154 Applic. Date: 2009-02-06

Inventor: SIU K W MICHAEL [CA]; RALHAN RANJU [CA]; MATTA AJAY [IN]; DESOUZA LEROI V [CA]


Application No.: US20110104098A1  Published: 05/May/2011

Title: Isolongifolanyl-Derivatives Suitable As Odorants

Applicant/Assignee: GIVAUDAN SA

Application No.: 13/000697   Filing Date: 29/Jun/2009

Abstract:

The present disclosure refers to 5,7-dioxatetracyclo[9.2.1.01.9,04.8]tetradecane derivatives of formula I wherein R1-R3 have the same meaning as given in the description. The disclosure furthermore refers to their preparation and to perfume compositions and fragrance applications including them.

Priority: GB20080012006 Applic. Date: 2008-07-01; WO2009CH00223 Applic. Date: 2009-06-29

Inventor: BAJGROWICZ JERZY A [CH]; FURNISS CHRISTOPHER [CH]


Application No.: US20110104225A1  Published: 05/May/2011

Title: POLYPEPTIDES, MATRICES, HYDROGELS AND METHODS OF USING SAME FOR TISSUE REGENERATION AND REPAIR

Applicant/Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD, THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER

Application No.: 12/673520   Filing Date: 13/Aug/2008

Abstract:

A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide

or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue.

Priority: US20070935487P Applic. Date: 2007-08-15; WO2008IL01120 Applic. Date: 2008-08-13

Inventor: ROCHKIND SHIMON [IL]; NEVO ZVI [IL]


Application No.: US20110104240A1  Published: 05/May/2011

Title: Nitric Oxide Device and Method for Wound Healing, Treatment of Dermatological Disorders and Microbial Infections

Applicant/Assignee: MICROPHARMA LIMITED

Application No.: 13/000555   Filing Date: 23/Jun/2009

Abstract:

The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides methods and uses for treating wounds, microbial infections and dermatological disorders and for preserving meat products.

Priority: US20080075040P Applic. Date: 2008-06-24; US20080097978P Applic. Date: 2008-09-18; US20090153696P Applic. Date: 2009-02-19; US20090166430P Applic. Date: 2009-04-03; WO2009CA00858 Applic. Date: 2009-06-23

Inventor: JONES MITCHELL LAWRENCE [CA]; PRAKASH SATYA [CA]


Application No.: US20110104241A1  Published: 05/May/2011

Title: PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME

Applicant/Assignee: TOA EIYO LTD

Application No.: 13/000635   Filing Date: 22/Jun/2009

Abstract:

Provided are a percutaneous absorption enhancer excellent in an enhancing effect on percutaneous absorption of a wide range of drugs and excellent in compatibility with an adhesive base, and a transdermal preparation using the percutaneous absorption enhancer. The percutaneous absorption enhancer includes a sulfosuccinate or a salt thereof and an alkyl glycoside or an alkyl thioglycoside.

Priority: JP20080162730 Applic. Date: 2008-06-23; WO2009JP02837 Applic. Date: 2009-06-22

Inventor: OHTAKE NAOTO [JP]; KOIDE YUUKI [JP]


Application No.: US20110104254A1  Published: 05/May/2011

Title: Medicament for treatment of tumors wherein hedgehog/smoothened signaling is employed for inhibition of apoptosis of the tumor cells

Applicant/Assignee:

Application No.: 12/930677   Filing Date: 13/Jan/2011

Abstract:

This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC's) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the undifferentiated cells of the normal epidermal basal layer and hair follicles. Causation of apoptosis by cyclopamine is by a non-genotoxic mechanism and thus unlike the radiation therapy and most of the currently used cancer chemotherapeutics which act by causing DNA-damage. These novel effects, previously unachieved by a cancer chemotherapeutic, make the use of cyclopamine highly desirable in cancer therapy, in the treatment of BCC's and other tumors that use the hedgehog/smoothened signal transduction pathway for proliferation and prevention of apoptosis.

Priority: US2003-682584 Applic. Date: 2003-10-09; WO2001TR00027 Applic. Date: 2001-07-02; WO2002TR00017 Applic. Date: 2002-04-19

Inventor: TAS SINAN [TR]; AVCI OKTAY [TR]


Application No.: US20110104262A1  Published: 05/May/2011

Title: Topical Combinations Comprising an Antimycotic Agent and an Antiviral Agent

Applicant/Assignee: CIPLA LIMITED

Application No.: 12/988155   Filing Date: 16/Apr/2009

Abstract:

There is provided a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, useful for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof.

Priority: IN2008MU00862 Applic. Date: 2008-04-16; WO2009GB00975 Applic. Date: 2009-04-16

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]


Application No.: US20110104272A1  Published: 05/May/2011

Title: GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF ACETAMINOPHEN AND PHENYLEPHRINE

Applicant/Assignee: DEPOMED, INC

Application No.: 12/940911   Filing Date: 05/Nov/2010

Abstract:

Compositions and methods for the treatment of a mammal suffering from pain and from nasal congestion or ophthalmic disorders are described. More specifically, a dosage form designed for release of acetaminophen and phenylephrine is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract ("GI") of a mammal for an extended period of time.

Priority: US20090258488P Applic. Date: 2009-11-05

Inventor: HOU SUI YUEN EDDIE [US]


Application No.: US20110104273A1  Published: 05/May/2011

Title: GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF PHENYLEPHRINE

Applicant/Assignee: DEPOMED, INC

Application No.: 12/940964   Filing Date: 05/Nov/2010

Abstract:

Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

Priority: US20090258460P Applic. Date: 2009-11-05

Inventor: HOU SUI YUEN EDDIE [US]


Application No.: US20110104278A1  Published: 05/May/2011

Title: Bone tissue substitute, a solidifiable bone precursor and method of making same

Applicant/Assignee:

Application No.: 12/588854   Filing Date: 30/Oct/2009

Abstract:

The present concerns a solidifiable bone precursor composition which can be used to produce a mineralized substitute bone tissue material and the method of making the substitute bone tissue material. The substitute bone tissue material includes a collagen matrix comprising pores, and an apatitic mineral within the pores of general formula: As(TOx)t(QOx)uZy wherein A is a cation selected from Na, K, Mg, Ca, Fe3+, Al3+ or combinations thereof, T and Q are an anion oxide selected from P or C, Z is a H, OH or a halogen group, and s is 1 to 10, x is 2 to 4, t is 1 to 3, is 0 to 3 and y is 0 to 3. The solidifiable bone precursor composition includes: an aqueous dispersion comprising: at least one cation

and a polyphosphate combined to produce a cation-polyphosphate granule

and a collagen.

Priority:

Inventor: OMELON SIDNEY [CA]


Application No.: US20110104279A1  Published: 05/May/2011

Title: HEALING POWDER AND METHOD OF USE THEREOF

Applicant/Assignee:

Application No.: 12/612084   Filing Date: 04/Nov/2009

Abstract:

A method for treating wounds, comprising providing a dry powder mixture, which when partially hydrated, forms a gel having an osmotic pressure sufficient to achieve and maintain antiseptic conditions in hydrated portions of the gel, the gelled portion comprising a biocompatible polymer, the dry powder being readily wettable by wound secretions

and applying the dry powder to a wound having wound secretions in sufficient excess to produce a self-adherent gel cake having a dry powder surface. The administration may be repeated by administration of the dry powder while wound healing progresses.

Priority:

Inventor: MARRACCINI PHILIP A [US]; DIOGUARDI MARIA [US]


Application No.: US20110104281A1  Published: 05/May/2011

Title: METHOD FOR TREATING PAIN USING A SUBSTITUTED 2-AMINOTETRALIN COMPOUND

Applicant/Assignee: UCB PHARMA GMBH

Application No.: 12/985058   Filing Date: 05/Jan/2011

Abstract:

A method for treating pain, particularly non-inflammatory musculoskeletal pain such as myofascial pain or back pain, in a subject comprises administering to the subject a substituted 2-aminotetralin compound as defined herein, illustratively rotigotine.

Priority: EP20060012815 Applic. Date: 2006-06-22; US2007-764907 Applic. Date: 2007-06-19

Inventor: BEYREUTHER BETTINA [DE]; SCHELLER DIETER [DE]; FREITAG JOACHIM [DE]; BIANCHINE JOSEPH [US]


Application No.: US20110104282A1  Published: 05/May/2011

Title: New Therapy of Treatment of the Irritable Bowel Syndrome

Applicant/Assignee: KAROLINSKA INSTITUTET INNOVATIONS AB

Application No.: 12/989447   Filing Date: 27/Apr/2009

Abstract:

The invention provides for new methods for treatment and diagnosis of irritable bowel syndrome (IBS). In particular, there is disclosed the use of a Chlamydia activating agent and one or several antibiotics selected from macroildes and benzoxazinorifamycins in the preparation of combination agent for simultaneous, concomitant or sequential administration for the treatment of IBS.

Priority: US20080047843P Applic. Date: 2008-04-25; WO2009SE50440 Applic. Date: 2009-04-27

Inventor: LINDBERG GREGER [SE]; DLUGOSZ ALDONA [SE]


Application No.: US20110105333A1  Published: 05/May/2011

Title: Seed Treatment Compositions and Methods

Applicant/Assignee:

Application No.: 12/673538   Filing Date: 17/Apr/2008

Abstract:

The present invention relates to seed treatment compositions comprising active ingredient and hyperbranched polymer. The hyperbranched polymer is used as seed coating agent, especially as a binder to promote adhesion of the active ingredient(s) to the seeds. The present invention also relates to methods of treating seed with such a composition.

Priority: EP20070114464 Applic. Date: 2007-08-16; WO2008US60673 Applic. Date: 2008-04-17

Inventor: ISRAELS RAFEL [DE]; LANDES ANDREAS [DE]; VOESTE DIRK [DE]; STEPHAN DORIS [DE]; SOWA CHRISTIAN [DE]; BRUCHMANN BERND [DE]; SCHOENFELDER DANIEL [DE]; CLAUSS JOACHIM [DE]


Application No.: US20110105620A1  Published: 05/May/2011

Title: ORGANIC COMPOUNDS

Applicant/Assignee:

Application No.: 12/987726   Filing Date: 10/Jan/2011

Abstract:

A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist

and (b) a sugar alcohol.

Priority: US2008-191098 Applic. Date: 2008-08-13; US2005-552005 Applic. Date: 2005-11-14; WO2004EP03656 Applic. Date: 2004-04-06; US20030461215P Applic. Date: 2003-04-08

Inventor: OOMURA TOMOYUKI [JP]; PUDIPEDDI MADHUSUDHAN [US]; RUEGGER COLLEEN [US]; ROYCE ALAN EDWARD [US]; SASAKI MASAKI [JP]; TAMURA TOKUHIRO [JP]


Application No.: US20110111028A1  Published: 12/May/2011

Title: Composition and Methods For Repair of Connective Tissue

Applicant/Assignee:

Application No.: 12/736314   Filing Date: 22/Dec/2008

Abstract:

Compositions and methods for repairing a ruptured connective tissue are disclosed. The composition may include a first biocompatible material to provide a scaffold for connective tissue cell growth and tissue repair. This first biocompatible material may withstand a tensile load of up to 250 N. The composition may also include a second biocompatible material including at least one bioactive agent that can stimulate connective tissue cell growth and tissue repair. The method may include positioning a first end of the first biocompatible material adjacent a first end of a ruptured connective tissue, positioning a second end of the first biocompatible material adjacent a second end of the ruptured connective tissue, and anchoring the first biocompatible material to the first and second tendon ends. The method may alternatively comprise or further include positioning a second biocompatible material between the first and second ends of the ruptured connective tissue.

Priority: US20070124814P Applic. Date: 2007-12-20; WO2008US88041 Applic. Date: 2008-12-22

Inventor: WANG HALI [US]; YAO JIAN Q [CN]


Application No.: US20110111029A1  Published: 12/May/2011

Title: COMPOSITION FOR TRANSDERMAL DELIVERY OF CATIONIC ACTIVE AGENTS

Applicant/Assignee: LTS LOHMANN THERAPIE-SYSTEME AG

Application No.: 12/737209   Filing Date: 16/Jun/2009

Abstract:

A composition for transdermal delivery, particularly iontophoretic transdermal delivery, having at least one cationic active agent or a salt thereof. The composition comprises at least one cationic active agent or a salt thereof, at least one polyamine and/or polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. Use of the composition as a component of a transdermal patch or of an iontophoretic transdermal patch is also provided, as well as the use of the composition in a method for transdermally or iontophoretically administering cationic active agents. A method for determining the in vitro skin permeation properties of an active agent-containing iontophoretic composition is also provided.

Priority: US20080132527P Applic. Date: 2008-06-19; WO2009EP04316 Applic. Date: 2009-06-16

Inventor: SCHMITZ CHRISTOPH [DE]; SAMETI MOHAMMAD [DE]; KOCH ANDREAS [DE]; HORSTMANN MICHAEL [DE]


Application No.: US20110111030A1  Published: 12/May/2011

Title: Method of Producing Progenitor Cells from Differentiated Cells

Applicant/Assignee:

Application No.: 12/866010   Filing Date: 05/Feb/2009

Abstract:

The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and/or tissue or organ repair and/or regeneration and/or building are also provides. Methods of using progenitor cells in treatment and prophylaxis of conditions alleviated by administering stem cells or tissue or organ derived from stem cells to a subject or by grafting stem cells or tissue or organ derived from stem cells into a subject or by transplanting stem cells or tissue or organ derived from stem cells into a subject are also provided. Also included are progenitor cells and differentiated cells and/or tissues and/or organs derived therefrom, and kits comprising same.

Priority: AU20080900534 Applic. Date: 2008-02-05; WO2009AU00138 Applic. Date: 2009-02-05

Inventor: BHASIN VISHAL [AU]


Application No.: US20110111031A1  Published: 12/May/2011

Title: Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof

Applicant/Assignee:

Application No.: 12/910575   Filing Date: 22/Oct/2010

Abstract:

The present specification provides drug delivery platforms useful for the controlled release of a compound over time in an individual.

Priority: US2010-873563 Applic. Date: 2010-09-01; US2010-764039 Applic. Date: 2010-04-20; US20090170895P Applic. Date: 2009-04-20

Inventor: JIANG GUANG-LIANG [US]; COLLETTE ADAM L [US]; HORAN REBECCA L [US]; CHEN JINGSONG [US]; ALTMAN GREGORY H [US]; IM WHA BIN [US]


Application No.: US20110111032A1  Published: 12/May/2011

Title: MANUFACTURING METHOD OF COLLAGEN GEL COMPOSITION FOR BONE REGENERATION

Applicant/Assignee: SEWON CELLONTECH CO., LTD

Application No.: 13/003157   Filing Date: 23/Jul/2008

Abstract:

Disclosed herein is a method for preparing a collagen gel composition for bone regeneration comprising collecting bone marrow from animal tissues and isolating nucleated cells from the bone marrow

and mixing the nucleated cells and a bio-matrix composed of type I collagen and apatite.

Priority: KR20080067692 Applic. Date: 2008-07-11; WO2008KR04287 Applic. Date: 2008-07-23

Inventor: JANG JAE-DEOG [KR]; KIM HUN [KR]; YU JI-CHUL [KR]; YEO SE-GEUN [KR]; KIM TAE-HYOUNG [KR]; PARK HYUN-SHIN [KR]; KIM SEON-AE [KR]; KIM JANG-HOON [KR]; KIM SEONG-SOO [KR]


Application No.: US20110111033A1  Published: 12/May/2011

Title: HYDROGEL WITH COVALENTLY CROSSLINKED CORE

Applicant/Assignee:

Application No.: 12/937110   Filing Date: 09/Apr/2009

Abstract:

A novel hydrogel system is provided. The hydrogel system comprises a biocompatible hydrogel core having dispersed therein a covalently crosslinked polymer matrix. The hydrogel system is useful per se or as an encapsulation system.

Priority: US20080071029P Applic. Date: 2008-04-09; WO2009CA00448 Applic. Date: 2009-04-09

Inventor: STOVER HARALD [CA]; BURKE NICHOLAS [CA]; MAZUMDER M A JAFAR [CA]; SHEN FENG [CA]; POTTER MURRAY [CA]


Application No.: US20110117018A1  Published: 19/May/2011

Title: COMPOSITIONS AND METHODS FOR TREATING BONE

Applicant/Assignee: BIOMIMETIC THERAPEUTICS, INC

Application No.: 12/819093   Filing Date: 18/Jun/2010

Abstract:

The present invention relates to compositions, methods and kits for the treatment of bone particularly impaired or damaged bone.

Priority: US2007-704685 Applic. Date: 2007-02-09; US2005-159533 Applic. Date: 2005-06-23; US2004-965319 Applic. Date: 2004-10-14; US20060771826P Applic. Date: 2006-02-09; US20060817988P Applic. Date: 2006-06-30; US20060859809P Applic. Date: 2006-11-17

Inventor: HART CHARLES E [US]; HOLLINGER JEFFREY O [US]; LYNCH SAMUEL E [US]


Application No.: US20110117046A1  Published: 19/May/2011

Title: NOVEL 4-ALKYL CYCLOHEXANEPROPANAL COMPOUNDS AND THEIR USE IN PERFUME COMPOSITIONS

Applicant/Assignee:

Application No.: 12/619325   Filing Date: 16/Nov/2009

Abstract:

The present invention is directed to novel 4-alkyl cyclohexanepropanal compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of the novel compounds.

Priority:

Inventor: LEVORSE JR ANTHONY T [US]; BELKO ROBERT P [US]; AMORELLI BENJAMIN [US]; MONTELEONE MICHAEL G [US]


Application No.: US20110117048A1  Published: 19/May/2011

Title: METHOD AND COMPOSITION FOR USE IN PREPARATION OF A PATIENT FOR SURGERY

Applicant/Assignee: NOVAPHARM RESEARCH (AUSTRALIA) PTY LTD

Application No.: 13/010197   Filing Date: 20/Jan/2011

Abstract:

Composition for application to skin comprising a biocide or combination of biocides (such as chlorhexidine, halogenated phenols, quaternary ammonium compounds

povidone-iodine

zinc pyridinethione

alcohols etc.) and at least one transcutaneous vehicle (for example alkyl methyl sulfoxides, alkyl pyrrolidones, glycols, glycol ethers and glycol esters) effective to convey the biocide to a sub epidermal "resident" micro-organism. Also a method for preparing a patient for surgery comprising the step of treating an area of the patient's skin at, and in the surrounding the vicinity of, the site of an intended surgical incision with a composition effective to kill more than 93% of both "transient" and "resident" micro-organisms.

Priority: AU20050902493 Applic. Date: 2005-05-16; US2007-914539 Applic. Date: 2007-11-15; WO2006AU00553 Applic. Date: 2006-04-28

Inventor: KRITZLER STEVEN [AU]


Application No.: US20110117193A1  Published: 19/May/2011

Title: ANTIRETROVIRAL DRUG FORMULATIONS FOR TREATMENT OF CHILDREN EXPOSED TO HIV/AIDS

Applicant/Assignee: DUQUESNE UNIVERSITY OF THE HOLY SPIRIT

Application No.: 12/863111   Filing Date: 16/Jan/2009

Abstract:

The present disclosure provides fast disintegrating formulations for the treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in patients such as neonatal, perinatal and pediatric children. Neonatal and perinatal formulations provide for the prevention or reduction of incidence of mother to child transmission of HIV. Also provided are formulations and methods for treating pediatric children having HIV/AIDS. The orally administered fast disintegrating formulations are in granule and tablet form and are specially formulation for children to increase adherence to treatment protocols.

Priority: US20080021790P Applic. Date: 2008-01-17; WO2009US31285 Applic. Date: 2009-01-16

Inventor: ADEYEYE MOJI C [US]; ESSEKU FREDRICK [US]; JOSHI ANAJALI [US]


Application No.: US20110117195A1  Published: 19/May/2011

Title: METHOD FOR IMPROVING MYOCARDIAL INFARCTION BY INTRAMYOCARDIAL OR TRANSENDOCARDIAL INJECTION OF PEPTIDE NANOFIBERS

Applicant/Assignee: NATIONAL CHENG KUNG UNIVERSITY

Application No.: 12/620890   Filing Date: 18/Nov/2009

Abstract:

A method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers is disclosed. The method firstly provides a pharmaceutical composition having a biologically compatible peptide hydrogel formed by a plurality of self-assembling peptide nanofibers and selectively having at least one type of autologous stem cells mixed with the self-assembling peptide nanofibers, and then the pharmaceutical composition is administered to an entire infarcted area of myocardium tissue with myocardial infarction by intramyocardial or transendocardial injection. Thus, adverse cardiac remodeling and dysfunction after acute infraction can be attenuated, while the therapeutic myocardial angiogenesis, the myocardial capillary density and potential myogenesis can be enhanced.

Priority:

Inventor: HSIEH CHING-HO [TW]; LIN YI-DONG [TW]; YANG YU-JEN [TW]; YEH MING-LONG [TW]


Application No.: US20110123470A1  Published: 26/May/2011

Title: NATURAL BIOACTIVE COMPOUNDS

Applicant/Assignee: AQUAPHARM BIO-DISCOVERY LTD

Application No.: 12/598744   Filing Date: 02/May/2008

Abstract:

The present invention relates to butenolide compounds having cytoprotection such as antioxidant, anti-inflammatory and/or antifungal properties, and which are derived from the marine fungus Aureobasidium.

Priority: GB20070008611 Applic. Date: 2007-05-04; GB20070023451 Applic. Date: 2007-11-30; WO2008GB01544 Applic. Date: 2008-05-02

Inventor: YAN LIMING [GB]; MEARNS SPRAGG ANDREW [GB]; JUKES KAREN [GB]


Application No.: US20110123472A1  Published: 26/May/2011

Title: LONG WEAR COSMETIC COMPOSITION

Applicant/Assignee: L'OREAL S.A

Application No.: 13/019435   Filing Date: 02/Feb/2011

Abstract:

The present invention relates to long-wearing, non-aqueous based cosmetic compositions, and related dermatological, pharmaceutical or hygiene compositions. The present invention provides a non-aqueous based composition comprising one or a mixture of two or more emulsifiers.

Priority: US2004-542452 Applic. Date: 2004-01-16; WO2004US01071 Applic. Date: 2004-01-16; US20030440626P Applic. Date: 2003-01-17

Inventor: ATIS BALANDA [US]


Application No.: US20110123619A1  Published: 26/May/2011

Title: BUCCAL DELIVERY SYSTEM

Applicant/Assignee: OZPHARMA PTY. LTD

Application No.: 13/021578   Filing Date: 04/Feb/2011

Abstract:

A buccal delivery system capable of being blended in a normal dry powder process and compressed using a standard tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active ingredients

(b) an amount of one or more polyethylene glycols or derivatives thereof having a molecular weight between 1000 to 8000 sufficient to provide the required hardness and time for dissolution of the matrix

(c) 0.05-2% by weight of the total matrix of one or more suspending agents

(d) 0.05-2% by weight of the total matrix of one or more flowing agents

and (e) 0.05-2% by weight of the total matrix of one or more sweeteners.

Priority: AU20050901758 Applic. Date: 2005-04-08; US2008-910902 Applic. Date: 2008-02-05; WO2006AU00472 Applic. Date: 2006-04-07

Inventor: HEWITT ERNEST ALAN [AU]; STENLAKE RICHARD JAMES [AU]


Application No.: US20110123620A1  Published: 26/May/2011

Title: SILICON DIOXIDE NANOPARTICLES AND THE USE THEREOF FOR VACCINATION

Applicant/Assignee: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG

Application No.: 13/054169   Filing Date: 13/Jul/2009

Abstract:

The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.

Priority: DE200810033175 Applic. Date: 2008-07-15; WO2009EP05078 Applic. Date: 2009-07-13

Inventor: WEIGANDT MARKUS [DE]; HANEFELD ANDREA [DE]; KUEBELBECK ARMIN [DE]; LARBIG GREGOR [DE]


Application No.: US20110129511A1  Published: 02/Jun/2011

Title: PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

Applicant/Assignee: VASCULAR BIOGENICS LTD

Application No.: 13/018447   Filing Date: 01/Feb/2011

Abstract:

Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed.

Priority: US2004-988487 Applic. Date: 2004-11-14; US2002-135447 Applic. Date: 2002-05-01; WO2001IL01059 Applic. Date: 2001-11-15; US2004-490746 Applic. Date: 2004-04-12; WO2002IL00339 Applic. Date: 2002-05-01; US20000248582P Applic. Date: 2000-11-17; US20010330118P Applic. Date: 2001-10-19

Inventor: HARATS DROR [IL]; GREENBERGER SHOSHANA [IL]; BREIBART EYAL [IL]; BANGIO LIVNAT [IL]; PELED MICHAEL [IL]


Application No.: US20110129531A1  Published: 02/Jun/2011

Title: Dermal Fillers Comprising Silk Fibroin Hydrogels and Uses Thereof

Applicant/Assignee: ALLERGAN, INC

Application No.: 12/906777   Filing Date: 18/Oct/2010

Abstract:

The present specification provides compositions useful as dermal fillers and methods using such compositions to treat a condition of skin.

Priority: US2010-883139 Applic. Date: 2010-09-15; US2010-764039 Applic. Date: 2010-04-20; US20090170895P Applic. Date: 2009-04-20

Inventor: COLLETTE ADAM L [US]; HORAN REBECCA L [US]; CHEN JINGSONG [US]; ALTMAN GREGORY H [US]


Application No.: US20110129532A1  Published: 02/Jun/2011

Title: METHOD AND MEANS FOR TREATING VIRAL DISEASE, IN PARTICULAR HIV/AIDS

Applicant/Assignee: ISR IMMUNE SYSTEM REGULATION AB

Application No.: 12/995062   Filing Date: 18/May/2009

Abstract:

A method of treating viral disease, in particular HIV/AIDS, comprises concomitant administration of GnRH or GnRH analog including pharmaceutically acceptable salts thereof in an amount sufficient to maintain in the patient an elevated unphysiological plasma level, in particular a castrating plasma level, of GnRH or GnRH analog, and of one or several natural, semi-synthetic or synthetic sexual hormones in a amount sufficient to compensate for the castration effect of GnRH or GnRH analog. Also disclosed is a corresponding pharmaceutical composition and a composition kit, and uses thereof.

Priority: SE20080001255 Applic. Date: 2008-05-29; WO2009SE00255 Applic. Date: 2009-05-18

Inventor: LJUNGBLAD ULF [SE]; LUNDGREN YEN BACKSTROEM [SE]; WINQVIST OLA [SE]


Application No.: US20110129533A1  Published: 02/Jun/2011

Title: POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF

Applicant/Assignee: ACUSPHERE, INC

Application No.: 13/022776   Filing Date: 08/Feb/2011

Abstract:

Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

Priority: US2004-924642 Applic. Date: 2004-08-24; US2002-053929 Applic. Date: 2002-01-22; US1999-433486 Applic. Date: 1999-11-04; US19990136323P Applic. Date: 1999-05-27; US19990158659P Applic. Date: 1999-10-08

Inventor: STRAUB JULIE [US]; ALTREUTER DAVID [US]; BERNSTEIN HOWARD [US]; CHICKERING III DONALD E [US]; KHATTAK SARWAT [US]; RANDALL GREG [US]


Application No.: US20110129534A1  Published: 02/Jun/2011

Title: REDUCTION OF DERMAL SCARRING

Applicant/Assignee: CANJI, INC

Application No.: 13/023757   Filing Date: 09/Feb/2011

Abstract:

Methods and compositions for reducing or inhibiting dermal scarring by expressing p21WAF1/Cip1 in a wound site are provided.

Priority: US2008-268311 Applic. Date: 2008-11-10; US2004-997769 Applic. Date: 2004-11-23; US20030524993P Applic. Date: 2003-11-24

Inventor: GU DANLING [US]; ZEPEDA MONICA [US]


Application No.: US20110129535A1  Published: 02/Jun/2011

Title: TRANSDERMAL TESTOSTERONE DEVICE AND DELIVERY

Applicant/Assignee: NOVEN PHARMACEUTICALS, INC

Application No.: 12/953019   Filing Date: 23/Nov/2010

Abstract:

Described are transdermal drug delivery systems for the transdermal administration of testosterone, comprising a polymer matrix and testosterone. Methods of making and using such systems also are described.

Priority: US20090265411P Applic. Date: 2009-12-01

Inventor: MANTELLE JUAN A [US]


Application No.: US20110129801A1  Published: 02/Jun/2011

Title: COMPOSITIONS AND METHODS TO PREVENT AND TREAT DRY SOCKET POST-OPERATIVELY AFTER TOOTH EXTRACTION SURGERY

Applicant/Assignee:

Application No.: 12/626866   Filing Date: 27/Nov/2009

Abstract:

The invention describes and claims compositions and methods for their use in the prevention and treatment of alveolar osteitis (dry socket) after tooth extraction surgery.

Priority:

Inventor: BARMAN SHIKHA PRAMANIK [US]


Application No.: US20110135583A1  Published: 09/Jun/2011

Title: Anionic Isosorbide Derivatives and Their Use (II)

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 12/961070   Filing Date: 06/Dec/2010

Abstract:

Disclosed are isosorbide derivatives of formula (I) wherein R and R' independently represent an isosorbide moiety, a hydrogen atom, or an alkyl group having 6 to 22 carbon atoms, and A stands for hydrogen, an alkali metal, ammonium or alkylammonium, with the proviso that at least one of R and R' is an isosorbide group. Also disclosed is the use of compounds (I) for the preparation of cleansers, detergents, personal care compositions, and cosmetic or pharmaceutical compositions.

Priority: EP20090015093 Applic. Date: 2009-12-05

Inventor: BREFFA CATHERINE [DE]; RATHS HANS-CHRISTIAN [DE]; BEHLER ANSGAR [DE]


Application No.: US20110135585A1  Published: 09/Jun/2011

Title: Complex, Emulsion Containing The Same, And Water-In-Oil Emulsion Cosmetic Containing The Same

Applicant/Assignee: SHISEIDO COMPANY, LTD, DOW CORNING TORAY CO., LTD

Application No.: 13/057177   Filing Date: 31/Jul/2009

Abstract:

A stable emulsion cosmetic having an excellent texture in use, and in particular, a solid emulsion cosmetic which is stable in a system containing a large amount of water is provided. The complex consists of an organosiloxane derivative represented by the following formula (1) or (2) and an amphoteric surfactant and/or semipolar surfactant.

Priority: JP20080200660 Applic. Date: 2008-08-04; WO2009JP63660 Applic. Date: 2009-07-31

Inventor: IKEDA TOMOKO [JP]; NISHIHAMA SHUJI [JP]; OSAWA TOMO [JP]; NAKAMA YASUNARI [JP]; IIMURA TOMOHIRO [JP]; OKAWA TADASHI [JP]


Application No.: US20110135699A1  Published: 09/Jun/2011

Title: PARTICLES OF COLLAGEN MATERIAL AND PROCESS FOR THE PREPARATION

Applicant/Assignee: GELITA AG

Application No.: 13/014951   Filing Date: 27/Jan/2011

Abstract:

In order to provide a product that is suitable as fat substitute in foods, which can be produced simply and inexpensively and is deemed safe from the nutritional physiology viewpoint and with which the typical texture of fat-containing foods can be simulated as favourably as possible, particles of collagen material are proposed which are substantially insoluble and swellable in water, wherein in swollen state the particles have an average diameter of less than approximately 150 [mu]m. A process for the production of this product is additionally proposed.

Priority: DE200810036576 Applic. Date: 2008-07-31; WO2009EP59442 Applic. Date: 2009-07-22

Inventor: DICK EBERHARD [DE]; WALTER SIMONE [DE]


Application No.: US20110135706A1  Published: 09/Jun/2011

Title: NERVE TREATMENT DEVICES AND METHODS

Applicant/Assignee: LIFECELL CORPORATION

Application No.: 12/956058   Filing Date: 30/Nov/2010

Abstract:

Devices and methods for treating defects in peripheral nerves are provided. The devices can include acellular arterial tissue matrices that facilitate regrowth of nerve tissue across a gap or defect in a peripheral nerve.

Priority: US20090266348P Applic. Date: 2009-12-03

Inventor: XU HUI [US]; SUN WENDELL [US]; CUI CUNQI [US]; WAN HUA [US]


Application No.: US20110135725A1  Published: 09/Jun/2011

Title: Lipid Construct for Delivery of Insulin to a Mammal

Applicant/Assignee: SDG, INC

Application No.: 11/920905   Filing Date: 16/May/2006

Abstract:

The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.

Priority: US2006-384728 Applic. Date: 2006-03-20; US2006-384659 Applic. Date: 2006-03-20; US20050683878P Applic. Date: 2005-05-23; WO2006US19119 Applic. Date: 2006-05-16

Inventor: LAU JOHN R [US]; GEHO W BLAIR [US]


Application No.: US20110135726A1  Published: 09/Jun/2011

Title: HYDROGEL COMPOSITES AND WOUND DRESSINGS

Applicant/Assignee: FIRST WATER LIMITED

Application No.: 12/866611   Filing Date: 06/Feb/2009

Abstract:

The present invention provides an absorbent hydrogel composite for use in the manufacture of an article for application to a fluid-emitting surface, e.g. a wound, the composite having a laminar structure comprising first and second layers, the first layer being a surface contacting layer comprising a porous net structure having a surface contacting face and an outwardly directed face, the second layer comprising a low-crosslinked absorbent hydrogel disposed over the outwardly directed face of the first layer and arranged so that in use it is in fluid flow communication with the surface through apertures of the net structure.

Priority: GB20080002284 Applic. Date: 2008-02-07; US20080026920P Applic. Date: 2008-02-07; WO2009GB50121 Applic. Date: 2009-02-06

Inventor: MUNRO HUGH SEMPLE [GB]; ANDREWS PHILIP [GB]; JEFFREY CHARLES [GB]


Application No.: US20110135727A1  Published: 09/Jun/2011

Title: Hepatocyte Delivery Vehicle for Delivery of a Combination of Recombinant Human Regular Insulin and Recombinant Human Insulin Isophane to a Mammal

Applicant/Assignee: SDG, INC

Application No.: 12/953013   Filing Date: 23/Nov/2010

Abstract:

The instant invention is drawn to a hepatocyte targeted composition comprising a mixture of free recombinant human insulin isophane and free Recombinant human regular insulin insulin and a mixture of recombinant human insulin isophane and Recombinant human regular insulin insulin associated with a water insoluble target molecule complex, wherein the complex comprises multiple linked individual units and a supra-molecular lipid construct matrix. Recombinant human insulin isophane and Recombinant human regular insulin insulin are present within the complex in at least one form wherein the recombinant human insulin isophane and Recombinant human regular insulin insulin have regions of positive charge which interacts with a negative charge on the complex. The invention also includes methods for the manufacture of the composition and methods of managing blood glucose levels in individuals with Type I and Type II diabetes.

Priority: US2006-384659 Applic. Date: 2006-03-20; US1999-313828 Applic. Date: 1999-05-18; US19980085969P Applic. Date: 1998-05-19

Inventor: LAU JOHN R [US]; GEHO W BLAIR [US]


Application No.: US20110135728A1  Published: 09/Jun/2011

Title: GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR EXTENDED RELEASE OF POLYPEPTIDES

Applicant/Assignee:

Application No.: 12/963520   Filing Date: 08/Dec/2010

Abstract:

Gastric retentive dosage forms for controlled release of polypeptides are described. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

Priority: US20090267669P Applic. Date: 2009-12-08

Inventor: MILLER JENNIFER L [US]; FELL RYAN DOUGLAS [US]; COWLES VERNE EARLE [US]


Application No.: US20110135729A1  Published: 09/Jun/2011

Title: Methods for Controlling Heat Generation of Magnetic Nanoparticles and Heat Generating Nanomaterials

Applicant/Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY

Application No.: 12/993329   Filing Date: 20/May/2009

Abstract:

The present invention relates to a method for controlling heat generation of a magnetic nanomaterial, comprising the steps of: (a) mixing (i) a nanomaterial precursor comprising a metal precursor material and a predetermined amount of a zinc precursor with (ii) a reaction solvent

and (b) preparing a zinc-containing magnetic nanomaterial from the mixture of step (a) comprising a zinc doped metal oxide nanomaterial matrix

and wherein a specific loss power of the zinc-containing magnetic nanomaterial is varied depending an amount of zinc to be doped, whereby the heat generation of the magnetic nanomaterial is controlled. In addition, the present invention relates to a heat-generating nanoparticle and a composition for hyperthermia. The present invention suggests a novel approach to improve a heat generation of a magnetic nanomaterial. According to the present invention, the specific loss power can be controlled by changing a zinc-content to be introduced into nanomaterials and therefore a composition for hyperthermia showing controlled heat generation potential can be successfully provided.

Priority: KR20080046591 Applic. Date: 2008-05-20; WO2009KR02662 Applic. Date: 2009-05-20

Inventor: CHEON JIN WOO [KR]; JANG JUNG TAK [KR]


Application No.: US20110135730A1  Published: 09/Jun/2011

Title: Oral Formulations of Glycyl-2-Methylprolyl-Glutamate

Applicant/Assignee:

Application No.: 13/026787   Filing Date: 14/Feb/2011

Abstract:

Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.

Priority: US2008-283684 Applic. Date: 2008-09-15; WO2007US06528 Applic. Date: 2007-03-14; US20060782148P Applic. Date: 2006-03-14

Inventor: WEN JINGYUAN [NZ]; THOMAS GREGORY BRIAN [AU]; BICKERDIKE MIKE JOHN [NZ]


Application No.: US20110135731A1  Published: 09/Jun/2011

Title: ABUSE-RESISTANT OPIOID DOSAGE FORM

Applicant/Assignee: ENDO PHARMACEUTICALS, INC

Application No.: 13/033899   Filing Date: 24/Feb/2011

Abstract:

We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.

Priority: US2010-894614 Applic. Date: 2010-09-30; US2002-143140 Applic. Date: 2002-05-10; US20010290438P Applic. Date: 2001-05-11

Inventor: KAO HUAI-HUNG [US]; ZENG YADI [US]; HOWARD-SPARKS MICHELLE [US]; JIM FAI [US]


Application No.: US20110135732A1  Published: 09/Jun/2011

Title: MULTIPLE PHASE CROSS-LINKED COMPOSITIONS AND USES THEREOF

Applicant/Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Application No.: 12/951221   Filing Date: 22/Nov/2010

Abstract:

The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.

Priority: US2006-434023 Applic. Date: 2006-05-15; US2001-883842 Applic. Date: 2001-06-18; US20000212511P Applic. Date: 2000-06-19

Inventor: STEIN STANLEY [US]; QIU BO [US]; SINKO PATRICK J [US]


Application No.: US20110139669A1  Published: 16/Jun/2011

Title: Preparing of products, in particular cellulose-containing products and/or spaces

Applicant/Assignee: BELL FLAVORS & FRAGRANCES DUFT UND AROMA GMBH

Application No.: 12/308780   Filing Date: 25/Jun/2007

Abstract:

The process of the invention for the preparation of products, in particular cellulose-containing products (1) and spaces includes the arrangement of at least one flavour and/or fragrance (3) and/or active substance, bound in a solid carrier material, in and/or at the product (1) and/or the direct proximity of the cellulose-containing product (1) and/or the space. Furthermore, means are provided for the preparation of products, in particular cellulose-containing products, and of spaces as described, as well as systems from these means and products, in particular cellulose-containing products.

Priority: DE200610029092 Applic. Date: 2006-06-24; WO2007EP05618 Applic. Date: 2007-06-25

Inventor: HUPPERT HANS-JUERGEN [DE]; BERRIDO COLIN [GB]


Application No.: US20110142783A1  Published: 16/Jun/2011

Title: [(4E, 4Z)-5-METHOXY-3-METHYL-4-PENTENYL]-BENZENE AND ITS USE IN PERFUME COMPOSITIONS

Applicant/Assignee:

Application No.: 12/637827   Filing Date: 15/Dec/2009

Abstract:

The present invention is directed to a novel compound, [(4E, 4Z)-5-methoxy-3-methyl-4-pentenyl]-benzene, and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of this novel compound.

Priority:

Inventor: NARULA ANUBHAV P S [US]; ARRUDA EDWARD MARK [US]


Application No.: US20110142901A1  Published: 16/Jun/2011

Title: SUSTAINED RELEASE COMPOSITION

Applicant/Assignee:

Application No.: 12/860470   Filing Date: 20/Aug/2010

Abstract:

A sustained release apparatus including at least one sustained release mini-implant or pellet

the or each mini-implant or pellet including: a sustained release support material

and a pharmaceutical composition including a Luteinising Hormone Releasing Hormone (HLRH) agonist and/or antagonist component the size and/or number and/or payload of mini-implant(s) or pellet(s) providing, release of LHRH agonist and/or antagonist at, or above, a desired threshold level for treatment of a selected indication, the apparatus providing approximately zero order release of the LHRH agonist and/or antagonist.

Priority: AU20040902893 Applic. Date: 2004-05-31; US2007-628036 Applic. Date: 2007-08-22; WO2005AU00766 Applic. Date: 2005-05-30

Inventor: BRANDON MALCOLM [AU]; MARTINOD SERGE R [US]


Application No.: US20110142902A1  Published: 16/Jun/2011

Title: Hypoxia Inducing Factor (HIF) Stabilising Glasses

Applicant/Assignee: IMPERIAL INNOVATIONS LIMITED

Application No.: 12/994463   Filing Date: 27/May/2009

Abstract:

The present invention relates to a glass composition formulated to provide the controlled release of certain transition metal ions to regulate the cellular hypoxia pathway and the use of these hypoxia-pathway regulating glasses in medicine and in biomedical research, including in the repair, restoration or regeneration of diseased or damaged tissue.

Priority: GB20080009577 Applic. Date: 2008-05-27; GB20080009578 Applic. Date: 2008-05-27; WO2009GB01323 Applic. Date: 2009-05-27

Inventor: JELL GAVIN [GB]; HILL ROBERT GRAHAM [GB]; STEVENS MOLLY MORAG [GB]; AZEVEDO MARIA [GB]


Application No.: US20110142935A1  Published: 16/Jun/2011

Title: CARDIAC DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS UNDER DEFINED CONDITIONS USING MATRIX OVERLAY METHODS

Applicant/Assignee:

Application No.: 12/946019   Filing Date: 15/Nov/2010

Abstract:

Methods for culturing the pluripotent stem cells to undergo epithelial-to-mesenchymal transition and for generating high-yield, high-purity cardiomyocyte cultures from pluripotent stem cells are described. Pluripotent stem cells are cultured on a support with an overlaid matrix and, optionally, exposed to one or more factors to induce epithelial-to-mesenchymal transition and cardiogenesis.

Priority: US20090261054P Applic. Date: 2009-11-13

Inventor: KAMP TIMOTHY J [US]; PALECEK SEAN [US]; ZHANG JIANHUA [US]; AZARIN SAMIRA [US]; LIAN XIAOJUN [US]


Application No.: US20110142936A1  Published: 16/Jun/2011

Title: IMPLANTS AND BIODEGRADABLE FIDUCIAL MARKERS

Applicant/Assignee:

Application No.: 12/968527   Filing Date: 15/Dec/2010

Abstract:

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

Priority: US20090286450P Applic. Date: 2009-12-15

Inventor: CAMPBELL PATRICK [US]; SAWHNEY AMARPREET S [US]


Application No.: US20110142937A1  Published: 16/Jun/2011

Title: Methods and Compositions To Treat Hemorrhagic Conditions of The Brain

Applicant/Assignee:

Application No.: 13/032514   Filing Date: 22/Feb/2011

Abstract:

The described invention provides a nonhuman animal model system for hemorrhagic brain conditions, methods for evaluating a substance for treating the hemorrhagic brain condition in a mammal, methods for treating hematoma expansion or recurrent rebleeding resulting from hemorrhagic brain conditions in a mammal, and pharmaceutical compositions for administration into or at a distance proximal to the hemorrhagic brain condition.

Priority: US2008-137320 Applic. Date: 2008-06-11; US20070943124P Applic. Date: 2007-06-11; US20070976902P Applic. Date: 2007-10-29; US20100306758P Applic. Date: 2010-02-22

Inventor: MACDONALD R LOCH [CA]


Application No.: US20110142938A1  Published: 16/Jun/2011

Title: Nanotubes as Mitochondrial Uncouplers

Applicant/Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION

Application No.: 13/035576   Filing Date: 25/Feb/2011

Abstract:

A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca2+ into mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided.

Priority: US2006-418208 Applic. Date: 2006-05-05; US20050678355P Applic. Date: 2005-05-06

Inventor: SULLIVAN PATRICK G [US]


Application No.: US20110142939A1  Published: 16/Jun/2011

Title: Use of a Combination of an Opioid Agonist and an Opioid Antagonist for the Treatment of Crohn's Disease and the Symptoms Associated with Crohn's Disease

Applicant/Assignee:

Application No.: 12/680352   Filing Date: 25/Sep/2008

Abstract:

The present invention is concerned with the use of combinations of opioid agonists and antagonists for treating Crohn's disease.

Priority: EP20070117241 Applic. Date: 2007-09-26; EP20080150834 Applic. Date: 2008-01-30; WO2008EP62834 Applic. Date: 2008-09-25

Inventor: BENNETT-KERR JO [GB]


Application No.: US20110144577A1  Published: 16/Jun/2011

Title: HYDROPHILIC COATINGS WITH TUNABLE COMPOSITION FOR DRUG COATED BALLOON

Applicant/Assignee:

Application No.: 12/636158   Filing Date: 11/Dec/2009

Abstract:

A tunable coating formulation is described for a drug delivery balloon comprising a therapeutic agent, an excipient and a plasticizer. The tunable coating includes a first therapeutic agent and a first excipient, and can have a second therapeutic agent and a second excipient. The first and second therapeutic agents have different dissolution rates during balloon inflation and therefore provide a coating that is tunable. The plasticizer in the formulation has a weigh ratio of excipient to plasticizer below 1:0.1.

Priority:

Inventor: STANKUS JOHN [US]; PACETTI STEPHEN [US]; TROLLSAS MIKAEL [US]; HOSSAINY SYED [US]


Application No.: US20110150765A1  Published: 23/Jun/2011

Title: Frozen compositions and methods for piercing a substrate

Applicant/Assignee: SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE

Application No.: 12/586070   Filing Date: 15/Sep/2009

Abstract:

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Priority: US2008-290671 Applic. Date: 2008-10-31; US2008-290683 Applic. Date: 2008-10-31; US2008-290685 Applic. Date: 2008-10-31; US2008-290686 Applic. Date: 2008-10-31; US2008-290690 Applic. Date: 2008-10-31; US2008-290691 Applic. Date: 2008-10-31; US2008-290684 Applic. Date: 2008-10-31; US2008-290670 Applic. Date: 2008-10-31; US2008-290664 Applic. Date: 2008-10-31; US2008-290659 Applic. Date: 2008-10-31; US2008-290658 Applic. Date: 2008-10-31; US2008-290665 Applic. Date: 2008-10-31; US2008-290677 Applic. Date: 2008-10-31; US2008-290687 Applic. Date: 2008-10-31; US2008-290676 Applic. Date: 2008-10-31; US2009-383264 Applic. Date: 2009-03-20; US2009-383263 Applic. Date: 2009-03-20; US2009-383260 Applic. Date: 2009-03-20; US2009-383265 Applic. Date: 2009-03-20; US2009-383851 Applic. Date: 2009-03-27; US2009-383863 Applic. Date: 2009-03-27; US2009-383821 Applic. Date: 2009-03-27; US2009-383829 Applic. Date: 2009-03-27; US2009-384202 Applic. Date: 2009-03-31; US2009-384201 Applic. Date: 2009-03-31; US2009-384212 Applic. Date: 2009-03-31; US2009-384215 Applic. Date: 2009-03-31; US2009-384216 Applic. Date: 2009-03-31; US2009-384218 Applic. Date: 2009-03-31; US2009-384214 Applic. Date: 2009-03-31; US2009-586076 Applic. Date: 2009-09-15; US2009-586074 Applic. Date: 2009-09-15; US2009-586072 Applic. Date: 2009-09-15; US2009-586073 Applic. Date: 2009-09-15; US2009-586077 Applic. Date: 2009-09-15; US2009-586075 Applic. Date: 2009-09-15; US2009-586071 Applic. Date: 2009-09-15

Inventor: BOYDEN EDWARD S [US]; COOK DANIEL B [US]; HYDE RODERICK A [US]; LEUTHARDT ERIC C [US]; MYHRVOLD NATHAN P [US]; SWEENEY ELIZABETH A [US]; WOOD JR LOWELL L [US]


Application No.: US20110150793A1  Published: 23/Jun/2011

Title: Clear or Translucent Composition

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: 12/640136   Filing Date: 17/Dec/2009

Abstract:

The present disclosure relates to a clear or translucent composition which takes the form of a solid, a semi-solid or a viscous gel. The inventive composition contains a mixture of at least two amino acid-based gelatinizing agents, a non-ionic unsaturated fatty alcohol in an amount which reduces the dissolution temperature of the gelatinizing agents to allow processing at or below 100 DEG C., an alkyl dimethicone, and an oil and/or a polymer component. Additional ingredients depending on the application may also be included in the clear or translucent composition. The present disclosure also relates to methods of producing the clear or translucent composition of the disclosure and uses thereof.

Priority:

Inventor: DO THI N [US]; MCNAMARA WILLIAM E [US]; HALES KELLY [US]


Application No.: US20110150980A1  Published: 23/Jun/2011

Title: CGRP ANALOG

Applicant/Assignee: VASOGENIX PHARMACEUTICALS, INC

Application No.: 12/949565   Filing Date: 18/Nov/2010

Abstract:

Sequence modified calcitonin gene related peptide (CGRP) compounds are useful for treating heart failure, stroke, hemorrhagic shock, or migraine, improving renal function, preventing or delaying the advancement of heart failure into advanced stages, treating angina, controlling pulmonary hypertension, counteracting ischemia due to a myocardial infarction, preventing vasospasms during angioplasty, preventing reocclusion of blood vessels during and/or after angioplasty, stent insertion, or the implantation of a vascular grafts, and for treating male impotence and female sexual arousal disorder.

Priority: WO2009US03097 Applic. Date: 2009-05-19; US20080054337P Applic. Date: 2008-05-19

Inventor: SOUTHARD GEORGE LEE [US]; SOUTHARD JEFFREY LEE [US]


Application No.: US20110150993A1  Published: 23/Jun/2011

Title: Fine Particle Croscarmellose and Uses Thereof

Applicant/Assignee: FMC CORPORATION

Application No.: 12/970153   Filing Date: 16/Dec/2010

Abstract:

The disclosure is directed to fine particle croscarmellose and its use in various compositions such as solid dosage forms. More specifically, the present disclosure relates to fine particle croscarmellose having a median particle size of 5 [mu]m to 36 [mu]m and a volume mean diameter of 40 [mu]m or less. The specific surface area is typically 0.3 m2/g or more. The fine particle croscarmellose is useful as a disintegrant.

Priority: US20090289048P Applic. Date: 2009-12-22

Inventor: ZHANG YELI [US]


Application No.: US20110150994A1  Published: 23/Jun/2011

Title: Modified Release Formulation

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/036928   Filing Date: 28/Feb/2011

Abstract:

The invention is directed to the use of an extended release tablet formulation for pramipexole.

Priority: EP20060002775 Applic. Date: 2006-02-10; US2008-278846 Applic. Date: 2008-09-12; WO2007EP51255 Applic. Date: 2007-02-09

Inventor: FRIEDL THOMAS [DE]; EISENREICH WOLFRAM [DE]


Application No.: US20110150995A1  Published: 23/Jun/2011

Title: Solid Dosage Forms of Essential Oils

Applicant/Assignee:

Application No.: 12/645446   Filing Date: 22/Dec/2009

Abstract:

Essential oils are extracted from plants and some have known medicinal properties. Some essential oils have been to known to show antibacterial, antifungal and antiviral activities. Some essential oils show sensual properties and others improve quality of sleep. The present invention describes a method to produce a solid dosage form (tablets or capsules) of these essential oils showing medicinal properties. The essential oils are adsorbed or absorbed on a substrate. The presence of a surfactant in the formulation helps solubilization of essential oils in the mouth cavity in vivo. Combination of various essential oils can be incorporated in the solid dosage forms.

Priority:

Inventor: JOSHI HEMANT NARAHAR [US]


Application No.: US20110150998A1  Published: 23/Jun/2011

Title: Methods For Producing ECM-Based Biomaterials

Applicant/Assignee:

Application No.: 12/644607   Filing Date: 22/Dec/2009

Abstract:

A method for forming an extracellular matrix material (ECM) material includes providing at least an ECM composition containing ECM particles varying in their capacity for migration through a fluid medium, including at least one population of expanded ECM particles. The ECM composition is combined in a fluid medium to form a flowable ECM composition. The flowable ECM composition is subjected to a centrifugal force in a mold for a period of time sufficient to distribute the ECM particles according to differences in their physical characteristics. The ECM composition is dried to form a dried ECM material having a density gradient extending from a less dense region to a more dense region. The dried ECM material may formed as a porous, substantially acellular ECM material expandable in an aqueous fluid environment by at least 100% in volume.

Priority:

Inventor: FARRELL LAURA-LEE [US]; JOHNSON CHAD E [US]


Application No.: US20110150999A1  Published: 23/Jun/2011

Title: Organo-Soluble Chitosan Salts and Chitosan-Derived Biomaterials Prepared Thereof

Applicant/Assignee:

Application No.: 12/935660   Filing Date: 01/Apr/2009

Abstract:

Organo-soluble chitosan salts, method for preparing organo-soluble salts, chitosan-derived materials prepared with organo-soluble chitosan salts, and methods for preparing chitosan-derived materials are disclosed.

Priority: US20080064887P Applic. Date: 2008-04-01; WO2009US02017 Applic. Date: 2009-04-01

Inventor: CHU CHIH-CHANG [US]; ZHONG CHAO [US]


Application No.: US20110151000A1  Published: 23/Jun/2011

Title: NITRIC OXIDE-RELEASING COMPOSITIONS, DEVICES AND METHODS

Applicant/Assignee:

Application No.: 12/988700   Filing Date: 20/Apr/2009

Abstract:

Nitric oxide releasing compositions, which comprise nanoparticles having an exterior surface comprising solid amorphous silica, the exterior surface having nitrosothiol-containing groups attached thereto, the nanoparticles being dispersible in an aqueous system, devices including the compositions, and methods of making and using the compositions and devices are disclosed.

Priority: US20080046659P Applic. Date: 2008-04-21; WO2009US41090 Applic. Date: 2009-04-20

Inventor: SCHULTZ WILLIAM J [US]; HADDAD LOUIS C [US]; STENDAHL JOHN C [US]; RADLOFF COREY J [US]; BERNATCHEZ STEPHANIE F [US]; SCHOLZ MATTHEW T [US]


Application No.: US20110151001A1  Published: 23/Jun/2011

Title: PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION CONTAINING PROCHLORPERAZINE

Applicant/Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD

Application No.: 12/991134   Filing Date: 03/Mar/2009

Abstract:

Disclosed is a novel pharmaceutical composition for external application for increasing the permeation of prochlorperazine or a pharmaceutically acceptable salt thereof through the skin to allow prochlorperazine or the pharmaceutically acceptable salt thereof to exhibit its excellent pharmacological activity. Specifically disclosed is a novel pharmaceutical composition for external application, which contains prochlorperazine or a pharmaceutically acceptable salt thereof as an active ingredient and further contains menthol. The composition contains, as an active ingredient, prochlorperazine which has been widely used clinically as the first-line drug of a therapeutic agent for nausea or vomiting before or after a surgery or the like, and is extremely highly useful as a transdermally absorbable antiemetic agent that has excellent efficacy and can be used safely over a long period.

Priority: JP20080128245 Applic. Date: 2008-05-15; WO2009JP53988 Applic. Date: 2009-03-03

Inventor: OBATA YASUKO [JP]; OTAKE YUKI [JP]; TAKAYAMA KOZO [JP]


Application No.: US20110151002A1  Published: 23/Jun/2011

Title: SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING QUETIAPINE

Applicant/Assignee: LUPIN LIMITED

Application No.: 13/002277   Filing Date: 29/Jun/2009

Abstract:

A sustained release dosage form comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more non-gellable release controlling polymer and one or more pharmaceutically acceptable excipient(s). A sustained release dosage form comprising first granulation comprising Quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof and one or more release controlling material

and second granulation comprising one or more release controlling material which is the same or different than the one or more release controlling material of the first granulation and optionally quetiapine or its pharmaceutically acceptable salts, polymorphs, solvates, hydrates thereof. A method of preparing the sustained release dosage form by first and second granulation followed by milling

blending the said milled granules after second granulation with lubricant followed by compression to form a sustained release dosage form. A sustained release dosage form comprising immediate release core comprising Quetiapine or a pharmaceutically acceptable salt, polymorphs, solvates, hydrates thereof and one or more pharmaceutically acceptable excipients

and sustained release coating comprising one or more non-gellable release controlling material.

Priority: IN2008KO01143 Applic. Date: 2008-07-01; WO2009IN00369 Applic. Date: 2009-06-29

Inventor: VELHAL AVINASH KRISHNAJI [IN]; MIRAJKAR SUNIL ANANTRAO [IN]; KURIL VIRENDRA RAMKRUPAL [IN]; RAGHAVAN VINEETH [IN]; DESHPANDAY NINAD [IN]


Application No.: US20110151005A1  Published: 23/Jun/2011

Title: METHODS AND MEANS FOR SOFT TISSUE ENGINEERING

Applicant/Assignee:

Application No.: 13/040957   Filing Date: 04/Mar/2011

Abstract:

Cellfree adipose tissue extracts, implants including the same and methods for the preparation thereof. The extracts and implants are capable of inducing adipogenesis and angiogenesis and are, thus, useful in applications including soft tissue repair and engineering and angiogenesis induction, e.g., in wound healing, treatment of burn injuries and ischemic conditions.

Priority: FI20080005839 Applic. Date: 2008-09-08; WO2009FI50715 Applic. Date: 2009-09-07; US20080095198P Applic. Date: 2008-09-08

Inventor: YLIKOMI TIMO [FI]; SARKANEN JERTTA-RIINA [FI]


Application No.: US20110151006A1  Published: 23/Jun/2011

Title: STIMULI-RESPONSIVE HYDROGEL

Applicant/Assignee:

Application No.: 12/996492   Filing Date: 05/Jun/2009

Abstract:

The present invention relates to a hydrogel comprising a polymer, a first polypeptide and a polypeptide binding partner, wherein the polypeptide binding partner is a second polypeptide, a nucleic acid or a small molecule, and wherein the interaction between the first polypeptide and the polypeptide binding partner stabilizes the hydrogel and is modulated by the addition of a modulating compound. A drug may be physically entrapped in the hydrogel, bound to the polymer forming the hydrogel structure, or bound to the first polypeptide or the polypeptide binding partner, and then be set free on addition of the modulating compound. Such a hydrogel comprising a drug may be injected into a patient, and drug release modulated by orally administering the modulating compound.

Priority: EP20080010312 Applic. Date: 2008-06-06; EP20080019267 Applic. Date: 2008-11-04; WO2009EP04050 Applic. Date: 2009-06-05

Inventor: WEBER WILFRIED [DE]; FUSSENEGGER MARTIN [CH]; SCHOENMAKERS RONALD [NL]


Application No.: US20110151011A1  Published: 23/Jun/2011

Title: Decellularized Adipose Tissue

Applicant/Assignee:

Application No.: 12/971531   Filing Date: 17/Dec/2010

Abstract:

This invention provides a method for decellularizing adipose tissue, comprising subjecting the adipose tissue to one or more incubations in an enzymatic digestion solution containing one or more enzymes, and one or more solvent extractions, wherein decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional structure is obtained. The invention also provides a decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional architecture, and bioscaffolds, microcarrier beads, and coatings comprising the decellularized adipose tissue.

Priority: US20090287236P Applic. Date: 2009-12-17

Inventor: FLYNN LAUREN E [CA]


Application No.: US20110158963A1  Published: 30/Jun/2011

Title: THREE-DIMENSIONAL MATRICES OF STRUCTURED POROUS MONETITE FOR TISSUE ENGINEERING AND BONE REGENERATION, AND METHOD OF THE PREPARATION THEREOF

Applicant/Assignee: HISTOCELL, S.L

Application No.: 13/002939   Filing Date: 08/Jul/2009

Abstract:

The present invention is comprised within tissue engineering and, specifically, within bone regeneration. The invention relates to a porous three-dimensional matrix of monetite which is biocompatible, has structured porosity and is predefined and reabsorbable, as well as to the method of synthesis capable of producing said material and the applications thereof. These matrices are a perfect base for cell colonization and proliferation, allowing the application thereof in tissue engineering and bone regeneration as a result of their advantageous properties of biocompatibility, reabsorption, osteoinduction, revascularization, etc.

Priority: WO2008ES00482 Applic. Date: 2008-07-08; WO2009ES00358 Applic. Date: 2009-07-08

Inventor: FONT PEREZ JULIO [ES]; CASTROFEO MARIA BEGONA [ES]; DEL OLMO BASTERRECHEA MAITE [ES]; GARCIA VAZQUEZ MARIA DOLORES [ES]; RUBIO RETAMA JORGE [ES]; LOPEZ CABARCOS ENRIQUE [ES]; RUEDA RODRIGUEZ CARMEN [ES]; TAMINI MARINO FALEH [ES]; ALKHRAISAT MOHAMMAD HAMDAN ALI [ES]


Application No.: US20110159079A1  Published: 30/Jun/2011

Title: High Delivery Rates for Lipid Based Drug Formulations, and Methods of Treatment Thereof

Applicant/Assignee:

Application No.: 12/983659   Filing Date: 03/Jan/2011

Abstract:

Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.

Priority: US2006-398859 Applic. Date: 2006-04-06; US2005-185448 Applic. Date: 2005-07-19; US2004-023971 Applic. Date: 2004-12-28; US2003-696389 Applic. Date: 2003-10-29; US20020421923P Applic. Date: 2002-10-29

Inventor: LI ZHILI [US]; BONI LAWRENCE T [US]; MILLER BRIAN S [US]; MALININ VLADIMIR [US]; LI XINGONG [US]


Application No.: US20110159097A1  Published: 30/Jun/2011

Title: EXTRACT OF THE PLANT RAVENALA MADAGASCARIENSIS AND USE AS COSMETIC HYDRATING AGENT

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/967560   Filing Date: 14/Dec/2010

Abstract:

An extract is from the plant Ravenala madagascariensis. The sap from the plant Ravenala madagascariensis or of an extract of that plant is used as a hydrating active agent in a cosmetic composition, to restore, maintain or reinforce the hydration state of the skin.

Priority: FR20090059651 Applic. Date: 2009-12-29

Inventor: RENIMEL ISABELLE [FR]; ANDRE PATRICE [FR]


Application No.: US20110159098A1  Published: 30/Jun/2011

Title: STABILIZATION AND DELIVERY OF NUCLEIC ACID COMPLEXES

Applicant/Assignee: SURMODICS, INC

Application No.: 12/968365   Filing Date: 15/Dec/2010

Abstract:

Compositions and methods for delivering nucleic acid, including siRNA, to a target cell are provided. In one embodiment, the composition includes the nucleic acid and a stabilizing protein. In another embodiment, the nucleic acid is complexed with a carrier, for example, a peptide carrier. In yet another embodiment, the nucleic acid combined with a protein which is cross-linked to form a proteinaceous controlled release matrix. Methods for making the compositions are also described.

Priority: US20090290989P Applic. Date: 2009-12-30

Inventor: SLAGER JORAM [US]


Application No.: US20110159099A1  Published: 30/Jun/2011

Title: BONE-FILLING TYPE AGENT FOR INDUCING CARTILAGE REGENERATION

Applicant/Assignee: NATIONAL UNIVERSITY CORPORATION, HOKKAIDO UNIVERSITY

Application No.: 13/060788   Filing Date: 26/Aug/2009

Abstract:

Provided is a medical material which enables a novel treatment method for cartilage regeneration being different from a treatment method through transplantation of autologous cartilage, a cartilage alternative or undifferentiated cells. Provided is a bone-filling type agent for inducing cartilage regeneration comprising a hydrogel which contains, as a monomer unit, an acid having an acidic group and/or a salt obtained by adding a metal to an acidic group and does not contain an interpenetrating network structure or a semi-interpenetrating network structure composed of two or more polymers. The bone-filling type agent for inducing cartilage regeneration can induce natural cartilage regeneration in the body by filling it in a hole or a groove provided in subchondral bone beneath cartilage defect.

Priority: JP20080217253 Applic. Date: 2008-08-26; WO2009JP64888 Applic. Date: 2009-08-26

Inventor: YASUDA KAZUNORI [JP]; OSADA YOSHIHITO [JP]; GONG JIAN PING [JP]


Application No.: US20110165242A1  Published: 07/Jul/2011

Title: IN SITU GELLING DRUG DELIVERY SYSTEM

Applicant/Assignee: PSIVIDA INC

Application No.: 12/870616   Filing Date: 27/Aug/2010

Abstract:

The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

Priority: US2004-877758 Applic. Date: 2004-06-25; US20030482677P Applic. Date: 2003-06-26; US20040575307P Applic. Date: 2004-05-28

Inventor: SU DONGLING [US]; ASHTON PAUL [US]; CHEN JIANBING [US]


Application No.: US20110165243A1  Published: 07/Jul/2011

Title: Concurrent delivery of multiple therapeutic agents via hydrogels for biomedical applications

Applicant/Assignee:

Application No.: 12/928206   Filing Date: 07/Dec/2010

Abstract:

A process for concurrent delivery of multiple therapeutic agents via hydrogels. The process includes polymerizing a hydrogel and combining said hydrogel with at least two biologically therapeutic agents. Encapsulation of whole viable cells into polymerized hydrogel for transplantation is also disclosed.

Priority: US20100283864P Applic. Date: 2010-01-04; US20100397001P Applic. Date: 2010-06-07

Inventor: BARKER ELIZABETH [US]


Application No.: US20110165244A1  Published: 07/Jul/2011

Title: BIORESPONSIVE POLYMER FORMULATIONS FOR DELIVERY OF BIOACTIVE AGENTS

Applicant/Assignee: ALLVIVO VASCULAR, INC

Application No.: 12/980293   Filing Date: 28/Dec/2010

Abstract:

Elutable coatings and materials comprising protein resistant polymer components and bioactive agent on medical devices are disclosed. The elutable coatings comprise labile linkers that can be cleaved in response to a targeted physiologic stimulus. Medical devices formed from elutable materials comprised of protein resistant polymer components and bioactive agents are also disclosed. The elutable materials comprise labile linkers that can be cleaved in response to a targeted physiologic stimulus.

Priority: US2004-969541 Applic. Date: 2004-10-20; US20030513057P Applic. Date: 2003-10-21

Inventor: NEFF JENNIFER A [US]


Application No.: US20110165245A1  Published: 07/Jul/2011

Title: COMPOSITIONS AND METHODS FOR DISTRACTION OSTEOGENESIS

Applicant/Assignee: BIOMIMETIC THERAPEUTICS, INC

Application No.: 13/048795   Filing Date: 15/Mar/2011

Abstract:

The present invention relates to compositions and methods for use in osteodistraction procedures. In one embodiment, a method of stimulating osteogenesis during and/or following bone distraction comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of bone distraction.

Priority: US2009-368242 Applic. Date: 2009-02-09; US20080026934P Applic. Date: 2008-02-07

Inventor: LYNCH SAMUEL E [US]; HART CHARLES E [US]; EHRLICH MICHAEL G [US]; MOORE DOUGLAS C [US]


Application No.: US20110165247A1  Published: 07/Jul/2011

Title: DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF A ROTIGOTINE BASE

Applicant/Assignee: UCB PHARMA GMBH

Application No.: 13/020414   Filing Date: 03/Feb/2011

Abstract:

The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(-)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(-)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1 naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 ?m, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.

Priority: DE20021061696 Applic. Date: 2002-12-30; US2004-517157 Applic. Date: 2004-12-06; WO2003EP14902 Applic. Date: 2003-12-24

Inventor: BREITENBACH ARMIN [DE]


Application No.: US20110166239A1  Published: 29/Apr/2010

Title: 2,3,3-Trimethylcyclopent-3-Enecarbaldehyde Derivatives Useful as Odorants

Applicant/Assignee:

Application No.: 12/444804   Filing Date: 16/Oct/2007

Abstract:

Described are 2,2,3-trimethylcyclopent-3-enecarbaldehyde derivatives of formula (I) wherein R1-R7 have the same meaning as given in the specification. The invention furthermore relates to a method of their production and to fragrance compositions comprising them.

Priority: WO2007CH00508 Applic. Date: 2007-10-16; GB20060020556 Applic. Date: 2006-10-18

Inventor: BAJGROWICZ JERZY A [CH]; KRAFT PHILIP [CH]


Application No.: US20110171285A1  Published: 14/Jul/2011

Title: Design of Fibrinogen and Fibrinogen Derived Products with Reduced Bacterial Binding by Using Modified Sequences of Fibrinogen Chains

Applicant/Assignee: THE TEXAS A&M UNIVERSITY SYSTEM

Application No.: 12/914511   Filing Date: 28/Oct/2010

Abstract:

The present invention describes the design and development of new fibrinogen and fibrinogen derived products with significantly reduced binding to bacteria while retaining normal physiological functions by using modified fibrinogen amino acid sequences. The present invention describes modified sequences of Fg [gamma]-chains and [beta]-chains with reduced binding to S. aureus ClfA and S. epidermidis SdrG respectively. Modified Fg with the described modifications will not bind other bacterial surface proteins that bind Fg using similar mechanisms as ClfA and SdrG. These new Fg and Fg derived products will therefore have less binding to bacteria and will be advantageous compared to normal human Fg in a number of different settings.

Priority: US20090255806P Applic. Date: 2009-10-28

Inventor: HOOK MAGNUS [US]; GANESH VANNAKAMBADI K [US]; SMEDS EMANUEL [US]


Application No.: US20110171302A1  Published: 14/Jul/2011

Title: METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS

Applicant/Assignee: CENTER LABORATORIES, INC

Application No.: 13/071520   Filing Date: 25/Mar/2011

Abstract:

Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.

Priority: WO2010CN01519 Applic. Date: 2010-09-29; US20090247057P Applic. Date: 2009-09-30

Inventor: SHANE GUANG-TZUU [TW]; CHEN CHIEN-FEN [TW]; DIN CHUEN-LIN [TW]; TSAI HUI-LING [TW]; TSAI PEI-CHEN [TW]


Application No.: US20110171304A1  Published: 14/Jul/2011

Title: INJECTABLE BETA-HAIRPIN PEPTIDE HYDROGEL THAT KILLS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS

Applicant/Assignee: UNIVERSITY OF DELAWARE

Application No.: 12/730656   Filing Date: 24/Mar/2010

Abstract:

A peptide comprising the sequence VKVKVRVKVDPPTKVKVRVKV-NH2 forms a hydrogel which has the ability to shear-thin and recover. The hydrogel, both before and after shear-thinning, is capable of killing bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Priority: US20090162810P Applic. Date: 2009-03-24

Inventor: SALICK DAPHNE A [US]; POCHAN DARRIN J [US]; SCHNEIDER JOEL P [US]


Application No.: US20110171305A1  Published: 14/Jul/2011

Title: DEHYDRATED HYDROGEL INCLUSION COMPLEX OF A BIOACTIVE AGENT WITH FLOWABLE DRUG DELIVERY SYSTEM

Applicant/Assignee: QLT USA INC

Application No.: 12/995956   Filing Date: 03/Jun/2009

Abstract:

The invention provides a controlled release biodegradable polymer formulation adapted for administering bioactive agents such as therapeutic proteins to a patient through implantation of a bolus that forms a depot within the patient's body tissues. The formulation includes a dehydrated inclusion complex of the bioactive agent within a hydrogel, wherein the hydrogel can comprise a polymerized polyalkyleneglycolyl diacrylate, and, optionally, polyalkyleneglycolyl monoacrylates, including methacrylates. Alternatively, the hydrogel can comprise hyaluronic acid, chitosan, agarose, polyvinylacetate, polyvinylpyrrolide, or polyvinylalcohol nanoparticles. The bioactive agent can be a macromolecular material, such as a protein. A method of forming the inventive formulation is also provided, as well as a method for using the formulation in the treatment of a malcondition in a patient in need thereof.

Priority: US20080058484P Applic. Date: 2008-06-03; WO2009US03361 Applic. Date: 2009-06-03

Inventor: DADEY ERIC [US]; WATKINS ANDREW DREW [US]


Application No.: US20110171306A1  Published: 14/Jul/2011

Title: METHODS AND PRODUCTS FOR TREATMENT OF DISEASES

Applicant/Assignee:

Application No.: 13/072545   Filing Date: 25/Mar/2011

Abstract:

The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.

Priority: US2006-457063 Applic. Date: 2006-07-12; US20050698723P Applic. Date: 2005-07-12; US20050711157P Applic. Date: 2005-08-24; US20050711158P Applic. Date: 2005-08-24

Inventor: BAR-OR DAVID [US]


Application No.: US20110171307A1  Published: 14/Jul/2011

Title: METHODS AND PRODUCTS FOR TREATMENT OF DISEASES

Applicant/Assignee:

Application No.: 13/072568   Filing Date: 25/Mar/2011

Abstract:

The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.

Priority: US2006-457063 Applic. Date: 2006-07-12; US20050698723P Applic. Date: 2005-07-12; US20050711157P Applic. Date: 2005-08-24; US20050711158P Applic. Date: 2005-08-24

Inventor: BAR-OR DAVID [US]


Application No.: US20110171308A1  Published: 14/Jul/2011

Title: PH-SENSITIVE SOLID PHARMACEUTICAL COMPOSITION FOR ORAL PREPARATION AND PREPARATION METHOD THEREOF

Applicant/Assignee:

Application No.: 12/812687   Filing Date: 01/Sep/2008

Abstract:

A pH-sensitive solid pharmaceutical composition for oral formulation and preparation method thereof is provided. The solid pharmaceutical composition contains a pharmaceutical active ingredient, a nano-matrix carrier and a pH-sensitive polymer material.

Priority: CN20071121430 Applic. Date: 2007-09-06; WO2008CN72222 Applic. Date: 2008-09-01

Inventor: ZHANG QIANG [CN]; WANG JIANCHENG [CN]; GUO YULAN [CN]; ZHANG XUAN [CN]; JIA ZENGGRONG [CN]; LIN PING [CN]; ZHANG JINYANG [CN]; ZHANG JIE [CN]


Application No.: US20110172591A1  Published: 14/Jul/2011

Title: PORTABLE TOPICAL HYPERBARIC SKIN THERAPY AND WOUND TREATMENT SYSTEM

Applicant/Assignee: BACOUSTICS LLC

Application No.: 12/686419   Filing Date: 13/Jan/2010

Abstract:

The invention discloses methods and devices for promotion of skin healing, skin conditioning and skin rejuvenation for skin and tissue repair. More specifically, the invention is directed toward the manufacture of a storable therapeutic pad containing a therapeutic solution within a matrix. The therapeutic solution is produced by mixing oxygen with a fluid such as normal saline using an ultrasound station. Alternatively, the matrix may be composed of gels, solids and fibrous materials. The ultrasound station can be used to form micro-bubbles containing oxygen which allow storage of relatively high quantities of oxygen in a storage container containing the therapeutic pad. Micro-bubbles may be attached to stands or contained within a closed-cell foam. At the appropriate time, the storage container is opened and the therapeutic pad is attached to the wound site. The therapeutic pad is held between an impermeable layer and the wound site with an adhesive layer.

Priority:

Inventor: BABAEV EILAZ [US]


Application No.: US20110177169A1  Published: 21/Jul/2011

Title: OPHTHALMIC FORMULATIONS OF REVERSED LIQUID CRYSTALLINE PHASE MATERIALS AND METHODS OF USING

Applicant/Assignee:

Application No.: 12/833516   Filing Date: 09/Jul/2010

Abstract:

The eye is effectively treated by providing it with formulations including uncoated cationically charged microparticles of reversed cubic phase or reversed hexagonal phase material. The treatment methods are effective

for a variety of diseases and conditions including dry eye. The structure, charge and components of the microparticles in dispersion, with or without an active ingredient, provide mucoadhesion, layering, protection and prolonged duration of ophthalmic action.

Priority: US2010-731901 Applic. Date: 2010-03-25; US2004-889313 Applic. Date: 2004-07-13; US20090224712P Applic. Date: 2009-07-10

Inventor: ANDERSON DAVID [US]; CONKLIN VINCE [US]; CAMERANSI BENJAMIN [US]; KLEINMAN DAVID M [US]; COOPER EUGENE R [US]


Application No.: US20110177170A1  Published: 21/Jul/2011

Title: IMPLANTABLE NEUROENDOPROSTHETIC SYSTEM, A METHOD OF PRODUCTION THEREOF AND A METHOD OF RECONSTRUCTIVE NEUROSURGICAL OPERATION

Applicant/Assignee:

Application No.: 13/121069   Filing Date: 13/Feb/2009

Abstract:

Intended for the use in neurosurgery and organ tissue engineering to replace defects of nervous tissue of a mammal brain and spinal cord (B&SC) in reconstructive neurosurgical operations, a tissue-replaceable artificial cell-biopolymer neuroendoprosthetic system (ACBP NEPS) for surgical plasty of defects of nervous tissue of B&SC, stimulating regeneration and growth of damaged axons of neural cells, comprises an elastic cell-biopolymer biologically active mass, produced from a heterogeneous collagen-containing matrix for implantation, and a biocomposition of cell preparations of various types of autologous cells of a patient. Also disclosed are a method of producing the ACBP NEPS, which provides for perfusion of the biocomposition of the cell preparations of various types of autologous cells of a patient into a heterogeneous collagen-containing matrix for implantation, and a method of reconstructive neurosurgical operation comprising implantation of the ACBP NEPS into a defect of neural tissue.

Priority: RU20080138161 Applic. Date: 2008-09-25; WO2009RU00067 Applic. Date: 2009-02-13

Inventor: BRYUKHOVETSKIY ANDREY S [RU]; SEVASTIANOV VIKTOR I [RU]


Application No.: US20110178502A1  Published: 21/Jul/2011

Title: CELL THERAPY FOR LIMITING OVERZEALOUS INFLAMMATORY REACTIONS IN TISSUE HEALING

Applicant/Assignee: ACTX, INC

Application No.: 13/031431   Filing Date: 21/Feb/2011

Abstract:

Cells of the B cell lineage including pre-pro-B cells, pro-B cells, pre-B cells, immature B cells, and some mature B cells, and/or cells of the T cell lineage, especially those with helper or regulatory function, most preferably autologous to the recipient, can be transplanted into damaged tissue to enhance recovery following injury. In a preferred embodiment, the cells are selected based on those cells which appear at the site of injury a few days after injury, such as macrophages, lymphocytes, which accelerate clean up and repair of the injured site and to mitigate the overzealous inflammatory response, presumably by inhibiting the inflammatory cells such as neutrophils and signals released thereby immediately following injury.

Priority: US2010-729653 Applic. Date: 2010-03-23; US2006-406508 Applic. Date: 2006-04-18; US20050672416P Applic. Date: 2005-04-18

Inventor: POZNANSKY MARK C [US]; CHRONOS NICOLAS A F [US]


Application No.: US20110182957A1  Published: 28/Jul/2011

Title: CELLULOSICS FOR TISSUE REPLACEMENT

Applicant/Assignee:

Application No.: 13/000125   Filing Date: 19/Jun/2009

Abstract:

This invention relates to biomaterial compositions, methods and kits for producing hydrogels with tunable physico-chemical properties. Specifically, the invention relates to producing cellulosic hydrogels having optimized physico-chemical properties enabling support of cell growth or as replacement or filler for tissue repair, reconstruction or augmentation.

Priority: US20080129338P Applic. Date: 2008-06-19; US20080114034P Applic. Date: 2008-11-12; WO2009US48061 Applic. Date: 2009-06-19

Inventor: NICOLL STEVEN B [US]; STALLING SIMONE S [US]; REZA ANNA T [US]


Application No.: US20110182989A1  Published: 28/Jul/2011

Title: COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR ADHESION OR DIRECTING DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES

Applicant/Assignee: ALLEGRO PHARMACEUTICALS, INC

Application No.: 12/943900   Filing Date: 10/Nov/2010

Abstract:

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH-CH(CH2-SO3H)COOH or Arg-Gly-NH-CH(CH2-SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Priority: US20090259748P Applic. Date: 2009-11-10

Inventor: MACKEL MICHAEL J [US]; PARK JOHN [US]


Application No.: US20110182990A1  Published: 28/Jul/2011

Title: NANOCOMPOSITE HYDROGEL AND METHOD FOR PREPARING IT, FOR INDUSTRIAL AND MEDICAL APPLICATIONS

Applicant/Assignee: FPINNOVATIONS

Application No.: 13/010020   Filing Date: 20/Jan/2011

Abstract:

Nanocrystalline cellulose (NCC) is employed as the cross-linker and reinforcement domain for developing nanocomposite hydrogels possessing high strength and improved diffusion property

the resulting nanocomposite hydrogels are shown to have high mechanical properties, reversible swelling ability, and are biodegradable and biocompatible

the approach relies on free radical polymerization to form the hydrogels using a variety of hydrophilic vinyl monomers. These hydrogels are suitable for developing highly absorbent hygiene products, as well as for applications in medicine, engineering materials and sensors.

Priority: US20100282319P Applic. Date: 2010-01-22

Inventor: SU SHUNXING [CA]; HAMAD WADOOD Y [CA]


Application No.: US20110182991A1  Published: 28/Jul/2011

Title: METHOD FOR IMPROVED FIBRIN SEALING

Applicant/Assignee:

Application No.: 13/015999   Filing Date: 28/Jan/2011

Abstract:

The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue.

Priority: US20100299127P Applic. Date: 2010-01-28

Inventor: ILAN EREZ [IL]; REGEV KFIR [IL]; NUR ISRAEL [IL]


Application No.: US20110184039A1  Published: 28/Jul/2011

Title: PHARMACEUTICAL FORMULATION

Applicant/Assignee:

Application No.: 13/000291   Filing Date: 04/Feb/2009

Abstract:

A pharmaceutical composition comprising: a) a 5-HT1 agonist

b) an NSAID

and c) a disintegrant characterised in that the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, said composition optionally comprising one or more other pharmaceutically acceptable excipients.

Priority: AU20080903115 Applic. Date: 2008-06-20; WO2009AU00132 Applic. Date: 2009-02-04

Inventor: MOONEY BRETT ANTONY [AU]; KERAMIDAS PANAGIOTIS [AU]


Application No.: US20110184381A1  Published: 28/Jul/2011

Title: REPAIR OF DEFECTS OR LESIONS IN CARTILAGE AND BONE USING A CHONDRO-REGULATIVE MATRIX

Applicant/Assignee: UNIVERSITAET BERN

Application No.: 12/673201   Filing Date: 11/Aug/2008

Abstract:

Methods and compositions are provided for the treatment and repair of defect in the cartilage in partial- or full-thickness defects in joints of animals, in particular humans. To induce cartilage formation, a defect in cartilage is filled with layers of thin flaps of synovium or of peritendineum, which contains chondro- and osteo-progenitor cells, with interposed layers of a matrix. The matrix contains a chondrogenic factor, which induces chondrogenesis of chondroprogenitor cells in the flaps, and an anti-hypertrophic agent, which arrest differentiation of chondrocytes in an early phase, in an appropriate delivery system. The matrix filling the bone area of a full-thickness defect may contain an osteogenic factor, which induces osteogenesis of osteoprogenitor cells. The layer of a flap between cartilage and bone areas may work as a barrier, which prevents blood vessels and associated cells from penetrating from the bone area into the cartilage area. To promote the induction of chondro- and osteo-genesis of the progenitor cells in the flaps of synovium or peritendineum effectively, the flaps may be treated with enzymes, e.g., matrix metalloproteinases or be punched by a needle before filling a defect.

Priority: EP20070405236 Applic. Date: 2007-08-14; WO2008EP06601 Applic. Date: 2008-08-11

Inventor: SHINTANI NAHOKO [CH]


Application No.: US20110189108A1  Published: 04/Aug/2011

Title: USE OF 1-(2,4-DIHYDROXY-PHENYL)-3-(3-HYDROXY-4-METHOXY-PHENYL)-PROPAN-1-ONE

Applicant/Assignee: SYMRISE AG

Application No.: 13/018906   Filing Date: 01/Feb/2011

Abstract:

The invention concerns the use of a deoxy hesperetin dihydrochalcone or a salt of the deoxy hesperetin dihydrochalcone (I) or a mixture comprising or consisting of a plurality of salts of the deoxy hesperetin dihydrochalcone (I) or a mixture comprising or consisting of deoxy hesperetin dihydrochalcone (I) and a salt or a plurality of salts of the deoxy hesperetin dihydrochalcone (I), to influence the strength of taste impressions of sweet-tasting, unpleasant-, in particular bitter-, tasting or both sweet- and unpleasant-, in particular bitter-, tasting substances or mixtures of substances.

Priority: EP20100152331 Applic. Date: 2010-02-01

Inventor: BACKES MICHAEL [DE]; VOESSING TOBIAS [DE]; LEY JAKOB PETER [DE]; PAETZ SUSANNE [DE]


Application No.: US20110189244A1  Published: 04/Aug/2011

Title: APPETISING MEDICAMENT FOR ORAL ADMINISTRATION IN SOLID FORM

Applicant/Assignee: VIRBAC

Application No.: 13/055539   Filing Date: 23/Jul/2009

Abstract:

The invention relates to a coating composition for application to a veterinary pharmaceutical composition for oral administration, by a film coating method, comprising a powder appetising material a binder and a solvent. The invention further relates to a coating method by film coating of a solid veterinary pharmaceutical for oral administration and appetising medicaments for animals comprising a veterinary pharmaceutical composition and an appetising coating arranged around said composition, comprising an appetising material and a binder.

Priority: FR20080004184 Applic. Date: 2008-07-23; WO2009FR00916 Applic. Date: 2009-07-23

Inventor: DERRIEU GUY [FR]; CORVAISIER DAVID [FR]


Application No.: US20110189253A1  Published: 04/Aug/2011

Title: BIOMATERIAL COMPOSITION AND METHOD

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 12/696124   Filing Date: 29/Jan/2010

Abstract:

The disclosure is directed to a composition includes a macromer having a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure and at least two pendant chains bearing crosslinkable groups, an amphiphilic comonomer, and a crosslinking initiator, wherein the composition has a setting time of less than about 3 minutes. The disclosure is further directed to a kit and a method of making the above-mentioned composition.

Priority:

Inventor: HADDOCK SEAN M [US]; DRAPEAU SUSAN J [US]; SIMONTON THOMAS ANDREW [US]


Application No.: US20110189270A1  Published: 04/Aug/2011

Title: Differential Loading Of Drug-Eluting Medical Devices

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 12/987259   Filing Date: 10/Jan/2011

Abstract:

A medical device includes a substrate having at least one surface. The surface has a central portion and a peripheral portion. At least one bioactive agent is disposed over at least a portion of the surface. The medical device having a concentration gradient of the at least one bioactive between the central and peripheral portions.

Priority: US20100301007P Applic. Date: 2010-02-03

Inventor: BROOM DANIEL [US]; STOPEK JOSHUA [US]; ELACHCHABI AMIN [US]


Application No.: US20110189284A1  Published: 04/Aug/2011

Title: Peptide Fibres

Applicant/Assignee: UNIVERSITY OF BRISTOL

Application No.: 12/974561   Filing Date: 21/Dec/2010

Abstract:

This invention relates to protein fibrils, to methods and kits of producing those protein fibrils comprising a plurality of first peptide monomer units arranged in a first strand and a plurality of second peptide monomer units arranged in a second strand in which said first and second strands form an overlapping staggered heterodimer coiled coil structure, and wherein the amino acid residues on the exposed surface of said first and second strands enable said protein fibril to interact with another protein fibril in a plurality of non-parallel orientations. This invention also relates to bundles of protein fibrils and matrices, in particular, hydrogels produced using those protein fibrils.

Priority: US20090288702P Applic. Date: 2009-12-21

Inventor: WOOLFSON DEREK [GB]; ABELARDO EDGARDO [GB]; BANWELL ELEANOR [JP]


Application No.: US20110189285A1  Published: 04/Aug/2011

Title: HYDROGEL CAPABLE OF CONTAINING AND CONVEYING CELLS

Applicant/Assignee:

Application No.: 12/994873   Filing Date: 29/May/2009

Abstract:

An interpenetrating biodegradable polymeric matrix hydrogel and the use thereof to support, encapsulate, convey and release several types of cells under conditions which allow the cells to be kept alive, grow and interconnect. The hydrogel may be used to prepare implants for integrally or partially regenerating, reconstructing and/or replacing damaged, dead or no longer functional tissues, in particular at the central nervous system or spinal marrow level. In such use, the biodegradability of the hydrogel allows a progressive release of the conveyed cells in order to promote their integration, even functional, with the surrounding tissue. The hydrogel may also be employed to support cells, for example, neural cells such as neuronal cells, on measuring devices, specifically realised for monitoring several parameters of cell activity, also during pharmacological and bio-mechanical tests.

Priority: IT2008MI01000 Applic. Date: 2008-05-29; IT2008MI02037 Applic. Date: 2008-11-17; WO2009IB05767 Applic. Date: 2009-05-29

Inventor: DANIELE FRANCESCO [IT]; GIORDANO CARMEN [IT]; MASI MAURIZIO [IT]; PERALE GIUSEPPE [IT]; ROSSI FILIPPO [IT]; TUNESI MARTA [IT]


Application No.: US20110189286A1  Published: 04/Aug/2011

Title: Pulsatile Release of Valsartan

Applicant/Assignee:

Application No.: 12/995577   Filing Date: 01/Jun/2009

Abstract:

The present invention provides gastroretentive pulsatile pharmaceutical delivery systems that improve the bioavailability of Valsartan wherein the medicament has improved solubility, improved residence time in the gastrointestinal tract and a pulsatile release profile.

Priority: US20080058233P Applic. Date: 2008-06-03; WO2009US45786 Applic. Date: 2009-06-01

Inventor: MATHARU AMOL SINGH [US]; TAILLARDAT AGNES [CH]


Application No.: US20110189287A1  Published: 04/Aug/2011

Title: METHODS AND COMPOSITIONS FOR WOUND HEALING

Applicant/Assignee:

Application No.: 13/024856   Filing Date: 10/Feb/2011

Abstract:

The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely charged polyelectrolytes to form a polyelectrolyte layer on a wound surface. The invention further relates to incorporating wound active agents into a polyelectrolyte layer for delivery to a wound.

Priority: US2009-363044 Applic. Date: 2009-01-30; US20100303104P Applic. Date: 2010-02-10; US20080024725P Applic. Date: 2008-01-30

Inventor: ABBOTT NICHOLAS L [US]; AGARWAL ANKIT [US]; MURPHY CHRISTOPHER J [US]; MCANULTY JONATHAN F [US]


Application No.: US20110189288A1  Published: 04/Aug/2011

Title: DIETHYLSTILBESTROL DOSAGE FORM AND METHODS OF TREATMENT

Applicant/Assignee:

Application No.: 13/040143   Filing Date: 03/Mar/2011

Abstract:

Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly diethylstilbestrol and pharmaceutically acceptable salts thereof to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.

Priority: US2009-608445 Applic. Date: 2009-10-29; US20080110775P Applic. Date: 2008-11-03

Inventor: RYOO JE PHIL [US]; CHU CHUN KWONG [HK]; WANG ZHENG [US]; CHOW DIANA SHU-LIAN [US]; AKO ROLAND A [US]


Application No.: US20110189289A1  Published: 04/Aug/2011

Title: Cell-Based Method and Means for Rebuilding Bone

Applicant/Assignee: TECHNISCHE UNIVERSITAET DRESDEN

Application No.: 13/057482   Filing Date: 04/Aug/2009

Abstract:

The invention relates to the use of in vitro isolated or in vitro differentiated osteoclasts for bone rebuilding, in particular by in vivo application, to trigger bone rebuilding by attracting osteoblasts and preferably also vascular cells to sites of bone defect. It has been found by the inventors that osteoclasts can control bone rebuilding by secreting chemotactic factors and attracting osteoblasts and vascular cells to a site of bone defect. The invention further relates to the use of osteoclasts for the manufacture of a pharmaceutical preparation or medical product containing osteoclasts for the use for bone rebuilding.

Priority: DE200810036060 Applic. Date: 2008-08-04; WO2009EP60078 Applic. Date: 2009-08-04

Inventor: HOFLACK BERNARD [DE]; SANCHEZ FERNADEZ MARIA ARANTZAZU [DE]


Application No.: US20110189290A1  Published: 04/Aug/2011

Title: Compositions Comprising Capture Peptides for A B-Amyloid Peptide

Applicant/Assignee: RECOMBINANT TECHNOLOGIES LLC

Application No.: 13/121709   Filing Date: 27/Oct/2009

Abstract:

Disclosed herein is a composition for the treatment and/or prevention of Alzheimer's disease and the delivery thereof. The composition comprises a PEG hydrogel having bound thereto a capture peptide, wherein the capture peptide is capable of binding beta-amyloid. In another embodiment, the capture peptide is attached to a solid support.

Priority: US20080193075P Applic. Date: 2008-10-27; WO2009US62141 Applic. Date: 2009-10-27

Inventor: SUNDARAM PAZHANI [US]; SUNDARAM RANJINI K [US]


Application No.: US20110189298A1  Published: 04/Aug/2011

Title: DOUBLE EMULSION AND METHOD TO PRODUCE SUCH

Applicant/Assignee:

Application No.: 13/122084   Filing Date: 01/Oct/2009

Abstract:

The invention is directed to a method to produce a water-in-oil-in-water (w/o/w) emulsion, comprising: a. preparing a water-in-oil (w/o) emulsion

b. atomizing said w/o emulsion in the presence of a carrier material comprising at least a water soluble matrix material and at least one emulsifier, to form agglomerates

c. dispersing said agglomerates in an aqueous liquid, such as water or an aqueous solution. Also provided is a new instant powder (obtained after step b) that can be used to prepare the w/o/w emulsion. The emulsion of the invention is advantageously suited for the encapsulation of active components.

Priority: NL20082002046 Applic. Date: 2008-10-01; WO2009NL50593 Applic. Date: 2009-10-01

Inventor: VOS HENDRIK [NL]; POORTINGA ALBERT THIJS [NL]


Application No.: US20110190566A1  Published: 04/Aug/2011

Title: POLYMER MICROGEL BEADS

Applicant/Assignee: UNIVERSITY OF SYDNEY

Application No.: 12/993047   Filing Date: 15/May/2009

Abstract:

The present invention relates to polymer microgel beads having a polymeric matrix with nanomagnetic particles dispersed substantially uniformly therethrough, wherein a steric stabiliser is associated with the particles, the steric stabiliser being a polymeric material that (i) does not form part of the polymeric matrix of the beads, and (ii) comprises a steric stabilising polymeric segment and an anchoring polymeric segment, wherein the steric stabilising polymeric segment is different from the anchoring polymeric segment, and wherein the anchoring polymeric segment has an affinity toward the surface of the nanomagnetic particles and secures the stabiliser to the particles.

Priority: AU20080902428 Applic. Date: 2008-05-16; WO2009AU00619 Applic. Date: 2009-05-15

Inventor: HAWKETT BRIAN STANLEY [AU]; JAIN NIRMESH [AU]


Application No.: US20110190688A1  Published: 04/Aug/2011

Title: Permeant Delivery System and Methods for Use Thereof

Applicant/Assignee:

Application No.: 12/893477   Filing Date: 29/Sep/2010

Abstract:

Disclosed are a patch, system, and method for delivery of a permeant composition into a subject via at least one formed pathway through a biological membrane of the subject. The patch comprises a matrix, at least one hydrophilic permeant disposed within the matrix, wherein at least a portion of the permeant can dissolve in biological moisture received from the subject, and at least one permeability enhancer disposed within the matrix. Also disclosed are systems and methods for delivery of a permeant composition into a subject via at least one formed pathway through a skin layer of the subject.

Priority: WO2009US39045 Applic. Date: 2009-03-31; US20080040744P Applic. Date: 2008-03-31; US20080133101P Applic. Date: 2008-06-25

Inventor: TAGLIAFERRI FRANK [US]; SMITH ALAN [US]; ENSCORE DAVID [US]; TOLIA GAURAV [US]; BAUDYS MIREK [US]


Application No.: US20110195038A1  Published: 11/Aug/2011

Title: COMPOUNDS HAVING SANDALWOOD ODORS

Applicant/Assignee: FIRMENICH SA

Application No.: 13/123776   Filing Date: 18/Nov/2009

Abstract:

Sandalwood perfuming ingredients that are 2-[perhydro-trialkyl-2-naphthalenylidene]-1-propanol or propanal derivatives of the formula wherein one dotted line represents a carbon-carbon single bond and the other a carbon-carbon single bond or double bond

X represents a CH2OH group or a CHO group

each R1 represents a hydrogen atom or a methyl group

and the R2, taken separately, represent each a hydrogen atom or the two R2 groups, taken together, represent a CH2 group or a carbon-carbon double bond

and said compound is in the form of any one of its stereoisomers or a mixture thereof, along with the use of such compound(s) in perfuming compositions or articles in the perfumery industry.

Priority: WO2008IB54962 Applic. Date: 2008-11-26; WO2009IB55142 Applic. Date: 2009-11-18

Inventor: CHAPUIS CHRISTIAN [CH]


Application No.: US20110195114A1  Published: 11/Aug/2011

Title: TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS

Applicant/Assignee: ANTARES PHARMA, IPL, AG

Application No.: 13/044447   Filing Date: 09/Mar/2011

Abstract:

A delivery vehicle for topical pharmaceutical formulations that include a C2 to C4 alkanol, a polyalcohol, and a monoalkyl ether of diethylene glycol present in relative amounts sufficient to provide permeation enhancement of an active agent through mammalian dermal or mucosal surfaces. Preferably, the delivery vehicle as well as the formulations that contain it are substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters in order to avoid potential undesirable odor and irritation effects caused by such compounds during use of the formulation. Without these additives, use of the formulations is facilitated and patient compliance is greater

Priority: WO2000EP07533 Applic. Date: 2000-08-03; US2009-614216 Applic. Date: 2009-11-06; US2004-798111 Applic. Date: 2004-03-10; US2007-755923 Applic. Date: 2007-05-31; US2006-371042 Applic. Date: 2006-03-07; WO2004EP11175 Applic. Date: 2004-10-06; US2006-634005 Applic. Date: 2006-12-04; US2003-343570 Applic. Date: 2003-05-19; WO2001EP09007 Applic. Date: 2001-08-03; US20030510613P Applic. Date: 2003-10-10; US20030453604P Applic. Date: 2003-03-11

Inventor: CARRARA DARIO NORBERTO R [CH]; GRENIER ARNAUD [FR]


Application No.: US20110195122A1  Published: 11/Aug/2011

Title: Extended Release Formulation

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 13/086980   Filing Date: 14/Apr/2011

Abstract:

The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof.

Priority: EP20060002777 Applic. Date: 2006-02-10; US2008-278848 Applic. Date: 2008-09-16; WO2007EP51258 Applic. Date: 2007-02-09

Inventor: FRIEDL THOMAS [DE]; EISENREICH WOLFRAM [DE]; HAERTTER SEBASTIAN [DE]


Application No.: US20110195123A1  Published: 11/Aug/2011

Title: METHODS, COMPOSITIONS AND SYSTEMS FOR LOCAL DELIVERY OF DRUGS

Applicant/Assignee: SILENSEED LTD

Application No.: 13/000656   Filing Date: 28/Jun/2009

Abstract:

Implantable medical device eluting drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation. The device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. The selection of drug is based on the advantageous of releasing drug locally and in prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention. One kind of drug is the gene silencing drugs based on RNA interference (RNAi), including but not limited to si RNA, sh RNA, or antisense RNA/DNA, ribozyme and nucleoside analogs. The modes of implantation in some embodiments are existing implantation procedures that are developed and used today for other treatments, including brachytherapy and needle biopsy. In such cases the dimensions of the new implant described in this invention are similar to the original implant. Typically a few devices are implanted during the same treatment procedure.

Priority: US20080129477P Applic. Date: 2008-06-30; WO2009IB52778 Applic. Date: 2009-06-28

Inventor: SHEMI AMOTZ [IL]


Application No.: US20110196502A1  Published: 11/Aug/2011

Title: Methods of Using Water-Soluble Inorganic Compounds for Implants

Applicant/Assignee:

Application No.: 13/019265   Filing Date: 01/Feb/2011

Abstract:

A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic material having a desired particle size and solubility, and mixing the water-soluble inorganic material with at least one poorly-water-soluble or biodegradable matrix material. The matrix material, after it is mixed with the water-soluble inorganic material, is placed into the patient in proximity to tissue so that the water-soluble inorganic material dissolves at a predetermined rate to generate biologically desirable voids in the matrix material into which bone or other tissue can then grow.

Priority: US20100301698P Applic. Date: 2010-02-05

Inventor: WALLS JAMES A [US]


Application No.: US20110200582A1  Published: 18/Aug/2011

Title: LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM

Applicant/Assignee: NOVARTIS AG

Application No.: 12/974906   Filing Date: 21/Dec/2010

Abstract:

Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.

Priority: US20090284787P Applic. Date: 2009-12-23

Inventor: BARYZA JEREMY [US]; BOWMAN KEITH [US]; GEALL ANDREW [US]; LABONTE TANZINA [US]; LEE CAMERON [US]; VARGEESE CHANDRA [US]; WEST LAURA [US]; ZHAO JUNPING [US]


Application No.: US20110200655A1  Published: 18/Aug/2011

Title: Systems and methods that kill infectious agents (bacteria) without the use of a systemic anti-biotic

Applicant/Assignee:

Application No.: 13/028460   Filing Date: 16/Feb/2011

Abstract:

A medical product is provided that is selected from at least one of, nasal cannulas, oxygen masks, wound dressings, bandages, band aids, catheters, endotrachial tubes, condoms, surgical and other gloves, sheaths for endoscopy probes, and medical products that physically touch the body. A coating is included with at least one of, a non-antibiotic, antimicrobial and/or antiviral substance that prevents further local, non-systemic, colonization of infections.

Priority: US20100304906P Applic. Date: 2010-02-16; US20100327838P Applic. Date: 2010-04-26; US20100327851P Applic. Date: 2010-04-26

Inventor: BLACK MICHAEL DARRYL [US]; CHAMBERS ANITA MARGARETTE [US]


Application No.: US20110200661A1  Published: 18/Aug/2011

Title: ACRYLIC HYDROGELS WITH PENDANT CYCLODEXTRINS, PREPARATION METHOD THEREOF AND USE OF SAME AS RELEASE SYSTEMS AND CONTACT LENS COMPONENTS

Applicant/Assignee: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Application No.: 13/057621   Filing Date: 04/Aug/2009

Abstract:

The invention relates to acrylic hydrogels with pendant cyclodextrins, the preparation and application thereof as release systems and components of contact lenses. The method for obtaining acrylic hydrogels with pendant cyclodextrins is characterized in that the hydrogels are formed by a polymer lattice obtained by polymerization of mono- and bifunctional acrylic or methacrylic monomers and monomers having glycidyl groups in their structure, to which cyclodextrin units are covalently bound once formed

and the use and applications of the compositions in the preparation of contact lenses with the capacity for incorporating drugs, active substances or demulcents useful in the treatment of pathological or physiological conditions, in the production of topical, transdermal or transmucosal release systems for medicinal products or active substances, and in the preparation of cosmetics.

Priority: ES20080002364 Applic. Date: 2008-08-06; WO2009ES70333 Applic. Date: 2009-08-04

Inventor: ALVAREZ LORENZO CARMEN [ES]; ROSA DOS SANTOS JOSE FERNANDO [ES]; TORRES LABANDEIRA JUAN JOSE [ES]; CONCHEIRO NINE ANGEL [ES]


Application No.: US20110200673A1  Published: 18/Aug/2011

Title: OXIDIZED HEPARIN FRACTIONS AND THEIR USE IN INHIBITING ANGIOGENESIS

Applicant/Assignee:

Application No.: 13/029584   Filing Date: 17/Feb/2011

Abstract:

The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also relates to methods of inhibiting angiogenesis and treating an angiogenesis-mediated disorder in a subject by administering a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 30,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. Another aspect of the present invention relates to compositions including the heparin fractions of the present invention.

Priority: US2003-667216 Applic. Date: 2003-09-19; US20020411851P Applic. Date: 2002-09-20

Inventor: MOUSA SHAKER A [US]


Application No.: US20110200675A1  Published: 18/Aug/2011

Title: DRUG DELIVERY VEHICLES, METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF

Applicant/Assignee: UNIVERSITY OF MASSACHUSETTS

Application No.: 12/845126   Filing Date: 28/Jul/2010

Abstract:

Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO2 in the environment of the hydrogel are described. The drug delivery vehicles include hydrogels that swell or shrink in response to changes in the partial pressure of CO2 in their environment, thus regulating release of an entrapped drug.

Priority: US20090229287P Applic. Date: 2009-07-29

Inventor: THAYUMANAVAN SANKARAN [US]


Application No.: US20110200695A1  Published: 18/Aug/2011

Title: GEL COMPOSITION FOR FILLING A BREAST MILK DUCT PRIOR TO SURGICAL EXCISION OF THE DUCT OR OTHER BREAST TISSUE

Applicant/Assignee:

Application No.: 13/093781   Filing Date: 25/Apr/2011

Abstract:

The invention is a gel composition for delivery to a breast milk duct prior to surgical excision of breast tissue including cancerous lesions. The invention also provides methods of mapping all or nearly all of a breast milk duct prior to surgical excision of breast tissue, and method of identifying part or all of a breast duct or ducts as a surgical aide to a breast surgeon. Kits to support these methods and including these compositions are also provided.

Priority: US2007-725928 Applic. Date: 2007-03-20; US2003-425177 Applic. Date: 2003-04-29; US2000-590517 Applic. Date: 2000-06-09; US19990138693P Applic. Date: 1999-06-11

Inventor: BIANCHI ANNETTE [US]; NIKOLCHEV JULIAN [US]; HUNG DAVID [US]; RON EYAL [US]; GONT LINDA K [US]; LOVE SUSAN [US]; PATEL TINA [US]


Application No.: US20110206630A1  Published: 25/Aug/2011

Title: SURFACTANT AND CLEANING COMPOSITIONS COMPRISING MICROBIALLY PRODUCED BRANCHED FATTY ALCOHOLS

Applicant/Assignee: LS9, INC

Application No.: 13/026871   Filing Date: 14/Feb/2011

Abstract:

The invention provides a surfactant and/or a cleaning composition comprising a microbially produced branched fatty alcohol or a derivative thereof. The invention also provides a household cleaning composition and a personal or pet care cleaning composition comprising a microbially produced branched fatty alcohol or a derivative thereof.

Priority: US20100304448P Applic. Date: 2010-02-14; US20100324310P Applic. Date: 2010-04-15

Inventor: RUDE MATHEW [US]


Application No.: US20110206759A1  Published: 25/Aug/2011

Title: CCR7 LIGAND DELIVERY AND CO-DELIVERY IN IMMUNOTHERAPY

Applicant/Assignee:

Application No.: 13/025009   Filing Date: 10/Feb/2011

Abstract:

Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.

Priority: US20100303442P Applic. Date: 2010-02-11

Inventor: SWARTZ MELODY A [CH]; HUBBELL JEFFREY A [CH]; TOMEI ALICE A [CH]; SHIELDS JACQUELINE D [GB]; KOURTIS IRAKLIS [GR]


Application No.: US20110206768A1  Published: 25/Aug/2011

Title: MEDICAL PREPARATION

Applicant/Assignee: THE UNIVERSITY OF WAIKATO

Application No.: 12/517755   Filing Date: 06/Dec/2007

Abstract:

A bone matrix, including: a bone matrix material, which has had organic material removed, and a replacement material that has replaced the organic material, the bone matrix characterised in that the bone matrix is formed from a single piece of bone.

Priority: NZ20060551965 Applic. Date: 2006-12-08; NZ20070552568 Applic. Date: 2007-01-10; WO2007NZ00354 Applic. Date: 2007-12-06

Inventor: LAIRD DOUGAL FRAZER [NZ]; MUCALO MICHAEL ROGER [NZ]; DIAS SUBASINGHE NISANKE GEORGE PREMALAL JAYANTHA [NZ]


Application No.: US20110206769A1  Published: 25/Aug/2011

Title: ORAL ANTIDEPRESSANT FORMULATION WITH REDUCED EXCIPIENT LOAD

Applicant/Assignee: CENERX BIOPHARMA, INC

Application No.: 12/860358   Filing Date: 20/Aug/2010

Abstract:

Provided are methods for reducing the excipient load of pharmaceutical formulations containing 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide as the active pharmaceutical ingredient, and compositions related thereto. In particular, provided is a pharmaceutical product comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide and a stabilizer admixed throughout a solid-form unilamellar matrix, wherein the ratio of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide to stabilizer ranges from about 2:3 to about 1:10, and related methods of forming the pharmaceutical product.

Priority: US20100301907P Applic. Date: 2010-02-05

Inventor: CHEN ANDREW [US]; CHEN HAILIANG [US]; FREE JAMES CECIL [US]; KESHTMAND MAJID [US]; RAHMAN MOHAMMED ABDUL [US]; LOOK SALLY A [US]


Application No.: US20110207786A1  Published: 25/Aug/2011

Title: Potentiated Biocidal Compositions and Methods of Use

Applicant/Assignee:

Application No.: 13/034916   Filing Date: 25/Feb/2011

Abstract:

The present technology relates to biocidal compositions and methods that contain and utilize at least one biocidal agent and at least one potentiator system wherein the resultant combination has an enhanced biocidal efficacy. The present technology also discloses a rapid screening assay for determining biocidal compositions with enhanced efficacy, e.g., a microbial contact kill time of 5 minutes or less. Further, the present technology provides a method of determining biocidally effective concentrations of biocidal compositions comprising at least one biocidal agent and at least one potentiator system.

Priority: WO2009US55064 Applic. Date: 2009-08-26; US20080092119P Applic. Date: 2008-08-27

Inventor: CALLAHAN MOLLY RYAN [US]; SHELTON DAVID [US]


Application No.: US20110212156A1  Published: 01/Sep/2011

Title: Use of a mixture of two or more enteric materials to regulate drug release via membrance or matrix for systemic therapeutics

Applicant/Assignee: SUPERNUS PHARMACEUTICALS, INC

Application No.: 12/929238   Filing Date: 10/Jan/2011

Abstract:

Disclosed are pharmaceutical compositions, particularly oral dosage forms, which comprise two or more enteric coating materials, either as a coating or as part of a matrix dosage form, and methods of making and using the same. The compositions are characterized by having a sustained release profile at lower pH and an accelerated dissolution profile at higher pH.

Priority: US2004-751766 Applic. Date: 2004-01-05; US20030437800P Applic. Date: 2003-01-03

Inventor: CHANG RONG-KUN [US]; SHAH NIRAJ [US]


Application No.: US20110212157A1  Published: 01/Sep/2011

Title: DERMAL DELIVERY

Applicant/Assignee: ANTERIOS, INC

Application No.: 13/000509   Filing Date: 26/Jun/2009

Abstract:

The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis. Methods generally involve administering nanoemulsions (e.g., nanoparticle compositions) comprising at least one therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions are prepared, e.g., by high pressure microfluidization, and comprise a particle size distribution exclusively between 10 nm and 300 nm.

Priority: US20080076065P Applic. Date: 2008-06-26; WO2009US48972 Applic. Date: 2009-06-26

Inventor: EDELSON JONATHAN [US]; KOTYLA TIMOTHY [US]; ZHANG BOKE [US]


Application No.: US20110212160A1  Published: 01/Sep/2011

Title: CONFIGURABLE MICROSCOPIC MEDICAL PAYLOAD DELIVERY DEVICE TO DELIVER NUCLEAR SIGNALING PROTEINS TO SPECIFIC CELLS TO MANAGE DIABETES MELLITUS AND GENETIC DEFICIENCY DISORDERS

Applicant/Assignee:

Application No.: 12/715377   Filing Date: 01/Mar/2010

Abstract:

The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver nuclear signaling proteins to specific cell types in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of nuclear signaling proteins into the target cell type. By delivering nuclear signaling proteins to specific cell types, genes can be activated or inactivated in those specific cell types. These medically therapeutic nuclear signaling proteins are intended to improve cell function or the longevity of the cell or eliminate cells that pose a hazard to the general health of the body.

Priority:

Inventor: SCHEIBER LANE BERNARD [US]; SCHEIBER II LANE BERNARD [US]


Application No.: US20110212177A1  Published: 01/Sep/2011

Title: CONFIGURABLE MICROSCOPIC MEDICAL PAYLOAD DELIVERY DEVICE TO DELIVER MEDICALLY THERAPEUTIC PAYLOADS TO SPECIFICALLY TARGETED CELL TYPES

Applicant/Assignee:

Application No.: 12/715362   Filing Date: 01/Mar/2010

Abstract:

The innovative strategy of treatment described here utilizes configurable microscopic medical payload delivery devices to act as a transport mechanism to deliver medically therapeutic payloads to specific cell types in the body. Utilizing probes on the exterior of the configurable microscopic medical payload delivery devices, these transport devices locate specific types of target cells in the body. Once a specific target cell is encountered and engaged, the configurable microscopic medical payload delivery device inserts its payload into the target cell. These medically therapeutic payloads are intended to improve cell function or the longevity of the cell or eliminate cells that pose a hazard to the general health of the body. By utilizing configurable microscopic medical payload delivery devices as a delivery system, the efficacy of medications and biologic tools are dramatically improved and there is a resultant significant reduction in the occurrence of unwanted side effects.

Priority:

Inventor: SCHEIBER LANE BERNARD [US]; SCHEIBER II LANE BERNARD [US]


Application No.: US20110217245A1  Published: 08/Sep/2011

Title: Substituted Butanol Derivatives And Their Use As Fragrance And Flavor Materials

Applicant/Assignee:

Application No.: 12/981758   Filing Date: 30/Dec/2010

Abstract:

The present invention is related to substituted butanol derivatives of the formula: wherein R is an unsubstituted or substituted C1-6 straight chain alkyl, an unsubstituted or substituted C3-6 branched chain alkyl, an unsubstituted or substituted C3-6 straight chain alkenyl, an unsubstituted or substituted C3-6 branched chain alkenyl, an unsubstituted or substituted C3-6 cycloalkyl, an unsubstituted or substituted C1-6 alkoxy, nitrile, halo, amino, an unsubstituted or substituted C1-6 alkylamino, an unsubstituted or substituted C1-6 dialkylamino, carboxy-C1-6 alkylamino, carboxy-C1-6 dialkylamino, an unsubstituted or substituted acetoxy, carboxy, an unsubstituted or substituted carboxyethyl, an unsubstituted or substituted C1-6 alkylcarbonyl, an unsubstituted or substituted C1-6 alkylcarboxy, an unsubstituted or substituted C1-6 alkylthio, an unsubstituted or substituted C1-6 alkyloxy, carboxamido, an unsubstituted or substituted C1-6 alkylcarboxamido or an unsubstituted or substituted C1-6 dialkylcarboxamido. Such compounds are useful in flavor or flavor compositions.

Priority: WO2008US68781 Applic. Date: 2008-06-30

Inventor: DEROSA FRANK [US]; LANKIN MICHAEL E [US]; LUPO JR ANDREW T [US]


Application No.: US20110217257A1  Published: 08/Sep/2011

Title: NOVEL 4-ALKYL CYCLOHEXANEPROPANAL COMPOUNDS AND THEIR USE IN PERFUME COMPOSITIONS

Applicant/Assignee:

Application No.: 13/109032   Filing Date: 17/May/2011

Abstract:

The present invention is directed to novel 4-alkyl cyclohexanepropanal compounds and a method of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of the novel compounds.

Priority: US2009-619325 Applic. Date: 2009-11-16

Inventor: BELKO ROBERT P [US]; LEVORSE JR ANTHONY T [US]; MONTELEONE MICHAEL G [US]


Application No.: US20110217356A1  Published: 08/Sep/2011

Title: CONTROLLED DELIVERY SYSTEM

Applicant/Assignee:

Application No.: 13/042126   Filing Date: 07/Mar/2011

Abstract:

Provided herein are keratin compositions (e.g., keratin gels, scaffolds, particulates, and the like) including a compound of interest, useful for release and/or delivery of the compound of interest (e.g., in vivo or in vitro). In some embodiments, the composition is a composition formulated for controlled release of the compound of interest.

Priority: US20100311003P Applic. Date: 2010-03-05

Inventor: VAN DYKE MARK E [US]; SAUL JUSTIN M [US]; SMITH THOMAS L [US]; GUZMAN ROCHE DE [US]


Application No.: US20110217371A1  Published: 08/Sep/2011

Title: CONTROLLED-RELEASE MICROPARTICLES AND METHOD OF PREPARING SAME

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: 13/127965   Filing Date: 10/Nov/2009

Abstract:

Disclosed is a controlled-release microparticle: including a matrix comprising a pharmacologically active component

and a controlled-release layer comprising a substance which forms a controlled-release stratum on the matrix. The disclosed controlled-release microparticle not only allows effective dual release control of a drug but can also exhibit outstanding dissolution characteristics even when a small amount of coating substance is used.

Priority: KR20080111234 Applic. Date: 2008-11-10; WO2009KR06590 Applic. Date: 2009-11-10

Inventor: SHIN KWANG-HYUN [KR]; KIM JAEKWAN [KR]; JUN JAI-LL [KR]; HONG DEOK-KI [KR]; BAE JOON-HO [KR]


Application No.: US20110217375A1  Published: 08/Sep/2011

Title: Dendrimeric peptides, pharmaceutical compositions and methods of using the same

Applicant/Assignee: NEW YORK UNIVERSITY SCHOOL OF MEDICINE

Application No.: 12/932742   Filing Date: 04/Mar/2011

Abstract:

Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I: The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.

Priority: US2008-154659 Applic. Date: 2008-05-22; US20070931317P Applic. Date: 2007-05-22

Inventor: KALLENBACH NEVILLE ROBERT [US]; YOUNG ANNE W [US]; LIU ZHIGANG [US]; ZHOU CHUNHUI [US]


Application No.: US20110217376A1  Published: 08/Sep/2011

Title: POLY(AMIDOAMINE) OLIGOMER HYDROGEL FOR DRUG DELIVERY AND DRUG CARRIER USING THE SAME

Applicant/Assignee: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION

Application No.: 12/938852   Filing Date: 03/Nov/2010

Abstract:

Disclosed is a temperature- and pH-sensitive hydrogel composed of a poly(amidoamine) oligomer only. The hydrogel is prepared in a simple manner and is readily released from the body. Further disclosed are a method for preparing the hydrogel and a drug carrier using the hydrogel.

Priority: KR20100019215 Applic. Date: 2010-03-03

Inventor: LEE DOO SUNG [KR]; KIM BONG SUP [KR]; NGUYEN MINH KHANH [KR]


Application No.: US20110217377A1  Published: 08/Sep/2011

Title: Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents

Applicant/Assignee:

Application No.: 13/108361   Filing Date: 16/May/2011

Abstract:

The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a [alpha]-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours.

Priority: US2009-638297 Applic. Date: 2009-12-15; US20080122479P Applic. Date: 2008-12-15; US20090249022P Applic. Date: 2009-10-06; US20090260200P Applic. Date: 2009-11-11

Inventor: ZALE STEPHEN E [US]; TROIANO GREG [US]; ALI MIR M [US]; HRKACH JEFF [US]; WRIGHT JAMES [US]; LOW SUSAN [US]


Application No.: US20110217379A1  Published: 08/Sep/2011

Title: MAGNETIC NANOMATERIALS AND METHODS FOR CHEMOEMBOLISATION

Applicant/Assignee: DAVIS LLP

Application No.: 13/040873   Filing Date: 04/Mar/2011

Abstract:

There are disclosed magnetic nanoparticles and embolisation compositions comprising the nanoparticles. There are also disclosed methods to make the nanoparticles and embolisation compositions and methods to deliver therapeutic agents to a subject.

Priority: US20100311647P Applic. Date: 2010-03-08

Inventor: WANG YIXIANG [CN]; LEUNG KEN CHAM-FAI [CN]; CHENG CHRIS HON KI [CN]; QIN LING [CN]


Application No.: US20110218252A1  Published: 08/Sep/2011

Title: Liquid Chromatographic Fraction of Enzymatically Polymerized Flavonoid as an Antioxidant

Applicant/Assignee: USA AS REPRESENTED BY THE SECRETARY OF THE ARMY

Application No.: 12/641368   Filing Date: 08/Mar/2010

Abstract:

Disclosed is a separated fraction of a reaction product of an enzymatically catalyzed polymerization of a flavonoid. The separated fraction is highly resistant to oxidation and is useful in numerous applications such as an antioxidant in food products and medical applications.

Priority:

Inventor: FAVREAU NICOLE [US]; BRUNO FERDINANDO F [US]


Application No.: US20110220265A1  Published: 15/Sep/2011

Title: Preparation for External Use

Applicant/Assignee: HISAMITSU PHARMACEUTICAL CO., INC

Application No.: 13/049242   Filing Date: 16/Mar/2011

Abstract:

A preparation for external use which, even when ingredients such as a drug, absorption accelerator, and plasticizer are contained therein in a large amount, is excellent in pressure-sensitive adhesive properties including cohesive force and which, when a drug is contained therein, enables the drug to have excellent percutaneous absorbability. The preparation for external use includes a pressure-sensitive-adhesive matrix layer, wherein the pressure-sensitive-adhesive matrix layer comprises a pressure-sensitive adhesive base comprising a hydroxylated polymer, a boron compound, and silicic acid.

Priority: JP20050239262 Applic. Date: 2005-08-22; US2008-064246 Applic. Date: 2008-02-20; WO2006JP316375 Applic. Date: 2006-08-22

Inventor: KAJITA RYOKO [JP]; NOMOTO MASATAKA [JP]


Application No.: US20110223226A1  Published: 15/Sep/2011

Title: SHELF STABLE CAPSULES

Applicant/Assignee: COLGATE-PALMOLIVE COMPANY

Application No.: 13/128243   Filing Date: 10/Nov/2008

Abstract:

A capsule slury including at least one coacervated capsule and at least 10 wt % humectant is disclosed. The humectant may be sorbitol, glycerin, polyethylene glycol, propylene glycol, xylitol, erythritol and/or betaine.

Priority: WO2008US82954 Applic. Date: 2008-11-10

Inventor: D AMBROGIO ROBERT [US]; PILCH SHIRA [US]; MASTERS JAMES [US]


Application No.: US20110223243A1  Published: 15/Sep/2011

Title: ARTIFICIAL OXYGEN CARRIERS AND USE THEREOF

Applicant/Assignee:

Application No.: 13/003400   Filing Date: 08/Jul/2009

Abstract:

The invention relates to dispersions of artificial oxygen carriers, wherein the dispersions contain capsules with reversible oxygen storage capacity, the capsules comprising an oxygen-permeable capsule material, that contains and/or encloses fluorinated, particularly perfluorinated hydrocarbons, preferably perfluorocarbons. The dispersions are particularly suitable as a blood substitute, preferably for the purpose of transfusion, e.g. in states of blood loss of the human or animal body, in particular following surgical interventions, accidents, injuries etc, or for the prophylactic treatment and/or treatment by therapy of ischaemic states or states following a reperfusion.

Priority: DE200810032183 Applic. Date: 2008-07-09; DE200810045152 Applic. Date: 2008-08-30; WO2009EP04925 Applic. Date: 2009-07-08

Inventor: DE GROOT HERBERT [DE]; MAYER CHRISTIAN [DE]; PETRAT FRANK [DE]; KIRSCH MICHAEL [DE]


Application No.: US20110223253A1  Published: 15/Sep/2011

Title: PHYSICALLY STABILIZED BIODEGRADABLE OSTEOCHONDRAL IMPLANT AND METHODS FOR ITS MANUFACTURE AND IMPLANTATION

Applicant/Assignee: ARTIMPLANT AB

Application No.: 12/723740   Filing Date: 15/Mar/2010

Abstract:

A physically stabilized biodegradable osteochondral implant includes a porous matrix element of a resilient material and blood coagulated in vitro in open pores of the element. Also disclosed is a method of manufacture of the implant and a method of restoring a damaged articular surface by use of the implant.

Priority:

Inventor: GISSELFAELT KATRIN [SE]; SVENSSON MAGNUS [SE]


Application No.: US20110224308A1  Published: 15/Sep/2011

Title: ORGANOSILICONE FINE PARTICLES, METHOD OF PRODUCTION THEREOF AND COSMETIC MATERIALS, RESIN COMPOSITIONS AND PAINT COMPOSITIONS CONTAINING SAME

Applicant/Assignee:

Application No.: 13/115456   Filing Date: 25/May/2011

Abstract:

Organosilicone fine particles which are capable of responding to the highly advanced requirements of recent years imposed on them for purposes of actual use, including further improvement in optical characteristics such as total light transmittance and haze as well as heat-resistant colorability related to resin compositions, further improvement in usability (extensions and expansions at the time of use) and feeling (stickiness, roughness and durability) related to cosmetic materials and further improvement in matte effect and factual sense related to paint compositions, as well as methods of their production and cosmetic materials, resin compositions and paint compositions containing such particles are provided. Organosilicone fine particles have tetrahedral general shapes with surfaces each having a concave part with an approximately circular opening. The maximum external diameters L of the organosilicone fine particles have an average value in the range of 0.5-20 [mu]m, the average value being taken from arbitrarily selected 20 of a scanning electron microscope photograph image of the organosilicone fine particles.

Priority: WO2010JP53965 Applic. Date: 2010-03-10

Inventor: SAITO CHIAKI [JP]; MAEDA MOTOKI [JP]; HATTA ERIKO [JP]


Application No.: US20110229426A1  Published: 22/Sep/2011

Title: PERFUMING INGREDIENTS OF THE FLORAL AND/OR ANIS TYPE

Applicant/Assignee:

Application No.: 13/123147   Filing Date: 03/Nov/2009

Abstract:

The present invention concerns the use as perfuming ingredient, for instance to impart odor notes of the floral and/or green type, of a compound of formula 5 wherein R is an ortho, meta or para substituent of the phenyl, and represents a hydrogen atom or a C 1-2 alkyl or alkoxyl group

R 1 represents a hydrogen atom or a methyl or ethyl group

10 R 2 represents a hydrogen atom or a C 1-3 alkyl group

and X represents a CHO, COOR 3, CH(OR 4) 2 or CN group, R 3 being a methyl or ethyl group, and R 4, taken seperately, being a methyl or ethyl group, or said R 4, taken together, a C 2-5 alkanediyl group

and at least one of said R, R 1 or R 2 represents a group containing at least one carbon atom.

Priority: WO2008IB54663 Applic. Date: 2008-11-07; WO2009IB54865 Applic. Date: 2009-11-03

Inventor: MORETTI ROBERT [CH]


Application No.: US20110229558A1  Published: 22/Sep/2011

Title: AGENT FOR TREATING MYELOFIBROSIS

Applicant/Assignee: NITTO DENKO CORPORATION

Application No.: 13/062214   Filing Date: 04/Sep/2009

Abstract:

Disclosed is a substance delivery carrier for an extracellular matrix-producing cell in the bone marrow, which comprises a retinoid. Also disclosed is an agent for treating myelofibrosis by utilizing a substance capable of regulating the activity or proliferation of an extracellular matrix-producing cell in the bone marrow.

Priority: JP20080228338 Applic. Date: 2008-09-05; WO2009JP04369 Applic. Date: 2009-09-04

Inventor: NIITSU YOSHIRO [JP]; MATSUNAGA TAKUYA [JP]


Application No.: US20110229572A1  Published: 22/Sep/2011

Title: DELIVERY OF DRUG COMBINATIONS

Applicant/Assignee: BIOCOMPATIBLES UK LIMITED

Application No.: 12/672031   Filing Date: 18/Aug/2008

Abstract:

A composition comprising microspheres of a polymer matrix, having two different pharmaceutical actives having complementary, usually synergistic, activity in killing cells. The compositions have particular utility for treating tumours. Useful combinations are doxorubicin with rapamycin, irinotecan with ibuprofen, ibuprofen with doxorubicin and irinotecan with doxorubicin. The polymer matrix is preferably a crosslinked polyvinyl alcohol. The drugs may be included in the same microsphere, or microspheres each with an individual pharmaceutical agent may be mixed together. The microspheres are preferably used in chemoembolisation of tumours.

Priority: GB20070016003 Applic. Date: 2007-08-16; EP20070121158 Applic. Date: 2007-11-20; WO2008GB50722 Applic. Date: 2008-08-18

Inventor: LEWIS ANDREW LENNARD [GB]; FORSTER RICHARD EDWARD JOHN [SG]; GONZALEZ-FAJARDO MROA VOCTORIA [ES]; TANG YIQING [GB]; LLOYD ANDREW WILLAM [GB]; PHILLIPS GARY JOHN [GB]


Application No.: US20110229574A1  Published: 22/Sep/2011

Title: POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATION

Applicant/Assignee: ALLERGAN, INC

Application No.: 13/052690   Filing Date: 21/Mar/2011

Abstract:

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Priority: US20100316283P Applic. Date: 2010-03-22

Inventor: GUILLEN KARINA H [US]; TEZEL AHMET [US]


Application No.: US20110230565A1  Published: 22/Sep/2011

Title: NOVEL COMPOUND CONTAINING VANILLIN AND ETHYLVANILLIN, AND PREPARATION AND APPLICATIONS THEREOF

Applicant/Assignee: RHODIA OPERATIONS

Application No.: 13/125833   Filing Date: 08/Oct/2009

Abstract:

A compound that includes vanillin and ethylvanillin, and a method for making same are described. The compound described can be obtained by the co-crystallisation of vanillin and ethylvanillin. Methods of using the compound in numerous applicable fields, particularly in human and animal food are also described.

Priority: FR20080005913 Applic. Date: 2008-10-24; WO2009EP63093 Applic. Date: 2009-10-08

Inventor: LE-THIESSE JEAN-CLAUDE [FR]


Application No.: US20110230816A1  Published: 22/Sep/2011

Title: Gels for Transdermal Delivery

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 12/872539   Filing Date: 31/Aug/2010

Abstract:

The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.

Priority: US20100315145P Applic. Date: 2010-03-18

Inventor: COPP-HOWLAND WARREN [US]


Application No.: US20110236483A1  Published: 29/Sep/2011

Title: RNA VECTOR THERAPY

Applicant/Assignee:

Application No.: 12/748433   Filing Date: 28/Mar/2010

Abstract:

The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver a wide variety of cellular ribonucleic acid molecules to specific types of cells in the body. Utilizing probes on the exterior of the transport devices, the transport devices locate a specific type of cell in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery devices insert their payload of cellular ribonucleic acid molecules into the target cells. By delivering cellular ribonucleic acid molecules into specific cells a wide variety of protein deficiencies are correctable, gene expression is capable of being modulated, and telomere synthesis is enhanced.

Priority:

Inventor: SCHEIBER LANE BERNARD [US]; SCHEIBER II LANE BERNARD [US]


Application No.: US20110236484A1  Published: 29/Sep/2011

Title: Genus-Wide Chlamydial Peptide Vaccine Antigens

Applicant/Assignee: WAYNE STATE UNIVERSITY

Application No.: 13/120071   Filing Date: 21/Sep/2009

Abstract:

Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent Chlamydia-associated or induced rheumatoid arthritis.

Priority: US20080098769P Applic. Date: 2008-09-21; WO2009US57700 Applic. Date: 2009-09-21

Inventor: WHITTUM-HUDSON JUDITH [US]; HUDSON ALAN P [US]


Application No.: US20110236485A1  Published: 29/Sep/2011

Title: SHELL AND CORE DOSAGE FORM APPROACHING ZERO-ORDER DRUG RELEASE

Applicant/Assignee: DEPOMED, INC

Application No.: 13/156225   Filing Date: 08/Jun/2011

Abstract:

Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.

Priority: US2010-770283 Applic. Date: 2010-04-29; US2002-213823 Applic. Date: 2002-08-07; US2000-498945 Applic. Date: 2000-02-04

Inventor: BERNER BRET [US]; LOUIE-HELM JENNY [US]; GUSLER GLORIA [US]; SHELL JOHN N [US]


Application No.: US20110237623A1  Published: 29/Sep/2011

Title: SUSTAINED-RELEASE DONEPEZIL FORMULATION

Applicant/Assignee:

Application No.: 13/036010   Filing Date: 28/Feb/2011

Abstract:

A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil.

Priority: US20100309013P Applic. Date: 2010-03-01

Inventor: PENHASI ADEL [IL]; GOMBERG MILA [IL]


Application No.: US20110237684A1  Published: 29/Sep/2011

Title: Process for preparing 4-cyclohexyl-2-methyl-2-butanol

Applicant/Assignee: BASF SE

Application No.: 13/071002   Filing Date: 24/Mar/2011

Abstract:

The present invention relates to a process for preparing 4-cyclohexyl-2-methyl-2-butanol. The process comprises the following steps: a) reaction of styrene with isopropanol at elevated temperature to obtain 4-phenyl-2-methyl-2-butanol, and b) heterogeneously catalyzed hydrogenation of 4-phenyl-2-methyl-2-butanol over a catalyst suitable for ring hydrogenation of aromatics.

Priority: US20100316870P Applic. Date: 2010-03-24

Inventor: EBEL KLAUS [DE]; RUEDENAUER STEFAN [DE]; PELZER RALF [DE]; BOCK MARTIN [DE]


Application No.: US20110237685A1  Published: 29/Sep/2011

Title: PHOTOLABILE FRAGRANCE STORAGE SUBSTANCES

Applicant/Assignee: HENKEL AG & CO. KGAA

Application No.: 13/156537   Filing Date: 09/Jun/2011

Abstract:

Photolabile fragrance storage substances capable of photo-induced release of odorant aldehydes and odorant ketones are described in addition to a process for long-lasting fragrancing of surfaces and a process for producing said fragrance storage substances.

Priority: DE200810060886 Applic. Date: 2008-12-09; WO2009EP63145 Applic. Date: 2009-10-09

Inventor: HUCHEL URSULA [DE]; KROPF CHRISTIAN [DE]; GRIESBECK AXEL [DE]; HINZE OLGA [DE]; SUNDERMEIER UTA [DE]


Application No.: US20110238036A1  Published: 29/Sep/2011

Title: SUSTAINED RELEASE DELIVERY DEVICES

Applicant/Assignee: PSIVIDA US, INC

Application No.: 12/975696   Filing Date: 22/Dec/2010

Abstract:

An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as "coatings," "skins," or "outer layers"). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.

Priority: US20090289954P Applic. Date: 2009-12-23

Inventor: ASHTON PAUL [US]


Application No.: US20110244010A1  Published: 06/Oct/2011

Title: Medical devices including medicaments and methods of making and using same

Applicant/Assignee:

Application No.: 13/065904   Filing Date: 02/Apr/2011

Abstract:

The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition.

Priority: US20100341824P Applic. Date: 2010-04-03

Inventor: DOSHI PRAFUL [US]


Application No.: US20110244013A1  Published: 06/Oct/2011

Title: MICROPOROUS MATERIAL FROM ETHYLENE-CHLOROTRIFLUOROETHYLENE COPOLYMER AND METHOD FOR MAKING SAME

Applicant/Assignee:

Application No.: 13/133427   Filing Date: 14/Dec/2009

Abstract:

Microporous material having a spherulitic matrix made from ethylene chlorotrifluoroethylene copolymer has a plurality of pores having an average pore size greater than about 0.01 micrometer. The material is made by thermally induced phase separation (TIPS) process that includes melt mixing ethylene chlorotrifluoroethylene copolymer, diluent and nucleating agent to provide a melt mixed composition

shaping the melt mixed composition

cooling the shaped melt mixed composition to induce phase separation of the ethylene chlorotrifluoroethylene copolymer to provide a phase separated material

and stretching the phase separated material to provide the microporous material. The microporous material may be incorporated into articles and the articles may include one, two or more layers of microporous material.

Priority: US20080139054P Applic. Date: 2008-12-19; WO2009US67807 Applic. Date: 2009-12-14

Inventor: MROZINSKI JAMES S [US]; SWENSON RANDALL P [US]; WEILANDT KARL-DIETER [US]; HESTER JONATHAN F [US]


Application No.: US20110244023A1  Published: 06/Oct/2011

Title: TRANSDERMAL DELIVERY PATCH

Applicant/Assignee: PHOSPHAGENICS LIMITED

Application No.: 12/782564   Filing Date: 18/May/2010

Abstract:

A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.

Priority: US20100319007P Applic. Date: 2010-03-30

Inventor: COTTRELL JEREMY [AU]; GAETANO GIACINTO [AU]; EL-TAMIMY MAHMOUD [AU]; KENNEDY NICHOLAS [AU]; GAVIN PAUL DAVID [AU]


Application No.: US20110244032A1  Published: 06/Oct/2011

Title: DISPERSIBLE PHOSPHOLIPID STABILIZED MICROPARTICLES

Applicant/Assignee: JAGOTEC AG

Application No.: 13/104094   Filing Date: 10/May/2011

Abstract:

Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.

Priority: US201113103457 Applic. Date: 2011-05-09; US2003-443772 Applic. Date: 2003-05-23; US1999-443863 Applic. Date: 1999-11-19; US19980109202P Applic. Date: 1998-11-20

Inventor: PARIKH INDU [CA]; MISHRA AWADHESH K [IN]; DONGA ROBERT [CA]; VACHON MICHAEL G [CA]


Application No.: US20110244042A1  Published: 06/Oct/2011

Title: STABILIZED FORMULATIONS OF CNS COMPOUNDS

Applicant/Assignee: SUPERNUS PHARMACEUTICALS, INC

Application No.: 13/075607   Filing Date: 30/Mar/2011

Abstract:

Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone.

Priority: US20100282787P Applic. Date: 2010-03-31

Inventor: CHANG RONG-KUN [US]; VIEIRA MICHAEL L [US]; LIANG LIKAN [US]; BHATT PADMANABH P [US]; HUANG AUSTIN B [US]; PATEL SACHIN V [US]


Application No.: US20110244043A1  Published: 06/Oct/2011

Title: Controlled releasing composition

Applicant/Assignee:

Application No.: 13/133656   Filing Date: 10/Dec/2009

Abstract:

A controlled releasing composition comprising a plurality of microparticles and a matrix as well as the preparation method thereof is disclosed. The plurality of microparticles comprise a first material and the matrix comprises a second material. The melting temperature of the first material is higher than the melting temperature of the second material.

Priority: CN20081182652 Applic. Date: 2008-12-10; WO2009CN75468 Applic. Date: 2009-12-10

Inventor: XU JIANJIAN [CN]; WANG SHILIANG [CN]; DING MANZHI [CN]


Application No.: US20110244044A1  Published: 06/Oct/2011

Title: COMPOUND, MEDICAMENT, VACCINE COMPOSITION AND NANOCAPSULES

Applicant/Assignee: MEDIPOL SA

Application No.: 13/133821   Filing Date: 09/Dec/2009

Abstract:

The present invention relates to a compound comprising a polyelectrolyte and, covalently linked thereto, an immunological adjuvant and/or cell targeting ligand, wherein the covalently linked entity can have both adjuvant and cell targeting characteristics. The compound is used in the preparation of hydrophilic vaccine nanoparticles, which preferably have an antigenic compound or therapeutic agent, or genetic information encoding such compounds or agents entrapped in their matrix, or covalently linked to their surfaces. Vaccine compositions comprising the particles of the invention are advantageous, because a strong and long-lasting immune response is obtained following administration of a single dose. In a preferred embodiment, the polyelectrolyte of the compound is an anionic polymer, and the particle comprises a matrix comprising chitosan.

Priority: EP20080171263 Applic. Date: 2008-12-10; WO2009IB55633 Applic. Date: 2009-12-09

Inventor: ROSSI NATHANAEL [CH]; KAUPER PETER [CH]; MCCULLOUGH KENNETH CHARLES [CH]; HARWOOD LISA [CH]


Application No.: US20110244045A1  Published: 06/Oct/2011

Title: CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION

Applicant/Assignee: TIARA PHARMACEUTICALS ,INC

Application No.: 12/595027   Filing Date: 11/May/2009

Abstract:

The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.

Priority: US20080052120P Applic. Date: 2008-05-09; US20090143105P Applic. Date: 2009-01-07; WO2009US43435 Applic. Date: 2009-05-11

Inventor: ARAD YADON [US]; DONG LIANG C [US]


Application No.: US20110245123A1  Published: 06/Oct/2011

Title: METHODS OF EMULSIFYING ORGANOSILOXANE POLYMERS

Applicant/Assignee:

Application No.: 13/078047   Filing Date: 01/Apr/2011

Abstract:

Emulsified organosiloxane polymers are useful in consumer product compositions. In one aspect, a method of making a consumer product having an organosiloxane polymer emulsion comprising the steps: providing a surfactant/solvent mixture

providing an organosiloxane polymer

mixing the surfactant/solvent mixture and the organosiloxane polymer to obtain a homogenous silicone premix

and adding to the homogenous silicone premix to a consumer product precursor composition to obtain the consumer product is disclosed.

Priority: US20100319939P Applic. Date: 2010-04-01

Inventor: COX JEREMY WAYNE [US]; PANANDIKER RAJAN KESHAV [US]; MENKHAUS JULIE ANN [US]; VETTER KERRY ANDREW [US]


Application No.: US20110250257A1  Published: 13/Oct/2011

Title: FIBROUS TISSUE SEALANT AND METHOD OF USING SAME

Applicant/Assignee:

Application No.: 13/129658   Filing Date: 31/Aug/2009

Abstract:

Disclosed herein is a fibrous tissue sealant in the form of an anhydrous fibrous sheet comprising a first component which is a fibrous polymer containing electrophilic or nucleophilic groups and a second component capable of crosslinking the first component when the sheet is exposed to an aqueous medium, thereby forming a crosslinked hydrogel that is adhesive to biological tissue. The fibrous tissue sealant may be useful as a general tissue adhesive for medical and veterinary applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures, tissue repair, and to prevent post-surgical adhesions. The fibrous tissue sealant may be particularly suitable for use as a hemostatic sealant to stanch bleeding from surgical or traumatic wounds.

Priority: US20080115968P Applic. Date: 2008-11-19; WO2009US55487 Applic. Date: 2009-08-31

Inventor: ARTHUR SAMUEL DAVID [US]; HUANG TAO [US]; DIMAIO JR WILLIAM GERALD [US]; KODOKIAN GEORGE K [US]


Application No.: US20110250262A1  Published: 13/Oct/2011

Title: METHOD FOR PRODUCING LIPOSOME AND METHOD FOR DISSOLVING CHOLESTEROL

Applicant/Assignee: BIOMEDCORE, INC

Application No.: 13/061833   Filing Date: 24/Dec/2009

Abstract:

Disclosed is a method for producing a liposome, which comprises: a first mixing step wherein one or more lipids are mixed with an aqueous solution containing a water-miscible organic solvent

a heating step wherein the mixture obtained by mixing the lipids with the aqueous solution is heated to a temperature at which the lipids are dissolved in the aqueous solution

and a cooling step following the heating step, wherein the resulting mixture is cooled down to a temperature at which a liposome is produced. Uniform-sized liposomes having a high encapsulation rate can be easily obtained by the method.

Priority: JP20080328724 Applic. Date: 2008-12-24; WO2009JP71484 Applic. Date: 2009-12-24

Inventor: SHIMIZU YOSHITAKA [JP]; MIBE YASUHIKO [JP]


Application No.: US20110250269A1  Published: 13/Oct/2011

Title: HIGHLY EFFICIENT AND LONG-ACTING SLOW-RELEASE FORMULATION OF POORLY SOLUBLE DRUGS AND PREPARATION METHOD THEREOF

Applicant/Assignee: JIANGSU UNIVERSITY

Application No.: 13/126183   Filing Date: 23/Nov/2009

Abstract:

A high-efficacy, long-acting, slow-release formulation of the poorly soluble drug, comprising solid dispersion of the poorly soluble drug, silica nanoparticles loaded with the poorly soluble drug, matrix material, and release enhancer, wherein the mass ratio of these components is solid dispersion of the poorly soluble drug: silica nanoparticles loaded with the poorly soluble drug: matrix material: release enhancer=1: 0.5 (approx.) 1.25: 0.1 (approx.) 0.3: 0.1 (approx.) 0.3

the said solid dispersion of the poorly soluble drug contains povidone K30, soybean lecithin, and acrylic resin IV, wherein the mass ratio of the drug and the accessory materials is poorly soluble drug: povidone K30: soybean lecithin: acrylic resin IV=1: 1-3: 0.3 (approx.) 0.8: 0.2 (approx.) 0.5. Compared with the existing formulations, the in vivo half life of the high-efficacy, long-acting formulation of the poorly soluble drug disclosed in this invention is 2.3 (approx.) 14.8 times longer while the mean residence time (MRT) of which is 7.94 (approx.) 4.52 times longer

when tested in vivo in Beagle dogs, this new formulation of the poorly soluble drug presents a smoother concentration-time curve and reaches a continuous release for 72 hours. This invention discloses its preparation method.

Priority: CN20081242994 Applic. Date: 2008-12-31; WO2009CN01299 Applic. Date: 2009-11-23

Inventor: XU XIMING [CN]; YU JIANGNAN [CN]; ZHU YUAN [CN]; CAO XIA [CN]


Application No.: US20110250274A1  Published: 13/Oct/2011

Title: ESTRIOL FORMULATIONS

Applicant/Assignee:

Application No.: 13/063803   Filing Date: 18/Sep/2009

Abstract:

Disclosed herein are oral dosage forms and methods of their use, in particular oral dosage systems for the delivery of estriol compounds. Embodiments described herein relate to rapidly disintegrating oral dosage formulations that disintegrate in the saliva of the buccal and/or sublingual and/or esophageal cavity. Oral dosage forms described herein relate to stabilized amorphous and nanocrystalline forms of the active ingredients of the formulations.

Priority: US20080098615P Applic. Date: 2008-09-19; WO2009US57524 Applic. Date: 2009-09-18

Inventor: SHAKED ZE EV [US]; ELGER WALTER [DE]; NICKISCH KLAUS [DE]


Application No.: US20110251067A1  Published: 13/Oct/2011

Title: Hydrolysis Resistant Organomodified Trisiloxane Surfactants

Applicant/Assignee: MOMENTIVE PERFORMANCE MATERIALS INC

Application No.: 13/166116   Filing Date: 22/Jun/2011

Abstract:

Three types of trisiloxane surfactants having the basic formula: MDM' are described wherein the substituents on the differing M and M' groups, in conjunction with pendant polyalkylene oxide substituents on the D group render the surfactant resistant to hydrolysis under either basic or acidic conditions outside the pH range of 6.0 to 7.5. The compositions are useful in agricultural, household and cosmetic applications.

Priority: US2006-356607 Applic. Date: 2006-02-17

Inventor: POLICELLO GEORGE A [US]; LEATHERMANI MARK D [US]; PENG WENQING [CN]; RAJARAMAN SURESH K [US]; XIA SOPHIA [CN]


Application No.: US20110251070A1  Published: 13/Oct/2011

Title: Agrochemical Oil Compositions Comprising Alkylpolysiloxane Adjuvants of High Silicone Character

Applicant/Assignee: EVONIK GOLDSCHMIDT GMBH

Application No.: 13/124522   Filing Date: 03/Sep/2009

Abstract:

The invention relates to agrochemical compositions comprising oils and alkylpolysiloxanes of high silicone character (HSCAS) with good oil compatibility which improve the spreading behavior and reduce surface tension of oil-based agricultural formulations, and optionally comprising agrochemically active ingredients such as fungicides, insecticides or herbicides and/or inert ingredients such as emulsifiers and other agrochemically acceptable components.

Priority: US20080106307P Applic. Date: 2008-10-17; WO2009EP61385 Applic. Date: 2009-09-03

Inventor: POFFENBERGER CRAIG [US]; LINDSAY DAVID [US]; SIMPELKAMP JOERG [US]; HARTUNG CHRISTIAN [DE]; FERENZ MICHAEL [DE]


Application No.: US20110251146A1  Published: 13/Oct/2011

Title: TOPICAL ANTIFUNGAL COMPOSITION

Applicant/Assignee: STIEFEL RESEARCH AUSTRALIA PTY LTD

Application No.: 13/165282   Filing Date: 21/Jun/2011

Abstract:

A topical, foamable composition is provided that includes at least one antifungal agent that is able to penetrate the upper layers of skin and is retained in or on an area to be treated for a prolonged period of time, and that has a residual non-volatile component content less than 25%. In addition, a method of treating fungal diseases including jock itch, tinea, dandruff and sebborheic dermatitis is provided, and includes applying to the affected area of patient requiring such treatment an antifungal composition.

Priority: AU1997PO09838 Applic. Date: 1997-10-17; AU1998PP01217 Applic. Date: 1998-01-06; US2008-293000 Applic. Date: 2008-12-02; US2000-529033 Applic. Date: 2000-04-05; WO1998AU00867 Applic. Date: 1998-10-19

Inventor: DAVEY GREG [AU]; ABRAM ALBERT ZORKO [AU]


Application No.: US20110256199A1  Published: 20/Oct/2011

Title: MELT EXTRUSION ENCAPSULATION OF FLAVORS AND OTHER ENCAPSULATES IN A CARRIER CONTAINING SPICES AND HERBS

Applicant/Assignee: MCCORMICK & COMPANY INCORPORATED

Application No.: 13/087732   Filing Date: 15/Apr/2011

Abstract:

Active encapsulation compositions which are stable in the glassy state at ambient temperatures are prepared by melt extrusion of a ternary carrier blend comprising of 1) a food polymer, 2) a spice or herb, and 3) a low molecular weight sugar or polyol. Such glassy matrices are useful for the encapsulation of encapsulates, in particular, flavors and medications.

Priority: US20100325099P Applic. Date: 2010-04-16

Inventor: ZASYPKIN DMITRIY [US]


Application No.: US20110256222A1  Published: 20/Oct/2011

Title: Recombinant Protein Enriched in a Heparin Binding Site and/or in a Heparan Sulfate Binding Site

Applicant/Assignee:

Application No.: 12/936739   Filing Date: 07/Apr/2009

Abstract:

The invention relates to a recombinant protein enriched in a heparin binding site and/or a heparan sulfate binding site. Such recombinant protein is used as an in vivo controlled release system of a protein of interest.

Priority: EP20080154329 Applic. Date: 2008-04-10; WO2009NL50179 Applic. Date: 2009-04-07

Inventor: DE BOER ARJO LYSANDER [NL]; BOUWSTRA JAN BASTIAAN [NL]


Application No.: US20110256223A1  Published: 20/Oct/2011

Title: GASTRIC RETAINED GABAPENTIN DOSAGE FORM

Applicant/Assignee: DEPOMED, INC

Application No.: 13/111575   Filing Date: 19/May/2011

Abstract:

A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

Priority: US2010-749101 Applic. Date: 2010-03-29; US2008-239591 Applic. Date: 2008-09-26; US2002-280309 Applic. Date: 2002-10-25; US20010335248P Applic. Date: 2001-10-25

Inventor: BERNER BRET [US]; HOU SUI YUEN EDDIE [US]; GUSLER GLORIA M [US]


Application No.: US20110257015A1  Published: 20/Oct/2011

Title: POLYMERS, COMPOSITIONS AND METHODS FOR USE FOR FOAMS, LAUNDRY DETERGENTS, SHOWER RINSES AND COAGULANTS

Applicant/Assignee: RHODIA INC

Application No.: 13/070655   Filing Date: 24/Mar/2011

Abstract:

The present invention relates to a polymeric material comprising units capable of having a cationic charge at a pH of from about 4 to about 12

provided that said polymeric material has an average cationic charge density from about 2.75 or less units per 100 daltons molecular weight at a pH of from about 4 to about 12. The polymeric material is a suds enhancer and a suds volume extender for hand dishwashing compositions and personal care products such as soaps, shaving cream foam, foaming shaving gel, foam dephiliatories and shampoos. The polymers are also effective as a soil release agent in fabric cleaning compositions. The polymers are also useful in agrochemical foam, fire-fighting foam, hard surface cleaner foam, and coagulant for titanium dioxide in paper making.

Priority: WO2000US14456 Applic. Date: 2000-05-25; US2000-698479 Applic. Date: 2000-10-30; US1999-318941 Applic. Date: 1999-05-26

Inventor: BERGERON VANCE [FR]; YEUNG DOMINIC WAI-KWING [CA]; BODET JEAN-FRANCOIS [US]; SIVIK MARK ROBERT [US]; KLUESENER BERNARD WILLIAM [US]; SCHEPER WILLIAM MICHAEL [US]


Application No.: US20110262516A1  Published: 27/Oct/2011

Title: AUTOLOGOUS CELLS ON A SUPPORT MATRIX FOR TISSUE REPAIR

Applicant/Assignee: GENZYME CORPORATION

Application No.: 13/179070   Filing Date: 08/Jul/2011

Abstract:

The present invention relates to a method for the effective treatment of tissue defects and for tissue regeneration. The method includes seeding autologous cells on a support matrix and implanting the cell-seeded support matrix into a site of transplantation. The present invention also relates to various tissue repair structures that include cells seeded onto a cell-free membrane. The present invention also provides methods for cultivation, seeding, and implantation of autologous cells.

Priority: US2007-801852 Applic. Date: 2007-05-10; US2003-672947 Applic. Date: 2003-09-26; US20020414098P Applic. Date: 2002-09-27

Inventor: ZHENG MING HAO [AU]; GIANNETTI BRUNO [DE]


Application No.: US20110262541A1  Published: 27/Oct/2011

Title: FOAM-FORMED COLLAGEN STRAND

Applicant/Assignee: OSTEOTECH, INC

Application No.: 12/766422   Filing Date: 23/Apr/2010

Abstract:

Foam-formed collagen strands and methods for forming strands involve depositing a dispersed solution of an isolated cleaned, de-fatted, enzymatically-treated (or non-enzyme treated) human-derived collagen product having a preserved amount of its natural constituents into grooves of a grooved plate, and processing the dispersed collagen product to provide a foam-formed collagen strand. Foam-formed collagen strands may be processed into threads having a matrix of reticulated pores to conduct biological materials in and through the strand, the collagen of the collagen strand comprising isolated, enzymatically-treated human derived collagen having a preserved amount of its natural collagen constituents.

Priority:

Inventor: LAURITZEN NELS [US]; SHIMP LAWRENCE A [US]; MITCHELL BRENT [US]


Application No.: US20110262542A1  Published: 27/Oct/2011

Title: Controlled Delivery of Tetracycline Compounds and Tetracycline Derivatives

Applicant/Assignee: GALDERMA LABORATORIES INC

Application No.: 13/177400   Filing Date: 06/Jul/2011

Abstract:

A composition is provided for delivering a tetracycline compound to a mammal. The composition includes an antibiotic tetracycline compound and a controlled-release agent having at least one controlled-release agent. The tetracycline compound is associated with the controlled-release matrix to provide a release profile whereby the mammal is treated substantially without antibiotic activity. Methods for treating a mammal with a tetracycline compound and a dosage unit are also provided utilizing the controlled-release tetracycline composition.

Priority: US2003-474240 Applic. Date: 2003-10-03; WO2002US10748 Applic. Date: 2002-04-05; US20010281854P Applic. Date: 2001-04-05

Inventor: ASHLEY ROBERT A [US]


Application No.: US20110263723A1  Published: 27/Oct/2011

Title: Pigment Composition Comprising Anthocyanic Vacuolar Inclusions

Applicant/Assignee: THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED

Application No.: 12/934941   Filing Date: 27/Mar/2009

Abstract:

The invention provides a pigment composition comprising anthocyanic vacuolar inclusions or "AVIs" from a plant, and an acceptable carrier. The invention also provides methods for colouring products with the pigment composition, and products comprising the pigment composition or AVIs.

Priority: NZ20080567036 Applic. Date: 2008-03-28; WO2009NZ00041 Applic. Date: 2009-03-27

Inventor: DEROLES SIMON [NZ]; ZHANG HUAIBI [NZ]; DAVIES KEVIN [NZ]


Application No.: US20110268666A1  Published: 03/Nov/2011

Title: NOVEL GASTRORETENTIVE DELIVERY SYSTEM

Applicant/Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE RESEARCH UNIVERSITY OF JERUSALEM, LTD, INTEC PHARMA LTD

Application No.: 13/121546   Filing Date: 29/Sep/2009

Abstract:

A novel gastroretentive delivery system comprising a tablet comprising a pharmaceutical ingredient or diagnostic, which tablet comprises a gas releasing ingredient or a tandem of two gas releasing ingredients, an ingredient capable of unrestricted swelling in gastric fluid, an ingredient capable of limiting the unrestricted swelling and a hardening ingredient. The said system is based on the use of three different gastroretentive mechanisms: flotation, swelling and mechanical strength, the three mechanisms acting in a complimentary way. Processes for manufacturing same and methods of treatment are also disclosed.

Priority: US20080136723P Applic. Date: 2008-09-29; WO2009IL00934 Applic. Date: 2009-09-29

Inventor: FRIEDMAN MICHAEL [IL]; KIRMAYER DAVID [IL]


Application No.: US20110268683A1  Published: 03/Nov/2011

Title: STRUCTURED SUSPENDING SYSTEMS

Applicant/Assignee: RHODIA, INC

Application No.: 13/018169   Filing Date: 31/Jan/2011

Abstract:

A pourable ringing gel surfactant composition comprising a mixture of at least one anionic surfactant having a C8-C18 carbon chain and at least one zwitterionic or amphoteric surfactant having a C8-C18 carbon chain, wherein the ringing gel is capable of suspending solid or liquid particles without sedimentation.

Priority: US20100299721P Applic. Date: 2010-01-29

Inventor: HAWKINS JOHN [GB]; HERVE PASCAL J [US]; MURPHY RYAN [US]; HOUGH LARRY [US]


Application No.: US20110268775A1  Published: 03/Nov/2011

Title: NANOPARTICLE PHARMACEUTICAL FORMULATIONS

Applicant/Assignee: PHARMANOVA, INC

Application No.: 13/143375   Filing Date: 05/Jan/2010

Abstract:

The present invention is directed to methods of preparing nanoparticles of aqueous-insoluble compounds, particularly aqueous-insoluble bioactive (drug) compounds, and to compositions and medicaments obtained by these methods. These methods, compositions, and other inventive aspects of the present invention are based particularly on the use of bile acid compound(s) to prepare nanoparticles of aqueous-insoluble compounds.

Priority: US20090142798P Applic. Date: 2009-01-06; WO2010US20109 Applic. Date: 2010-01-05

Inventor: HOLT KRIS [US]; THASSU DEEPAK [US]; VIOLANTE MICHAEL R [US]


Application No.: US20110268792A1  Published: 03/Nov/2011

Title: SURFACE ACTIVE PROTEINS AS EXCIPIENTS IN SOLID PHARMACEUTICAL FORMULATIONS

Applicant/Assignee: BASF SE

Application No.: 13/130128   Filing Date: 13/Nov/2009

Abstract:

The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical properties of the galenic form. In a preferred embodiment of the invention hydrophobins are used to improve the properties of a pharmaceutical composition, e.g. to act as a surfactant or to increase resistance to disintegration of the galenic forms to achieve a retarded drug release. The galenic form to be modified by the use of surface active proteins as excipients can be capsules, tablets, pills, microparticles, vesicles, and suppositories, although further galenic forms are envisioned. The surface active proteins used for the purpose of present invention can either be isolated from their respective natural source or prepared by recombinant techniques and expression in a suitable host.

Priority: EP20080170101 Applic. Date: 2008-11-27; WO2009EP65100 Applic. Date: 2009-11-13

Inventor: BUTHE ANDREAS [DE]; HAFNER ANDREAS [CH]; KAUFMANN FRANZ [DE]; GABOR ESTHER [DE]; MEURER GUIDO [DE]; ECK JUERGEN [DE]; BRADLEY GORDON [CH]


Application No.: US20110269789A1  Published: 03/Nov/2011

Title: Compositions and Methods for Achieving Sustained Therapeutic Drug Concentrations in a Subject

Applicant/Assignee: NEKTAR THERAPEUTICS

Application No.: 13/120551   Filing Date: 23/Sep/2009

Abstract:

Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.

Priority: US20080099516P Applic. Date: 2008-09-23; US20080106931P Applic. Date: 2008-10-20; US20090173433P Applic. Date: 2009-04-28; WO2009US05284 Applic. Date: 2009-09-23

Inventor: ELDON MICHAEL A [US]; HARITE SHIBANI S [US]; BARKER TAMRA L [US]


Application No.: US20110269846A1  Published: 03/Nov/2011

Title: Formulations with high percentage cis-p-menthan-7-ol and preparation thereof

Applicant/Assignee: BEDOUKIAN RESEARCH, INC

Application No.: 12/799682   Filing Date: 29/Apr/2010

Abstract:

Perfumed compositions or articles, and particularly perfumes, soaps, cosmetics, aftershaves, eye creams, insecticides and antiseptics formulations, containing p-menthane-7-ol wherein the cis portion of the p-menthane-7-ol exceeds 90% by weight, preferably comprises 93% or more, and more preferably comprises 95% or more, provide greatly improved fragrance characteristics wherein the odor produced is a more natural, strong, fresh muguet lily-of-the valley fragrance.

Priority:

Inventor: BEDOUKIAN ROBERT H [US]; PAWLAK MANFRED [US]


Application No.: US20110269847A1  Published: 03/Nov/2011

Title: STORAGE-STABLE COMPOSITIONS OF GLYCEROL MONOALKYL ETHERS

Applicant/Assignee: AIR LIQUIDE SANTE (INTERNATIONAL)

Application No.: 13/097618   Filing Date: 29/Apr/2011

Abstract:

Compositions having a combination a) of one or more glycerol monoalkyl ether(s) of the general formula R-O-CH2-CHOH-CH2OH in which R is a branched or unbranched C3-C18-alkyl group, where the alkyl group can be substituted by one or more hydroxyl and/or C1-C4-alkoxy group(s) and/or the alkyl chain can be interrupted by up to four oxygen atoms, with b) an antioxidant or two or more antioxidants as stabilizer(s), the simultaneous presence of phosphocholines and phosphocholine derivatives being excluded.

Priority: DE20001028638 Applic. Date: 2000-06-09; US2005-159056 Applic. Date: 2005-06-22; US2002-297795 Applic. Date: 2002-12-09; WO2001IB00865 Applic. Date: 2001-05-17

Inventor: BEILFUSS WOLFGANG [DE]; GRADTKE RALF [DE]


Application No.: US20110269851A1  Published: 03/Nov/2011

Title: REDUCING ASTRINGENCY IN COMPOSITIONS CONTAINING PHENOLIC COMPOUNDS

Applicant/Assignee: NESTEC S.A

Application No.: 13/121107   Filing Date: 14/Sep/2009

Abstract:

The present invention in general relates to the field of taste. In particular it relates to the reduction of astringency. One embodiment of the present invention relates to the use of at least one phospholipid for the preparation of a phenol containing composition to reduce the astringency of the composition.

Priority: EP20080105432 Applic. Date: 2008-09-25; WO2009EP61891 Applic. Date: 2009-09-14

Inventor: BORTLIK KARLHEINZ [CH]; BEGGIO MAURIZIO [CH]; LAMBELET PIERRE [CH]; HUYNH-BA TUONG [CH]; AESCHBACH ROBERT [CH]


Application No.: US20110271973A1  Published: 10/Nov/2011

Title: SOLUTION FOR FORMING DOUBLE EYELID AND METHOD FOR FORMING DOUBLE EYELID USING SAME

Applicant/Assignee:

Application No.: 13/124611   Filing Date: 27/Jan/2010

Abstract:

[Object] To provide a solution for forming a double eyelid which enables extremely easy formation of a natural and ideal double eyelid without giving a displeased feeling or an uncomfortable feeling to a user, and a method for forming a double eyelid using the solution for forming a double eyelid. [Solving Means] A solution for forming a double eyelid 1 according to the present invention is formed by dissolving, into a solvent having volatility, a fibrous material which forms a film 1a onto a skin 5a of an eyelid 5 and shrinks with vaporization of the solvent. By applying the solution 1, in a successive-curve form, over an imaginary line I forming a fold 5d of a double eyelid in the eyelid 5 onto which a user want to make a fold and vaporizing the solvent so as to shrink the film 1a, successive concaved groove-like constricted part 5c is formed on the imaginary line I and the fold 5d of a double eyelid along the constricted part 5c is formed. [Selected Drawings] FIG. 3

Priority: JP20090017327 Applic. Date: 2009-01-28; WO2010JP51033 Applic. Date: 2010-01-27

Inventor: IWAGAKI NAOKO [JP]; KAMAGATA MASAYUKI [JP]; TANIYAMA JIROU [JP]


Application No.: US20110274731A1  Published: 10/Nov/2011

Title: Production Method Of Fine O/W Emulsion External Preparation

Applicant/Assignee: SHISEIDO COMPANY, LTD

Application No.: 13/144114   Filing Date: 14/Jan/2010

Abstract:

The present invention provides a production method of a fine O/W emulsion external preparation having the emulsion particle size of 50 to 500 nm comprising the steps of: mixing with stirring, at 70 to 80 DEG C., (A) a hydrophilic nonionic surfactant, (B) a linear higher alcohol having 16 or more carbon atoms, (C) an oil component, (D) an aqueous solvent which can be soluble in water, wherein the critical micelle concentration (c.m.c.) of the hydrophilic nonionic surfactant in the aqueous solvent is higher than that in water, and (E) water in the amount of 5 to 25 mass % of the total amount of (A) to (E), to prepare a W/O emulsion

and adding, while mixing with stirring, (F) water or an aqueous formulation at 10 to 35 DEG C. into the W/O emulsion to invert the W/O emulsion to a fine O/W emulsion. The production method needs not to use any cooling apparatus, has excellent economical efficiency, can easily produce a fine O/W emulsion external preparation excellent in safety and stability.

Priority: JP20090005531 Applic. Date: 2009-01-14; WO2010JP50341 Applic. Date: 2010-01-14

Inventor: MIYAHARA REIJI [JP]; ARAKI HIDEFUMI [JP]


Application No.: US20110275723A1  Published: 10/Nov/2011

Title: Azeotrope-Like Compositions Of Tetrafluoropropene And Water

Applicant/Assignee: HONEYWELL INTERNATIONAL INC

Application No.: 13/082980   Filing Date: 08/Apr/2011

Abstract:

Provided are azeotropic and azeotrope-like compositions of trans-1,3,3,3-tetrafluoropropene (HFO-1234ze(E)) and water. Such azeotropic and azeotrope-like compositions are useful in isolating trans-1,3,3,3-tetrafluoropropene from impurities during production. Azeotropes of the instant invention are similarly useful in final compositions or for the manufacture of final compositions, such as blowing agent, propellants, refrigerants, diluents for gaseous sterilization and the like.

Priority: US20100331980P Applic. Date: 2010-05-06

Inventor: HULSE RYAN [US]; KOPKALLI HALUK [US]; PHAM HANG T [US]


Application No.: US20110275724A1  Published: 10/Nov/2011

Title: Azeotrope-Like Compositions Of Pentafluoropropene And Water

Applicant/Assignee: HONEYWELL INTERNATIONAL INC

Application No.: 13/083230   Filing Date: 08/Apr/2011

Abstract:

Provided are azeotropic and azeotrope-like compositions of 1,2,3,3,3-pentafluoropropene (HFO-1225ye) and water. Such azeotropic and azeotrope-like compositions are useful in isolating 1,2,3,3,3-pentafluoropropene from impurities during production. Azeotropes of the instant invention are similarly useful in final compositions or manufacturing final compositions, such as blowing agent, propellants, refrigerants, diluents for gaseous sterilization and the like.

Priority: US20100331971P Applic. Date: 2010-05-06

Inventor: HULSE RYAN [US]; KOPKALLI HALUK [US]; PHAM HANG T [US]


Application No.: US20110275725A1  Published: 10/Nov/2011

Title: GLYCEROL ESTER ACTIVE AGENT DELIVERY SYSTEMS AND METHODS

Applicant/Assignee:

Application No.: 13/104383   Filing Date: 10/May/2011

Abstract:

Embodiments of the invention include glycerol esters and use of the same for active agent delivery systems and methods. In an embodiment, the invention includes an active agent eluting device including a glycerol ester, an active agent dispersed within the glycerol ester, the active agent eluting device configured to elute the active agent from the glycerol ester in response to degradation of the glycerol ester. In an embodiment, the invention includes a composition including a glycerol ester

an active agent dispersed within the glycerol ester

the active agent eluting device configured to elute the active agent from the glycerol ester in response to degradation of the glycerol ester. Other embodiments are also included herein.

Priority: US20100333036P Applic. Date: 2010-05-10

Inventor: MEYERING EMILY R R [US]; CHUDZIK STEPHEN J [US]


Application No.: US20110280822A1  Published: 17/Nov/2011

Title: Structured surfactant system

Applicant/Assignee:

Application No.: 13/068388   Filing Date: 10/May/2011

Abstract:

An aqueous structured surfactant composition contains an anionic surfactant selected from isethionate surfactants, taurate surfactants, and sarcosinate surfactants, and mixtures thereof, and an electrolyte and is useful in personal care applications.

Priority: US2007-903999 Applic. Date: 2007-09-25; US20060847211P Applic. Date: 2006-09-26

Inventor: GRIFFIN JAMES F [US]; WARBURTON STEWART A [US]; FUTTERER TOBIAS JOHANNES [US]


Application No.: US20110281809A1  Published: 17/Nov/2011

Title: METHODS AND COMPOSITIONS FOR RAPID TREATMENT OF OTITIS EXTERNA

Applicant/Assignee: TRIAD SPECIALTY PRODUCTS LLC

Application No.: 12/943810   Filing Date: 10/Nov/2010

Abstract:

Methods for treating and preventing otitis externa with a course of treatment consisting of as little as a single dose are provided. The methods are practiced by topical administration of compositions having a lipid carrier, such as liposomes and non-vesicular lipids, to the outer ear canal. Such compositions lack viscocity-enhancing celluloses or adhesives, and are preferably not in the form of a gel. Active agents useful for treating pain, inflammation, fungal or parasitic infestation and/or infections in the outer ear are co-administered in or with the composition.

Priority: US20090260309P Applic. Date: 2009-11-11

Inventor: CAMPBELL WILLIAM R [US]; PAULSEN NEIL E [US]; JOHNSON ROLAND H [US]; HEPLER DOUGLAS I [US]


Application No.: US20110281810A1  Published: 17/Nov/2011

Title: Composition

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 13/086210   Filing Date: 13/Apr/2011

Abstract:

The present invention relates to the use of a solubilizer for enhancing the solubility of an active pharmaceutical ingredient in water. The present invention further relates to a composition comprising a solubilizer and at least one active pharmaceutical ingredient. In both cases the solubilizer is an alkoxylated monoalcohol or a mixture of alkoxylated monoalcohols, where the alkoxylated monoalcohol or, if a mixture of alkoxylated monoalcohols is present, at least one alkoxylated monoalcohol in the mixture comprises at least one oxypropylene unit.

Priority: EP20100003932 Applic. Date: 2010-04-14

Inventor: PETERSEN KIRSTEN [DE]; MUELLER BERND W [DE]; ROSEN THOMAS [DE]


Application No.: US20110287078A1  Published: 24/Nov/2011

Title: NOVEL POROUS BIOMATERIALS

Applicant/Assignee: UNIVERSITY OF WASHINGTON

Application No.: 13/156966   Filing Date: 09/Jun/2011

Abstract:

The invention provides porous biomaterials and methods for forming porous biomaterials. The porous biomaterials of the invention comprise a biocompatible polymer scaffold defining an array of pores, wherein substantially all the pores have a similar diameter, wherein the mean diameter of the pores is between about 20 and about 90 micrometers, wherein substantially all the pores are each connected to at least 4 other pores, and wherein the diameter of substantially all the connections between the pores is between about 15% and about 40% of the mean diameter of the pores. The invention also provides implantable devices comprising a layer of a biomaterial, and methods for promoting angiogenesis in and around an implantable biomaterial.

Priority: US2007-595233 Applic. Date: 2007-01-23; WO2004US32639 Applic. Date: 2004-10-01; US20030507734P Applic. Date: 2003-10-01

Inventor: RATNER BUDDY D [US]; MARSHALL ANDREW [US]


Application No.: US20110288363A1  Published: 24/Nov/2011

Title: Biologically Enhanced Irrigants

Applicant/Assignee: NUORTHO SURGICAL INC

Application No.: 13/118152   Filing Date: 27/May/2011

Abstract:

Compositions, systems and methods utilizing engineered surgical irrigants providing delivery of components with therapeutic or other secondary benefits. Engineered irrigants provide targeted delivery of desired agents, including agents for propulsion of nano-devices, agents including molecular probes, gene expression agents, magnetically orientable agents, agents for discrete tissue temperature detection and tissue regeneration agents.

Priority: US2006-444724 Applic. Date: 2006-06-01; US2002-157651 Applic. Date: 2002-05-28; US20010293809P Applic. Date: 2001-05-26

Inventor: MORGAN ROY E [US]; AUGE II WAYNE K [US]


Application No.: US20110288462A1  Published: 24/Nov/2011

Title: HAEMOSTATIC WOUND CARE ARTICLE

Applicant/Assignee:

Application No.: 12/672020   Filing Date: 01/Aug/2008

Abstract:

The subject matter of the invention is a wound care article exhibiting a quantity of super-absorbent polymers. The wound care article is characterized in that characterized in that it exhibits at least one agent which can restrict the bleeding or the tendency to bleed. In the process it can be a chemically and/or pharmacologically and/or physiologically acting active ingredient or active ingredient complex.

Priority: DE200710036755 Applic. Date: 2007-08-03; WO2008EP60164 Applic. Date: 2008-08-01

Inventor: RIESINGER BIRGIT [DE]


Application No.: US20110293687A1  Published: 01/Dec/2011

Title: HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING

Applicant/Assignee:

Application No.: 13/115049   Filing Date: 24/May/2011

Abstract:

The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Priority: US20100348896P Applic. Date: 2010-05-27

Inventor: BENNETT STEVEN [US]; MAST NATHANIEL [US]; LAVIGNE KEVIN [US]; SKALLA WALTER [US]; BANERJEE SAUMYA [US]; SARGEANT TIMOTHY [US]; STOPEK JOSHUA [US]


Application No.: US20110293699A1  Published: 01/Dec/2011

Title: HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING

Applicant/Assignee:

Application No.: 13/115079   Filing Date: 24/May/2011

Abstract:

The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Priority: US20100348896P Applic. Date: 2010-05-27

Inventor: BENNETT STEVEN [US]; MAST NATHANIEL [US]; LAVIGNE KEVIN [US]; SKALLA WALTER [US]; SARGEANT TIMOTHY [US]; STOPEK JOSHUA [US]


Application No.: US20110293720A1  Published: 01/Dec/2011

Title: PROGESTIN-CONTAINING DRUG DELIVERY SYSTEM

Applicant/Assignee: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Application No.: 13/057299   Filing Date: 07/Aug/2009

Abstract:

The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one protective agent. The protective agent provides effective taste-masking of the progestin due to limited release of the progestin in the mouth. The progestin is hence not absorbed via the buccal route, but rather via the enteral (per-oral) route.

Priority: EP20080162105 Applic. Date: 2008-08-08; WO2009EP00904 Applic. Date: 2009-02-10; US20080087334P Applic. Date: 2008-08-08; WO2009EP60298 Applic. Date: 2009-08-07

Inventor: GENERAL SASCHA [DE]; TEREBESI ILDIKO [DE]; BRACHT STEFAN [DE]; FUNKE ADRIAN [DE]


Application No.: US20110293722A1  Published: 01/Dec/2011

Title: HYDROGEL SPONGES, METHODS OF PRODUCING THEM AND USES THEREOF

Applicant/Assignee: TECHION RESEARCH AND DEVELOPMENT FOUNDATION LTD

Application No.: 13/132669   Filing Date: 06/Dec/2009

Abstract:

A macroporous hydrogel sponge is provided selected from: (i) a synthetic polymer hydrogel sponge, and (ii) a synthetic polymer-polypeptide conjugate hydrogel sponge, the macroporous hydrogel sponge being at least 20% porous and having a pore diameter of 50-1000 [mu]m, wherein said synthetic polymer is crosslinked to an extent determined by effecting the crosslinkig of the synthetic polymer or synthetic polymer-polypeptide conjugate in the presence of at least about 30% by weight crosslinking agent.

Priority: US20080193505P Applic. Date: 2008-12-04; WO2009IL01151 Applic. Date: 2009-12-06

Inventor: KAULLY TAMAR [IL]; LEVENBERG SHULAMIT [IL]


Application No.: US20110300080A1  Published: 08/Dec/2011

Title: ACIDIFIED CHLORITE DISINFECTANT COMPOSITIONS WITH OLEFIN STABILIZERS

Applicant/Assignee: ECOLAB USA INC

Application No.: 13/209692   Filing Date: 15/Aug/2011

Abstract:

A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part comprises an acid, and wherein the first part, the second part, or both the first and second parts comprise an olefin compound.

Priority: US2005-106798 Applic. Date: 2005-04-15; US2003-374690 Applic. Date: 2003-02-25; US2001-859902 Applic. Date: 2001-05-16

Inventor: MORELLI JOSEPH P [US]; LAPORTE KARLA [US]; LI JUNZHONG [US]


Application No.: US20110301100A1  Published: 08/Dec/2011

Title: Pharmaceutical Compositions Comprising Polyethylene Glycol Having a Molecular Weight of Less Than 600 Daltons

Applicant/Assignee: NOVARTIS AG

Application No.: 13/209472   Filing Date: 15/Aug/2011

Abstract:

A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent.

Priority: GB20040012866 Applic. Date: 2004-06-09; US2007-570061 Applic. Date: 2007-11-13; WO2005EP06173 Applic. Date: 2005-06-08

Inventor: LAMBERT OLIVIER [FR]


Application No.: US20110305648A1  Published: 15/Dec/2011

Title: Methods of Preparing Personal Care Compositions

Applicant/Assignee:

Application No.: 13/156862   Filing Date: 09/Jun/2011

Abstract:

Disclosed herein are embodiments of a method of predicting and adjusting the viscosity of consumer product compositions prior to their final formulation. The prediction aides the determination of the amount of a viscosity modifier to introduce in the manufacture of the final formulation to ensure the compositions have viscosities that satisfies consumer preferences, among other things.

Priority: US20100353034P Applic. Date: 2010-06-09

Inventor: KNAPEK DAWN RENEE [US]; MORRISON JR LOWEN ROBERT [US]; CAGGIONI MARCO [US]; WORLEY WILLIAM JOSEPH [US]; ROYCE DOUGLAS ALLAN [US]; HILVERT JENNIFER ELAINE [US]


Application No.: US20110305656A1  Published: 15/Dec/2011

Title: Aqueous fragrancing composition comprising at least one volatile linear alkane

Applicant/Assignee: L'OREAL

Application No.: 12/949441   Filing Date: 18/Nov/2010

Abstract:

The present invention relates to an anhydrous fragrancing composition free of C1-C5 alkanol, comprising, in a cosmetically acceptable medium: a) at least 5% by weight of water relative to the total weight of the composition

b) at least 2% by weight of a fragrancing substance

c) at least one volatile liquid linear alkane or a mixture of volatile linear alkanes. The present invention also relates to a process for fragrancing human keratin materials or clothing, which consists in applying to the said keratin materials or the said clothing an aqueous fragrancing composition as defined previously.

Priority: FR20090058193 Applic. Date: 2009-11-19; US20090265617P Applic. Date: 2009-12-01

Inventor: GRANDJON VINCENT [FR]


Application No.: US20110305760A1  Published: 15/Dec/2011

Title: TISSUE REGENERATION SYSTEM

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: 12/796743   Filing Date: 09/Jun/2010

Abstract:

A system for growing tissue based upon layers of an inorganic extracellular matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution.

Priority:

Inventor: MURPHY WILLIAM L [US]; MARKEL MARK D [US]; GRAF BEN K [US]; LU YAN [US]; LEE JAE SUNG [US]


Application No.: US20110305768A1  Published: 15/Dec/2011

Title: QUICK-DISSOLVING ORAL THIN FILM FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: 13/002222   Filing Date: 24/Dec/2008

Abstract:

This invention describes a quick-dissolving thin film strips comprising bioactive components encapsulated within pH-sensitive polymeric microparticles. The microparticles are embedded within the thin film and provide protection to components encapsulated within. The invention further describes methods to incorporate bioactive components encapsulated within pH-sensitive polymeric microparticles into a quick-dissolving thin film strip while maintaining the bioactivity of the contained therapeutic agents during thin film formation and microencapsulation.

Priority: US20080133672P Applic. Date: 2008-07-01; WO2008US88300 Applic. Date: 2008-12-24

Inventor: MAO HAI-QUAN [US]; YU CHRISTOPHER KU [US]; TRUONG VU LINH [US]; LI YANG [US]; RANGARAJ DHANYA [US]; JIANG XUESONG [US]; SHAH SAGAR RAMESH [US]; SING DEREK [US]


Application No.: US20110306500A1  Published: 15/Dec/2011

Title: Method of Treating a Material Using a Sol-gel Derived Composition

Applicant/Assignee:

Application No.: 13/157280   Filing Date: 09/Jun/2011

Abstract:

Disclosed is a method and system that includes treating a material by applying a sol-gel derived composition loaded with a first sorbate under conditions effective to treat the material with the first sorbate.

Priority: US2010-819940 Applic. Date: 2010-06-21; US20100353417P Applic. Date: 2010-06-10; US20100356094P Applic. Date: 2010-06-18

Inventor: EDMISTON PAUL L [US]


Application No.: US20110306539A1  Published: 15/Dec/2011

Title: PROCESS FOR MAKING PARTICLES FOR DELIVERY OF DRUG NANOPARTICLES

Applicant/Assignee:

Application No.: 13/120146   Filing Date: 24/Sep/2009

Abstract:

A process for making particles for delivery of drug nanoparticles is disclosed herein. The process comprises the steps of (a) forming a suspension of drug nanoparticles by mixing a precipitant solution with an anti-solvent solution under micro-mixing environment, where the formed nanoparticles have a narrow particle size distribution

(b) providing an excipient to at least one of the precipitant solution, the anti-solvent solution and the suspension of drug nanoparticles, the excipient being selected to maintain said drug nanoparticles in a dispersed state when in liquid form

and (c) drying the suspension of drug nanoparticles containing the excipient therein to remove solvent therefrom, wherein removal of the solvent causes the excipient to solidify and thereby form micro-sized matrix particles, each micro-sized particle being comprised of drug nanoparticles dispersed in a solid matrix of the excipient.

Priority: GB20090009154 Applic. Date: 2009-05-29; US20080100133P Applic. Date: 2008-09-25; WO2009SG00353 Applic. Date: 2009-09-24

Inventor: SHEN ZHIGANG [CN]; YUN JIMMY SUNG LAI [SG]; HU JUN [SG]; JUGADE ARVIND [SG]; ZHANG JIYAO [SG]; CHEN WENHAO [SG]; WANG ZHE [SG]; GAO LINGYAN [SG]; CHEN JIAN FENG [CN]


Application No.: US20110307054A1  Published: 15/Dec/2011

Title: IMPLANT COATING WITH NUCLEIC ACIDS

Applicant/Assignee:

Application No.: 12/959684   Filing Date: 03/Dec/2010

Abstract:

One example embodiment of the present invention relates to an implant with a coating or a cavity filling containing a nucleic acid, which i) can inhibit the expression of at least one representative of the Ras gene family by means of RNA interference

or ii) encodes for a nucleic acid that can inhibit the expression of at least one representative of the Ras gene family by means of RNA interference.

Priority: US20090266520P Applic. Date: 2009-12-04

Inventor: BORCK ALEXANDER [DE]; GRATZ MATTHIAS [DE]


Application No.: US20110311583A1  Published: 22/Dec/2011

Title: NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS

Applicant/Assignee: ALNYLAM PHARMACEUTICALS, INC

Application No.: 13/128287   Filing Date: 10/Nov/2009

Abstract:

(A1) Translate this text The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure (I) wherein R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand

R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand

E is O, S, N(Q), C(O), N(Q)C(O), C(0)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O-N, aryl, heteroaryl, cyclic or heterocycle

and, Q is H, alkyl, ?-aminoalkyl, ?-(substituted)aminoalky, ?-phosphoalkyl or ?-thiophosphoalkyl.

Priority: US20080113179P Applic. Date: 2008-11-10; US20090154350P Applic. Date: 2009-02-20; US20090171439P Applic. Date: 2009-04-21; US20090185438P Applic. Date: 2009-06-09; US20090225898P Applic. Date: 2009-07-15; US20090234098P Applic. Date: 2009-08-14; WO2009US63931 Applic. Date: 2009-11-10

Inventor: MANOHARAN MUTHIAH [US]; RAJEEV KALLANTHOTTATHIL G [US]; JAYARAMAN MUTHUSAMY [US]; BUTLER DAVID [US]; NARAYANANNAIR JAYAPRAKASH K [US]; MAIER MARTIN [US]; ELTEPU LAXMAN [US]


Application No.: US20110311629A1  Published: 22/Dec/2011

Title: NON-ADHESIVE ELASTIC GELATIN MATRICES

Applicant/Assignee: COVALON TECHNOLOGIES INC

Application No.: 13/166433   Filing Date: 22/Jun/2011

Abstract:

The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix is a lyophilized mixture of protein(s), polymer(s), cross-linking agent(s) and optional plasticizer(s). The invention also provides methods for making the non-adhesive elastic gelatin matrix.

Priority: US2005-664184 Applic. Date: 2005-06-15; WO2005CA00925 Applic. Date: 2005-06-15; US20040614414P Applic. Date: 2004-09-30

Inventor: DITIZIO VALERIO [CA]; DICOSMO FRANK [CA]; XIAO YUEHUA [CA]


Application No.: US20110312496A1  Published: 22/Dec/2011

Title: PESTICIDES FORMULATIONS

Applicant/Assignee: SIPCAM S.P.A

Application No.: 13/221346   Filing Date: 30/Aug/2011

Abstract:

Concentrated microemulsions comprising: 1) 10-25 parts by weight of a pesticide with a solubility in water at 20 DEG C. lower than 1% l by weight and having a melting point from 10 DEG C. to 60 DEG C.

2) 8-25 parts by weight of one or more solvents containing oxygen atoms, having a solubility in water at 20 DEG C. lower than 5% by weight and the Hildebrand solubility parameter in the range 16-21 MPa1/2

3) 10-20 parts by weight of a polyol

4) 10-25 parts by weight of one or more non ionic surfactants having a HLB value from 9 to 15

5) 2-10 parts by weight of one or more anionic surfactants

6) water up to 100 parts by weight

wherein-the ratio by weight between 2) and 1) ranges from 0.8:1 to 1.5:1

-the ratio by weight between 4) +5) and 1) is in the range 0.5:1-3:1

-the ratio by weight between 4) and 5) ranges from 1:1 to 4.1.

Priority: IT2003MI00411 Applic. Date: 2003-03-06; US2004-547612 Applic. Date: 2004-02-26; WO2004EP01906 Applic. Date: 2004-02-26

Inventor: BERNARDINI MARCO [IT]; BORGO FRANCESCA [IT]; CAPUZZI LUIGI [IT]; DOMENICHINI PIETRO [IT]; FRESCHI GIORGIO [IT]


Application No.: US20110318413A1  Published: 29/Dec/2011

Title: EXTENDED RELEASE FORMULATIONS CONTAINING DARIFENACIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

Applicant/Assignee: MICRO LABS LIMITED

Application No.: 13/166446   Filing Date: 22/Jun/2011

Abstract:

The present invention relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof and one or more release controlling hydrophobic materials optionally coated with combination of one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials

wherein said formulation provides controlled release of the darifenacin over the period of 24 hours. The present invention further relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof, wherein darifenacin is incorporated in a matrix comprising one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials.

Priority: IN2010CH01766 Applic. Date: 2010-06-23

Inventor: KSHIRSAGAR RAJESH [IN]; SHINDE GANESH [IN]; KAMBLE PRAVIN [IN]


Application No.: US20110318414A1  Published: 29/Dec/2011

Title: REGENERATIVE TISSUE GRAFTS AND METHODS OF MAKING SAME

Applicant/Assignee:

Application No.: 13/129636   Filing Date: 05/Aug/2009

Abstract:

A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.

Priority: US20080117814P Applic. Date: 2008-11-25; WO2009US04482 Applic. Date: 2009-08-05

Inventor: JACKSON WESLEY M [US]; NESTI LEON J [US]; TUAN ROCKY S [US]


Application No.: US20110319341A1  Published: 29/Dec/2011

Title: METHOD OF CONTROLLING PESTS WITH BIOSURFACTANT PENETRANTS AS CARRIERS FOR ACTIVE AGENTS

Applicant/Assignee:

Application No.: 13/181746   Filing Date: 13/Jul/2011

Abstract:

A penetrating composition can include an active agent that has an activity that is either beneficial for plants or controls pests. The composition can also include a penetrant that is present in an effective amount for carrying the at least one active agent into or through a medium, the medium being at least one of a plant, soil, or pest. Also, penetrating composition can be used for increasing the permeation of an active agent in an animal. The composition includes an active agent having an activity that is beneficial for an animal. Also, the composition includes a penetrant selected from the group consisting of biosurfactants, glycolipids, lipopeptides, favolipids, lipoproteins, phospholipids, lipopolysaccharide-protein complexes, polysaccharide-protein-fatty acid complexes, and combinations thereof. A biosurfactant composition can include an effective amount of a biosurfactant for controlling a pest, preserving a plant cutting, or reducing effects of environmental stress on a plant.

Priority: US2005-209132 Applic. Date: 2005-08-22; US2005-141669 Applic. Date: 2005-05-31; US20040575913P Applic. Date: 2004-06-01; US20040604139P Applic. Date: 2004-08-23

Inventor: AWADA SALAM M [US]; AWADA MOHAMED M [US]; SPENDLOVE REX S [US]

US Applications Published in 2011
US Applications Published in 2009
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..
US PROVISIONAL PATENT APPLICATIONS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL COMPOSITIONS PUBLISHED IN 2010
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included pharmaceutical formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained drug release;
polysaccharides, polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal, nasal, ocular
or buccal administration of medications, etc.
Clck to enlarge and view details